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Abstract 
LIM-homeodomain (LIM-HD) transcription factors act as key developmental regulators, both 
through their ability to bind DNA through homeodomain-DNA interactions, and through their 
ability to form larger complexes through protein-protein interactions. Many interactions that 
have been characterised are formed using their N-terminal LIM domains, but likely also 
involve other regions, which have not yet been described for many LIM-HD proteins. 
 
The LIM-HD protein Isl1 has been implicated in the development of many tissues, such as 
the nervous system, heart, and pancreas. However, relatively little detail is known about how 
Isl1 functions in these systems and the pathways in which it acts. The first part of this thesis 
aimed to identify and characterise novel binding partners for Isl1. Close to 180 potential 
binding partners were isolated through use of yeast two-hybrid mating screens in an earlier 
project; over the course of this thesis, further methodology was developed to identify 
additional proteins in a medium throughput manner. Downstream validation protocols were 
then applied to determine which interactors were likely to represent biologically relevant 
interaction partners for Isl1. 
 
The second part of this thesis focussed on the mechanisms by which Isl1 and another LIM-
HD protein, Lhx3, play a role in cell fate determination in the developing central nervous 
system. These proteins, along with Ldb1, interact via LIM:LID interactions to form cell-
specific transcriptional complexes that target genes different to those targeted by either LIM-
HD protein alone. It was not known if the homeodomains target these different sites solely 
because of the LIM:LID interactions or if the homeodomains themselves bind cooperatively 
to DNA. The DNA-binding behaviour of various iterations of the Lhx3/Isl1/Ldb1 complex 
are described, and structural characterisation of the Isl1/Lhx3 DNA-binding unit has been 
pursued. These data provide new insights into the mechanisms by which Isl1 and Lhx3 work 
together in regulating gene expression. 
  
iii 
 
Acknowledgements 
Firstly I would like to acknowledge and thank Jacqui for supervising me over the duration of 
my PhD and giving me the opportunity to work on this project. You allowed me to pursue 
something that evolved much further than it was planned to, and I’ve learned and grown 
immensely from the experience. 
 
Huge thanks also go to the people who helped to edit this thesis: Mario, Lorna, Ana, Jill, and 
Jacqui. I know you all had a lot of important things you had to do besides reading this, so I 
appreciate the energy and effort you gave me. 
 
Thank you to Ann, Jill, Tim, and the other SAXS beamline scientists at the Australian 
Synchrotron, for helping me with all the SAXS data collection and analysis. 
 
I’d also like to thank all the people of the Structural Biology discipline, for their advice and 
support. Every person that’s been through the lab while I’ve been here has had something to 
teach me, and I really appreciate that. Special thanks to Mario, Lorna, Ana, Jason, and Flyp 
for many morning and afternoon teas talking about experiments and troubleshooting. Thanks 
also to my older Matthews brother Neil, for always being willing to chat and throw ideas 
around.  
 
I’d also like to thank Angela, Ben, Trudie, and the autoclaving/glassware team, without 
whom most of this thesis would not have been possible. You make working in a lab so much 
easier and more pleasant, I think we’d all fall apart without you. 
 
I acknowledge the support of an Australian Postgraduate Award/Research Training Program 
scholarship. 
 
On a personal note, a lot of people have helped me along this journey, and I owe them a lot. 
As these are personal thanks that are owed, however, I will thank them in person, and not 
here. 
 
  
iv 
 
Contents 
 
Declaration .................................................................................................................................. i 
Abstract ...................................................................................................................................... ii 
Acknowledgements .................................................................................................................. iii 
Contents .................................................................................................................................... iv 
List of Figures and Tables......................................................................................................... xi 
Publications ............................................................................................................................ xvii 
Abbreviations ....................................................................................................................... xviii 
1 Introduction ............................................................................................................................. 1 
1.1 Developmental gene regulation ....................................................................................... 1 
1.2 The LIM-homeodomain family of transcription factors .................................................. 1 
1.2.1 Similarities within the LIM-HD family .................................................................... 3 
1.2.2 Structural features of LIM-HD proteins ................................................................... 3 
1.3 Isl1.................................................................................................................................... 7 
1.3.1 Conservation of Isl1 .................................................................................................. 9 
1.4 The role of Isl1 in development ..................................................................................... 11 
1.4.1 Isl1 in motor neuron development .......................................................................... 11 
1.4.2 Isl1 is necessary for correct heart development ...................................................... 14 
1.4.3 Development of the pancreas requires Isl1 ............................................................. 16 
1.4.4 Brain development requires Isl1 ............................................................................. 18 
1.4.5 Isl1 is involved in development of the kidney and urinary tract............................. 20 
1.4.6 Isl1 in the developing retina .................................................................................... 21 
1.4.7 Other roles of Isl1 in development.......................................................................... 21 
1.5 Known binding partners of Isl1 ..................................................................................... 22 
1.6 Alternative forms of Isl1 ................................................................................................ 23 
1.6.1 Isl1-β ....................................................................................................................... 23 
v 
 
1.6.2 Phosphorylation of Isl1 ........................................................................................... 23 
1.6.3 Isl2........................................................................................................................... 23 
1.7 Aims of this thesis .......................................................................................................... 24 
2. Materials and Methods ......................................................................................................... 25 
2.1 Materials ........................................................................................................................ 25 
2.1.1 Chemicals and reagents........................................................................................... 25 
2.1.2 Enzymes .................................................................................................................. 29 
2.1.3 Media ...................................................................................................................... 29 
2.1.4 Oligonucleotides and plasmids ............................................................................... 30 
2.1.5 Antibodies and peptides .......................................................................................... 31 
2.1.6 Organisms ............................................................................................................... 32 
2.2 Cloning ........................................................................................................................... 33 
2.2.1 Gibson cloning ........................................................................................................ 33 
2.2.2 Restriction cloning .................................................................................................. 35 
2.3 Yeast handling procedures ............................................................................................. 36 
2.3.1 Preparation and transformation of competent yeast ................................................ 36 
2.3.2 Yeast two-hybrid spot test assays ........................................................................... 37 
2.3.3 Mating library screens ............................................................................................. 37 
2.3.4 Extraction of plasmid DNA from mated yeast ....................................................... 38 
2.3.5 Isolation and identification of prey plasmid ........................................................... 39 
2.3.6 Extraction of protein from transformed yeast ......................................................... 40 
2.4 Validation of interactions from screening through FLAG pulldowns ........................... 41 
2.4.1 Cell growth conditions ............................................................................................ 41 
2.4.2 Transfections ........................................................................................................... 41 
2.4.3 Expression checks ................................................................................................... 41 
2.4.4 Cell lysis and FLAG-affinity immunoprecipitation ................................................ 42 
2.4.5 Western blot analysis .............................................................................................. 42 
vi 
 
2.5 Production of homeodomain containing protein constructs .......................................... 43 
2.5.1 Bacterial transformations ........................................................................................ 43 
2.5.2 Protein overexpression ............................................................................................ 43 
2.5.3 Protein Purification ................................................................................................. 44 
2.5.4 Protein concentration, dialysis and storage ............................................................. 45 
2.6 Homeodomain characterisation and DNA binding studies ............................................ 46 
2.6.1 Far-UV Circular dichroism (CD) ............................................................................ 46 
2.6.2 Nuclear magnetic resonance (NMR) ...................................................................... 46 
2.6.3 Fluorescent electrophoretic mobility shift assay (EMSA) ...................................... 46 
2.6.4 Microscale thermophoresis (MST) ......................................................................... 47 
2.6.5 Isothermal titration calorimetry (ITC) .................................................................... 47 
2.6.6 Size exclusion chromatography with multi-angle laser light scattering (SEC-
MALLS) ........................................................................................................................... 47 
2.6.7 X-ray crystallography ............................................................................................. 48 
2.6.8 Small angle X-ray scattering (SAXS) ..................................................................... 49 
3 Screening for novel Isl1-interacting proteins through yeast two-hybrid library screening .. 52 
3.1 Introduction .................................................................................................................... 52 
3.2 The Yeast two-hybrid system for probing interactions.................................................. 52 
3.2.1 Classifying yeast two-hybrid interactions according to strength ............................ 54 
3.3 Yeast two-hybrid library screens were conducted using Isl1 as bait ............................. 55 
3.3.1 Three constructs of Isl1 were chosen as baits for screening ................................... 55 
3.3.2 Construction of the Clontech Mate & Plate Library ............................................... 57 
3.3.3 Mating screens against Isl1 were conducted successfully ...................................... 58 
3.4 Prey plasmids were isolated and prey proteins identified .............................................. 60 
3.5 Not all identified prey encoded proteins ........................................................................ 61 
3.5.1 Investigation of frameshifted proteins .................................................................... 62 
3.6 Primary validation of putative interactors to check for prey auto-activation ................ 65 
vii 
 
3.7 Further assessing false positives and non-specific interactions ..................................... 67 
3.7.1 The CRAPome database was used to screen for non-specific binders ................... 67 
3.7.2 Subcellular localisation can be used to assess likelihood of an interaction occurring
.......................................................................................................................................... 68 
3.7.3 Using yeast two-hybrid to check for specific binders reveals many non-specific 
interactors ......................................................................................................................... 70 
3.8 Discussion ...................................................................................................................... 74 
3.8.1 Analysing the methodology used ............................................................................ 75 
3.8.2 Intrinsic flaws in the initial library used ................................................................. 76 
3.8.3 Considering the pool of prey................................................................................... 78 
4 Assessing potential Isl1 interactors ....................................................................................... 80 
4.1 Introduction .................................................................................................................... 80 
4.2 Assessing the literature .................................................................................................. 82 
4.2.1 Isl1∆LIM interactors .................................................................................................. 82 
4.2.2 Isl1LIM interactors .................................................................................................... 86 
4.2.3 Ldb1LID/Isl1LIM interactors ...................................................................................... 91 
4.2.4 Mkln1 ...................................................................................................................... 92 
4.3 Validating the interaction with Muskelin ...................................................................... 94 
4.3.1 Yeast two-hybrid shows an interaction between Isl1 and the CTLH region of 
Mkln1 ............................................................................................................................... 96 
4.3.2 Co-immunoprecipitation results do not clearly indicate a minimal binding region 
of Mkln1........................................................................................................................... 98 
4.3.3 Classifying the Isl1/Mkln1 interaction.................................................................. 101 
4.4 Discussion .................................................................................................................... 102 
4.4.1 Assessing the pool of remaining prey ................................................................... 102 
4.4.2 Assessing the success of library screening for identifying new binding partners 104 
4.4.3 Future work to map the interaction partners of Isl1 .............................................. 107 
4.4.4 Conclusion ............................................................................................................ 108 
viii 
 
5 Investigating the mechanisms behind the action of the motor neuron complex ................. 110 
5.1 Introduction .................................................................................................................. 110 
5.2 Construct design........................................................................................................... 110 
5.2.1 Single homeodomain constructs ........................................................................... 110 
5.2.2 Fusion homeodomain constructs........................................................................... 111 
5.3 Optimisation of homeodomain expression and purification ........................................ 113 
5.4 Isolated homeodomains are folded in solution ............................................................ 118 
5.4.1 Investigation of protein fold stability of individual homeodomains ..................... 119 
5.5 Using electrophoretic shift assays to probe in vivo DNA binding ............................... 121 
5.5.1 Lhx3HD binds with specificity, but Isl1HD does not .............................................. 122 
5.5.2 Lhx3HD and Isl1HD do not bind co-operatively when separated............................ 124 
5.6 Seeking an explanation for the observed binding behaviour of Isl1HD ........................ 126 
5.6.1 The presence of upstream LIM:LID interaction regions has no direct effect on 
binding of Isl1HD or Lhx3HD ........................................................................................... 126 
5.6.2 The presence of a dimerising domain can affect DNA binding preferences of 
homeodomains ............................................................................................................... 128 
5.7 Fusion constructs of Isl1 and Lhx3 behave differently to the individual homeodomains
............................................................................................................................................ 130 
5.8 Quantitation of DNA-binding affinities ....................................................................... 133 
5.9 Further investigations into characterising the binding of homeodomain-DNA 
complexes .......................................................................................................................... 134 
5.9.1 Trialling the use of circular dichroism to observe changes in the stability of 
homeodomains upon DNA binding ............................................................................... 134 
5.9.2 Quantification of binding affinities ....................................................................... 137 
5.10 Discussion .................................................................................................................. 142 
5.10.1 Comparing the observed binding behaviour to the reported behaviour in the 
literature ......................................................................................................................... 142 
5.10.2 Isl1 binding in the literature ................................................................................ 143 
ix 
 
5.10.3 Checking Isl1HD sequence against overall homeodomain conservation ............. 144 
5.10.4 Potential non-canonical roles for Isl1HD ............................................................. 146 
5.10.5 Consequences of a weak DNA-binding Isl1 ....................................................... 147 
6 Structural studies on the 2HDLL:M100 complex ............................................................... 148 
6.1 The 2HDLL:M100 complex is monodisperse in solution ........................................... 148 
6.2 Attempting to solve the structure of 2HDLL:M100 through crystallography ............. 150 
6.2.1 Initial crystallisation condition screening ............................................................. 150 
6.2.2 Optimising 2HDLL:M100c20 crystals ................................................................. 155 
6.3 Investigating low resolution structure with small angle X-ray scattering ................... 158 
6.3.1 SAXS background ................................................................................................ 158 
6.3.2 Trialling SAXS with the 2HDLL:M100 complex ................................................ 161 
6.3.3 SEC-SAXS indicates the 2HDLL:M100 complex is homogenous ...................... 162 
6.3.4 Analysing static SAXS data .................................................................................. 162 
6.3.5 Modelling the 2HDLL:M100 complex ................................................................. 166 
6.4 Discussion .................................................................................................................... 170 
6.4.1 Mechanisms of Isl1 and Lhx3 cooperation ........................................................... 170 
6.4.2 Future directions ................................................................................................... 171 
6.4.3 Conclusion ............................................................................................................ 172 
7 Conclusions ......................................................................................................................... 173 
7.1 The role of the Isl1 in a broader context ...................................................................... 174 
References .............................................................................................................................. 177 
Appendix A - Oligonucleotides used for binding studies ...................................................... 197 
Appendix B - Amino acid sequences of protein fusion tags .................................................. 198 
Appendix C - Sequencing primers ......................................................................................... 199 
Appendix D - Library titering experiments ........................................................................... 200 
Appendix E - SAXS reporting ............................................................................................... 202 
Appendix F - Amino acid sequences of Mkln1 constructs and Isl1 constructs ..................... 206 
x 
 
Appendix G - Amino acid sequences of homeodomain constructs ....................................... 210 
Appendix H - Protein Purification ......................................................................................... 212 
 
xi 
 
List of Figures and Tables 
Table 1.1: The role of LIM-HD proteins in mammalian development. ..................................... 2 
Figure 1.1: The family of LIM-HD proteins. ............................................................................. 3 
Figure 1.2: Structural schematic of a LIM domain, showing residues important for zinc ion 
coordination. .............................................................................................................................. 4 
Figure 1.3: Structures of LIDs bound to LIM domains. ............................................................ 5 
Figure 1.4: Structure of a homeodomain bound to DNA........................................................... 6 
Figure 1.5: Structural features of Isl1. ....................................................................................... 8 
Figure 1.6: Sequence alignment of Isl1 homologs................................................................... 10 
Figure 1.7: Schematic of the developing notochord. ............................................................... 12 
Figure 1.8: Schematics of LIM-HD neuronal transcriptional complexes. ............................... 13 
Figure 1.9: Early stages of heart development......................................................................... 15 
Figure 1.10: Formation of the pancreas. .................................................................................. 17 
Figure 1.11: Schematic of the adult brain. ............................................................................... 19 
Figure 1.12: Schematics of the kidney. .................................................................................... 20 
Table 1.2: Expression of Isl1 in development of a multitude of other tissues. ........................ 21 
Table 1.3: Known protein interaction partners of Isl1. ............................................................ 22 
Table 2.1: Chemicals and reagents used throughout this thesis............................................... 25 
Table 2.2: Enzymes used throughout this thesis. ..................................................................... 29 
Table 2.3: Media used throughout this thesis. ......................................................................... 29 
Table 2.4: Additional nutrients present in selective yeast media............................................. 30 
Table 2.5: Antibodies used throughout this thesis. .................................................................. 31 
Table 2.6: Organism strain genotypes. .................................................................................... 32 
Table 2.7: Constructs produced through Gibson cloning. ....................................................... 33 
Table 2.8: Constructs produced through restriction cloning. ................................................... 35 
Table 2.9: Composition of screening plates used for different bait in mating screens. ........... 38 
Table 2.10: Extinction coefficients of purified proteins. ......................................................... 45 
xii 
 
Figure 3.1: Schematic representation of the yeast two-hybrid system. ................................... 53 
Table 3.1: Selective media used for yeast two-hybrid screening. ............................................ 54 
Figure 3.2: Schematic representations of Isl1 constructs used for library screening. .............. 56 
Figure 3.3: Schematic of the production of the cDNA library used for interaction partner 
screening. ................................................................................................................................. 58 
Table 3.2: Comparison of yeast isolated from mating screens. ............................................... 59 
Figure 3.4: Comparison of good quality and anomalous sequencing data of library prey 
plasmids. .................................................................................................................................. 61 
Table 3.3: Proportion of isolated prey encoding proteins across library screens. ................... 62 
Table 3.4: Expected size of potentially frameshifted prey. ..................................................... 63 
Figure 3.5: Anti-HA Western blots of protein extracts from yeast. ......................................... 64 
Figure 3.6: An example of yeast two-hybrid assays to assess auto-activation. ....................... 66 
Table 3.5 Distribution of interaction strengths according to the Isl1 construct used as bait. .. 67 
Figure 3.7: Prevalence of putative Isl1-interacting proteins in CRAPome database. .............. 68 
Figure 3.8: Analysing subcellular localisations of Isl1-interacting proteins. .......................... 69 
Table 3.6: Subcellular localisations of non-redundant protein hits. ........................................ 69 
Table 3.7: Screening putative interactors for interaction specificity. ...................................... 70 
Figure 3.9: Yeast two-hybrid spot test validations for specificity of Ldb1LID/Isl1LIM 
interacting proteins................................................................................................................... 72 
Figure 3.10: Representative yeast two-hybrid spot test validations for specificity of 
Ldb1LID/Isl1LIM interacting proteins. ........................................................................................ 73 
Table 3.8: Potential Isl1-interacting proteins from yeast two-hybrid screening. ..................... 75 
Figure 3.11: Domain structure of Fhl1. ................................................................................... 77 
Table 4.1: Isl1-interacting proteins remaining after validations. ............................................. 80 
Figure 4.1: Domain structure of Kctd9. ................................................................................... 83 
Figure 4.2: Structure of Usp8................................................................................................... 84 
Figure 4.3: Cops5 and Cyc1 yeast two-hybrid spot tests. ........................................................ 85 
Figure 4.4: Domain structure of Zfand1. ................................................................................. 88 
xiii 
 
Figure 4.5: Domain structure of Dfna5. ................................................................................... 88 
Figure 4.6: Electron microscopy model of an intact mouse ribosome. ................................... 90 
Figure 4.7: Domain structure of Mkln1. .................................................................................. 93 
Figure 4.8: Schematic of Mkln1 truncations identified throughout yeast two-hybrid screening.
.................................................................................................................................................. 94 
Figure 4.9: Truncation constructs of Mkln1 produced to validate interaction with Isl1. ........ 95 
Figure 4.10: Spot tests of Mkln1 constructs against Isl1 constructs. ....................................... 97 
Figure 4.11: Expression of FLAG- and HA-tagged proteins from HEK293 cells. ................. 99 
Figure 4.12: Detecting the interaction between Isl1 and Mkln1 using co-immunoprecipitation.
................................................................................................................................................ 100 
Table 4.2: Classification of identified proteins according to likelihood of biological relevance 
of the interaction. ................................................................................................................... 103 
Figure 4.13: Breakdown of the categorisation of hits isolated in yeast two-hybrid library 
screening. ............................................................................................................................... 105 
Figure 5.1: Single homeodomain constructs used in the project. .......................................... 111 
Figure 5.2: Homeodomain fusion constructs used throughout the project. ........................... 112 
Figure 5.3: Variability of 2HDN purification. ....................................................................... 113 
Figure 5.4: Amylose affinity purifications of homeodomain constructs with an N-terminal 
MBP tag. ................................................................................................................................ 114 
Table 5.1: Testing for leaky expression and toxicity. ............................................................ 115 
Figure 5.5: Removal of nucleic acid contamination by PEI precipitation. ............................ 116 
Figure 5.6: Examples of purifications of homeodomain constructs. ..................................... 117 
Figure 5.7: Far-UV CD spectra of single homeodomains. .................................................... 118 
Figure 5.8: 
1
H 1D NMR spectra. ........................................................................................... 119 
Figure 5.9 Comparison of NMR spectra taken at 25 °C and 37 °C. ...................................... 120 
Figure 5.10: Far-UV CD melting profiles of single homeodomains. .................................... 121 
Table 5.2: Binding sequences used for EMSA binding studies. ............................................ 122 
Figure 5.11: Fluorescent EMSA titrations of NHD3. ............................................................ 123 
xiv 
 
Figure 5.12: Fluorescent EMSA titrations of NHD1. ............................................................ 124 
Figure 5.13: Assessing cooperative binding between Isl1HD and Lhx3HD to the M100 
sequence. ................................................................................................................................ 125 
Figure 5.14: EMSA titrations of homeodomain constructs with N-terminal LIM domains. . 127 
Figure 5.15: Behaviour of GST-fusion NHD1 and NHD3. ................................................... 129 
Figure 5.16: Examples of M100 binding by 2HDLL and 2HDN. ......................................... 130 
Figure 5.17: Binding to single homeodomain binding site oligonucleotides by 2HDN and 
2HDLL. .................................................................................................................................. 131 
Figure 5.18: Comparison of DNA binding behaviour for 2HDN and 2HD23. ..................... 132 
Table 5.3: Kds (M) of homeodomain:DNA complexes, as determined from EMSAs (n = 2-3).
................................................................................................................................................ 133 
Figure 5.19: Far-UV CD signals of oligonucleotides. ........................................................... 135 
Table 5.4: Observed and theoretical melting temperatures of DNA sequences used in far-UV 
CD. ......................................................................................................................................... 135 
Figure 5.20 CD spectra of homeodomain with and without DNA (M100). .......................... 136 
Table 5.5: Comparison of homeodomain melting temperatures (°C) with and without DNA 
present. ................................................................................................................................... 136 
Table 5.6: Comparison of DNA melting temperatures (°C) with and without homeodomain 
present. ................................................................................................................................... 137 
Figure 5.21: Microscale thermophoresis data for the interaction between 2HDLL and M100.
................................................................................................................................................ 138 
Figure 5.22: Capillary fluorescence scan of 2HDLL:M100 samples prior to thermophoresis 
measurements. ........................................................................................................................ 139 
Figure 5.23: ITC titrations of homeodomains against binding sequences. ............................ 141 
Figure 5.24: Sequence conservation across 213 human homeodomains. .............................. 144 
Table 5.7: Conserved amino acids in the homeodomain fold ................................................ 145 
Figure 6.1: Elution profiles of 2HDLL:M100 from SEC-MALLS. ...................................... 149 
Table 6.1: Oligonucleotide sequences used for crystallography trials. ................................. 150 
Figure 6.2: Examples of nucleation in 2HDLL:M100c21 wells. .......................................... 151 
xv 
 
Figure 6.3: Conditions showing 2HDLL:M100c20 crystallisation. ...................................... 153 
Figure 6.4: SYPRO Ruby stained SDS-PAGE of putative 2HDLL:M100 crystals. ............. 154 
Table 6.2: Initial crystallisation conditions that grew putative protein-DNA crystals. ......... 155 
Figure 6.5: Optimised crystals grown in the hexanediol gradient screen. ............................. 156 
Figure 6.6: Optimised crystals grown in the MPD gradient screen. ...................................... 157 
Figure 6.7: Schematic of SAXS, showing the diffraction and detection of X-rays. .............. 158 
Figure 6.8: Examples of Kratky plots. ................................................................................... 160 
Figure 6.9: Elution profile of 2HDLL:M100 on SEC-SAXS, showing absorbance at three 
wavelengths............................................................................................................................ 162 
Figure 6.10: Baseline subtracted static SAXS data for concentration series. ........................ 163 
Table 6.3: Experimental Rgs (Å) for M100 and 2HDLL:M100 SAXS samples. .................. 164 
Figure 6.11: Guinier plots of M100 alone and 2HDLL:M100 SAXS datasets. .................... 164 
Figure 6.12: Kratky plots of SAXS data. ............................................................................... 165 
Figure 6.13: Dimensionless Kratky plots of SAXS data. ...................................................... 166 
Figure 6.14: Examples of 2HDLL:M100 models generated using MONSA. ....................... 168 
Figure 6.15: Assessing the fits of 2HDLL:M100 models generated. .................................... 169 
Table B.1: Fusion protein tags used. ...................................................................................... 198 
Table C.1: sequencing primers used. ..................................................................................... 199 
Table D.1: Conditions used for library titering experiments ................................................. 200 
Table D.2: Library viabilities. ................................................................................................ 200 
Table D.3: Viability of mated yeast in interaction screening. ............................................... 201 
Table D.4: Screening efficiencies of yeast two-hybrid library screens. ................................ 201 
Table D.5: Mating efficiencies of yeast two-hybrid library screens. ..................................... 201 
Table E.1: SAXS Experimental details. ................................................................................. 202 
Table E.2: Data processing details and parameters. .............................................................. 203 
Table E.3: Parameters from Guinier analyses of datasets. ..................................................... 204 
Table E.4: Parameters from P(r) analyses of all datasets. ...................................................... 205 
xvi 
 
Table F.1: Amino acid sequences of Isl1 constructs used for interaction testing. ................. 206 
Table F.2: Amino acid sequences of Mkln1 constructs used for interaction testing. ............ 207 
Table G.1: Amino acid sequences of homeodomain containing constructs. ......................... 210 
Figure H.1: Further examples of purifications of homeodomain constructs. ........................ 212 
  
xvii 
 
Publications 
Below are listed publications that arose from the work described in this thesis. While no 
content is taken directly from these publications, they form the basis for some of the work 
presented here. 
 
Smith, N.C., Matthews & Matthews, J.M. Mechanisms of DNA-binding specificity and 
functional gene regulation by transcription factors. Current Opinion in Structural Biology, 
2016. 38: p. 68-74. 
 
This is a review researched by me and co-written by me and Professor Matthews. The content 
of this review contributes to various chapter introductions and discussions, as well as portions 
of Chapter 1. 
 
Robertson, N.O., Smith, N.C., Manakas, A., Mahjoub, M., McDonald, G., Kwan, A. H. & 
Matthews, J.M. Disparate binding kinetics by an intrinsically disordered domain enables 
temporal regulation of transcriptional complex formation. Proceedings of the National 
Academy of Science, 2018. 115(18): p. 4643-4648. 
 
This paper describes efforts to characterise the kinetic interplay of LIM-HD transcription 
factors during spinal motor neuron development. DNA-binding experiments presented in this 
paper were performed by me, and can be found in Chapter 5, specifically Sections 5.5-5.8. 
 
In addition to the statements above, in cases where I am not the corresponding author of a 
published item, permission to include the published material has been granted by the 
corresponding author. 
Ngaio Smith   14 March 2019 
 
As supervisor for the candidature upon which this thesis is based, I can confirm that the 
authorship attribution statements above are correct. 
 
Jacqueline Matthews  14 March 2019  
xviii 
 
Abbreviations 
Abbreviation Meaning 
3-AT 3-amino-1,2,4-triazole   
AD Activation domain 
APS Ammonium persulfate 
Art3 Ecto-ADP-ribosyltransferase 3  
Asrgl1 Isoaspartyl peptidase/L-asparaginase 
Bicine 2-(Bis(2-hydroxyethyl)amino)acetic acid  
Bis-Tris 2-[Bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-
diol  
BLAST Basic Local Alignment Search Tool 
Bmp Bone morphogenic protein 
Bmp4 Bone morphogenetic protein 4 
BSA Bovine serum albumin 
CD Circular dichroism 
cDNA complementary DNA 
ChIP Chromatin immunoprecipitation 
Chx10 Visual system homeobox 2 
Cited2 Cbp/p300-interacting transactivator 2 
Co-IP/MS Co-immunoprecipitation coupled with mass spectrometry 
Copb1 Coatomer subunit beta 
Cops5 COP9 signalosome complex subunit 5 
CRAPome Contaminant Repository for Affinity Purification 
CSM Complete supplement media 
CTLH C-terminal to LisH 
Cuz1 Cdc48-associated UBL/zinc finger protein-1 
Cyc1 Cytochrome C1  
DBD DNA-binding domain 
Ddx20/Dp103/Gemin3 DEAD-box helicase DDX20  
Dfna5/Gsdme/Dfna5h Gasdermin-E  
Dkk1 Dickkopf-related protein 1 
Dkk2 Dickkopf-related protein 2 
xix 
 
DMSO Dimethyl sulfoxide  
dNTPs Deoxyribonucleotide triphosphates  
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid  
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylene ditetraacetic acid  
Egr Early growth response 
EMSA Electrophoretic mobility shift assay 
Fgf10 fibroblast growth factor 10 
Fhl1 Four and a half LIM domains protein 1 
Foxa1 Hepatocyte nuclear factor 3-alpha 
Foxa2 Hepatocyte nuclear factor 3-beta 
GA Proglucagon 
Gata4 GATA binding protein 4 
GST Glutathione S-transferase 
GSU Glycoprotein hormone subunit α 
h hour 
HA Hemagglutinin 
HEK Human embryonic kidney 
HEPES 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid  
Hopx homeodomain-only protein 
HRP Horseradish peroxidase 
HSQC Heteronuclear single quantum coherence 
IPTG Isopropyl β-D-thiogalactopyranoside  
Isl1/2 Islet-1/2 
ITC Isothermal titration calorimetry 
Jmjd3 Lysine-specific demethylase 6B 
kb kilobase 
Kctd9 BTB/POZ domain-containing protein KCTD9  
Kd Dissociation constant 
kDa kilodalton 
Lace1/Afg1l AFG1-like ATPase  
LB Luria-Bertani broth  
xx 
 
Ldb1/2 LIM domain-binding protein 1/2 
Lhx LIM/homeobox protein 
LID LIM interaction domain 
LIM Domain found in Lin11, Isl1, Mec3  
LIM-HD LIM-homeodomain 
Limk2 LIM kinase 2 
LisH Lissencephaly-1 homology 
Lmo4 LIM domain only protein 4 
Lmx1a/b LIM homeobox transcription factor 1 alpha/beta 
Lrrc51 Leucine-rich repeat-containing protein 51  
Ly6c1 Lymphocyte antigen 6C1  
mAb monoclonal antibody 
MALLS Multi-angle laser light scattering 
MBP Maltose binding protein 
MCS Multiple cloning site 
Mec3 Mechanosensory protein 3 
Mef2c Myocyte-specific enhancer factor 2C 
Mep1b Meprin A subunit beta  
MES 2-ethanesulfonic acid 
min minute 
Mkln1 Muskelin 
Mnx1 Motor neuron and pancreas homeobox protein 1 
MPD (+/−)-2-Methyl-2,4-pentanediol 
MQW MilliQ® water 
Ms4a5 Membrane-spanning 4-domains, subfamily A, member 5  
MST Microscale thermophoresis 
MWCO Molecular weight cut-off 
NeuroD1 Neurogenic differentiation factor 1 
Nkiras1 NF-kappa-B inhibitor-interacting Ras-like protein 1  
Nkx2.5 Homeobox protein Nkx-2.5 
NLS Nuclear localisation sequence 
NMR Nuclear magnetic resonance 
Nup50 Nuceloporin 50 
xxi 
 
Oct1 Octamer-binding protein 1 
Oct4 Octamer-binding protein 4 
OD600 Optical density at 600 nm 
Oscp1 Oxidored-nitro domain-containing protein 1  
Pax6 Paired box protein 6 
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline supplemented with 0.1% Tween 
PCR Polymerase chain reaction 
Pbx Pre-B-cell leukaemia transcription factor 
Pdx1 Pancreas/duodenum homeobox protein 1 
PEG Polyethylene glycol 
PEI Polyethylimine 
Phox2a Paired mesoderm homeobox 2A 
Pias4 Protein inhibitor of activated STAT protein gamma 
PIPES Piperazine-N,N′-bis(2-ethanesulfonic acid)  
PMSF Phenylmethanesulfonyl fluoride  
poly dG Poly deoxyguanine 
poly dT Poly deoxythymine 
Pou4f2 POU domain, class 4, transcription factor 2 
RanBPM Ran-binding protein M 
Rg Radius of gyration 
Rnf167 E3 ubiquitin-protein ligase RNF167 
Rps18 40S ribosomal protein S18  
Rps23 20S ribosomal protein S23 
Rps26 20S ribosomal protein S26 
Rps29 20S ribosomal protein S29 
s second 
S. cerevisiae Saccharomyces cerevisiae 
SA Self-association domain 
SAXS Small angle X-ray scattering 
SD Synthetic dextrose broth 
SDS Sodium dodecyl sulfate 
Scpep1 Retinoid-inducible serine carboxypeptidase  
xxii 
 
SEC-MALLS Size exclusion chromatography coupled to multi angle laser light 
scattering 
SEC-SAXS Size exclusion chromatography coupled to small angle X-ray 
scattering 
SELEX Selective evolution of ligands by exponential enrichment 
Set7/9 Pancreas/duodenum homeobox protein 1 
Shh Sonic Hedgehog 
snRNP small nuclear ribonucleoprotein 
Sparc Secreted protein, acidic and rich in cysteine 
Sparcl1/Ecm2/Sc1 SPARC-like protein 1  
Spata7 Spermatogenesis-associated protein 7 homolog  
SPR Surface plasmon resonance 
Ssbp3 Single-stranded DNA-binding protein 3 
Stam1 Signal transducing adapter molecule 1 
Stat3 Signal transducer and activator of transcription 2 
SV40 Simian virus 40 
Tbx T-box 
Tbx20 T-box transcription factor 20 
TCEP tris(2-carboxyethyl)phosphine  
TEMED N,N,N′,N′-Tetramethylethylenediamine  
Tigd2 Tigger transposable element-derived protein 2 
Tris 2-Amino-2-(hydroxymethyl)propane-1,3-diol  
Trpc1 Transient receptor potential channel 1 
Ubd/Fat10 Ubiquitin D 
Usp8 Ubiquitin carboxyl-terminal hydrolase 8  
UTR Untranslated region 
Wif1 Wnt inhibitory factor 1 
X-α-gal 5-bromo-4-chloro-3-indolyl-α-D-galactopyranoside  
YPD Yeast peptone dextrose broth 
Zdhhc20 Palmitoyltransferase ZDHHC20  
Zfand1 AN1-type zinc finger protein 1  
 
 
1 
 
1 Introduction 
1.1 Developmental gene regulation 
In order to correctly control the development of an organism, the genomes of higher order 
eukaryotic organisms have evolved to rely on many layers of gene regulation [1, 2]. One of 
the most prevalent of these is the interplay of transcription factors that promote or repress 
expression of specific genes at distinct times during development [3]. Many transcription 
factors have individual DNA-binding preferences, but most commonly the action of multiple 
transcription factors acting in a complex is required to precisely modulate gene expression, 
especially in the context of development [4, 5]. Dysregulation of these systems leads to 
developmental defects, and anomalies of the temporal control of these systems can also lead 
to disease states such as cancer in fully developed organisms [6, 7]. Understanding systems 
that regulate gene expression can thus give us deep insights into how organisms develop, and 
how to prevent or correct instances of dysregulation. 
 
1.2 The LIM-homeodomain family of transcription factors 
The LIM-homeodomain (LIM-HD; LIM derived from Lin11, Isl1, Mec3) proteins are a 
family of transcription factors found in animals. This family is highly conserved, with all 
proteins implicated in mammalian development (Table 1.1) [8]. The knock out or knock 
down of many of the LIM-HD proteins have severe impact, and can be lethal, or lead to 
developmental disorders [9]. Many LIM-HD proteins play a role in development in multiple 
tissues (Table 1.1). This is especially the case with the LIM-HD protein Isl1, which is the 
focus of this thesis.  
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Table 1.1: The role of LIM-HD proteins in mammalian development.  
LIM-HD 
protein 
Developmental tissue Knockout phenotype 
Isl1 Discussed in detail in Section 1.4 Embryonic lethal [10] 
Isl2 Motor neurons [11] 
Retina [12] 
Death <24 hours after birth [13] 
Lmx1a Forebrain [14] 
Spinal cord [15] 
Behavioural and cognitive defects [16] 
Lmx1b Eye [17] 
Spinal cord [15] 
Limb patterning, kidneys [18] 
Nail-Patella syndrome [19] 
Lhx1 Cerebellum [20] 
Early definition of body axes [21] 
Forebrain [22] 
Embryonic lethal [23] 
Lhx2 Eye, cerebral cortex, erythrocytes [24] 
Olfactory neurons [25] 
Embryonic lethal [24] 
Lhx3 V2a Interneurons [26] 
Inner ear [27] 
Pituitary gland [28, 29] 
Motor neurons [30] 
Death <24 hr after birth [31] 
Lhx4 Pituitary gland [28, 29] 
Motor neurons [30] 
Death <15 min after birth [32] 
Lhx5 Cerebellum [20] 
Forebrain [22] 
Death a few days after birth, or severe 
cognitive defects [33, 34] 
Lhx6 Forebrain, teeth [35]  Unknown 
Lhx7/8 Teeth [35, 36] 
Forebrain [35] 
Death within 24 hours after birth, or 
cleft palate [37] 
Lhx9 Gonads [38] 
Cerebral cortex [39] 
Forebrain [40] 
Urogenital defects, entirely female 
phenotype [38] 
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1.2.1 Similarities within the LIM-HD family 
Phylogenetic analysis reveals distinct paralogue pairs (i.e., closely related genes that probably 
arose through gene duplication) within the family of LIM-HD proteins (Figure 1.1) [41]. 
These pairs are found to have similar, but not entirely redundant, functional roles [11, 15, 30, 
35, 39, 42]. 
 
 
Figure 1.1: The family of LIM-HD proteins. (A) Phylogenetic tree of LIM-HD 
proteins. (B) Domain organisation of the LIM-HD proteins from (A). 
 
The paralogous pairs of LIM-HD proteins have a high level of evolutionary conservation, 
with all mammals possessing six paralogous pairs of LIM-HD proteins (Figure 1.1A) [43]. 
This suggests that both paralogues are necessary for normal growth or function, and therefore 
it is possible that the redundant pairs have evolved to act in spatially or temporally separate 
environments, but with very similar functions. 
 
1.2.2 Structural features of LIM-HD proteins 
The LIM-HD family of proteins derives its name from the two domains contained in all 
family members: an N-terminal pair of closely spaced LIM domains, and a downstream 
homeodomain (Figure 1.1B) [44, 45]. These motifs are crucial for forming interactions that 
facilitate the function of the proteins. The LIM domains are protein-protein interaction 
motifs, allowing association with other regulatory proteins [45]. The homeodomain is a well-
characterised DNA binding domain, often found in developmental transcription factors [46]. 
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1.2.2.1 LIM domains and LIDs 
A LIM domain is a zinc finger that contains two tandemly arrayed zinc-coordinating motifs 
[47]. Each zinc-coordinating motif chelates two zinc ions, through cysteine and histidine 
residues (Figure 1.2). Unlike classical DNA-binding zinc fingers, LIM domains appear to act 
solely as protein-protein interaction domains [45, 48]. Working with isolated LIM domains 
from LIM-HD and related LIM-only (Lmo) proteins has proved difficult to date, as 
recombinantly expressed forms of these proteins tend to aggregate when not in the presence 
of a binding partner, suggesting they may be obligate binding domains [49, 50].  
 
 
Figure 1.2: Structural schematic of a LIM domain, showing residues 
important for zinc ion coordination.  
 
The motif that has been found to most commonly interact with LIM domains from the LIM-
HD family of proteins is the LIM interaction domain (LID). The most ubiquitous of these is 
the LID found in LIM domain-binding protein 1 (Ldb1) [51]. Many structures of LIM-
HD/Lmo LIM domains in complex with a LID from Ldb1 or another protein have been 
published, revealing a very consistent binding mechanism, despite low levels of sequence 
conservation (Figure 1.3) [52-57]. Isolated LIDs tend to be intrinsically disordered, and fold 
upon binding to LIM domains [58]. When bound, the LID forms an extended structure, lying 
across the surface of the LIM domains, contributing an extra strand to the beta-sheets of the 
zinc binding modules that make up the LIM domains [53, 58]. The LID binding surface on 
the LIM domains is referred to as the peptide-binding interface [50]. 
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Figure 1.3: Structures of LIDs bound to LIM domains.  N- and C-termini are 
labelled N and C respectively. (A) Ldb1LID (yellow) bound to Lhx3LIM (blue) (PDB: 2JTN); 
(B) Isl1LID (salmon) bound to Lhx3LIM (blue) (PDB: 2RGT); (C) Ldb1LID (yellow) bound to 
Isl1LIM (salmon) (PDB: 4JCJ). Zinc ions are shown in grey.  
 
1.2.2.2 Conservation of the LIM domain 
LIM-HD proteins are the focus of this thesis, but there are many other proteins that contain 
LIM domains [48, 59]. There are an additional 13 families of LIM domain containing 
proteins, with diverse functions and subcellular localisations [48, 59, 60]. Many of these 
proteins are involved in regulating actin dynamics in the cytoskeleton, but several families 
can also translocate between the cytoskeleton and the nucleus, depending on their protein 
binding partners [59, 60]. LIM-HD proteins are conserved across metazoan (animals), but 
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some families of LIM domain containing proteins are conserved across filozoa (animals and 
their nearest unicellular relatives) [60]. 
 
1.2.2.3 Homeodomains 
The homeodomain is a highly conserved ~60 amino acid DNA-binding domain, found 
throughout the kingdom of animals, as well as in fungi and plants [46, 61-64]. It contains 
three helices that pack in a helix-turn-helix motif, with the third helix being the DNA-binding 
recognition helix (Figure 1.4) [65]. The N-terminal residues of the homeodomain also 
contribute to DNA binding, through interacting with the minor groove of the DNA (Figure 
1.4 B) [63]. These residues are disordered when not in complex with DNA [66]. 
 
 
Figure 1.4: Structure of a homeodomain bound to DNA. The homeodomain from 
LIM-HD protein Lhx4 is shown, bound to its consensus sequence. N- and C-termini are 
labelled N and C respectively (PDB: 5HOD). (A) Interaction between Helix 3 of the 
homeodomain and DNA. (B) Interaction between the N-terminal tail of the homeodomain 
and the minor groove of DNA. 
 
The majority of homeodomain structures available show the protein bound to DNA and were 
determined through the use of X-ray crystallography [67]. The presence of DNA can aid in 
crystallographic structure determination of this type of protein by providing a favoured 
conformation for the protein and facilitating packing in crystals, due to the opposing charges 
of the two macromolecules. 
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Homeodomains from different proteins tend to have very similar sequence preferences for 
DNA binding, due to their highly conserved structure and binding mechanism [68]. 
Generally, homeodomains target a TAATXX sequence, with the final two bases varying 
between individual homeodomains [69]. Electrostatic forces are the primary driving force for 
DNA binding by the recognition helix [70]. There is relatively little distortion of the DNA 
double helix upon homeodomain binding [63]. 
 
As homeodomains target sequences that are only six base pairs long, it is very common to 
observe homeodomain-containing proteins in higher order complexes with other DNA-
binding proteins, presumably to achieve specific binding of chromatin [66]. The LIM-HD 
family of proteins are a prime example of this, as they can make both protein-DNA and 
protein-protein interactions to form higher order transcriptional complexes. 
 
1.3 Isl1 
Islet-1 (Isl1) was first discovered in the pancreatic islets [44]. It was one of the first LIM 
domain containing proteins discovered, contributing to the naming of the domain along with 
two other LIM-HD proteins: lin-11 (LIM homeobox gene lin-11), Isl1, and mec-3 
(mechanosensory protein 3) [71]. In addition to the LIM domains and homeodomain, Isl1 
contains a C-terminal LID (Figure 1.5A) [44, 53, 58]. There is also a short glutamine-rich 
region immediately downstream of the homeodomain with no known function (not shown in 
Figure 1.5). 
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Figure 1.5: Structural features of Isl1.  (A) Schematic of domain organisation of Isl1. 
(B) Full ensemble of 50 models of the NMR solution structure of Isl1HD (PDB:1BW5). (C) 
Representative structure of Isl1HD (PDB: 1BW5). 
 
The solution structure of the homeodomain from Isl1 was determined by NMR (nuclear 
magnetic resonance) techniques (Figure 1.5B and 1.5C) [72]. This structure depicts Isl1HD in 
the absence of DNA. Regions normally involved in DNA binding (The N-terminus, as well as 
the C-terminal end of helix 3) appear more flexible in this structure than in homeodomain-
DNA structures (Figure 1.5B). Apart from these differences, Isl1HD shows a canonical 
homeodomain structure.  
 
Isl1 and its paralog Isl2 are the only LIM-HD proteins known to possess both a LID and a 
pair of LIM domains [53]. This combination potentially allows intramolecular LIM:LID 
binding to occur. Such an interaction could prevent non-specific, or weak, binding of the LIM 
domains to inappropriate partner proteins [54]. In this way, an extra layer of regulation may 
exist within Isl1/2, ensuring that only appropriate interactions occur in the cell. Structures 
that contain each of the LIM domains and the LID of Isl1 in complex with partner proteins 
have been determined (Figure 1.3B and 1.3C) [54, 58]. The presence of a LID in the 
sequence of Isl1 provides a second motif for interaction with other proteins, allowing 
formation of higher order transcriptional complexes. An example of this can be seen in the 
development of motor neurons, as discussed in detail in Section 1.4.1 [13]. 
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1.3.1 Conservation of Isl1 
Isl1 is highly conserved in animals, with well characterised homologs present in mice (100% 
identical to the human Isl1), Drosophila melanogaster (59% identical to the human Isl1) and 
Caenorhabditis elegans (38% identical to the human Isl1), as well as lesser characterised 
homologs in basal metazoan organisms [8, 73, 74]. An alignment of the human, D. 
melanogaster, and C. elegans sequences is shown in Figure 1.6. 
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Figure 1.6: Sequence alignment of Isl1 homologs.  Alignment generated using 
Praline [75]. 
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Very few genetic variants of Isl1 have been identified in humans. The majority of those 
observed are silent mutations, with only two producing a change in the amino acid sequence 
of the protein [76, 77]. The first, Q310X, is a mutation that was discovered in diabetes 
patients that results in the production of truncated Isl1 [77]. The C-terminal 40 amino acids 
are lost in this mutant, but there is no effect on the LIM domains, homeodomain, or LID. The 
effect of this mutation appears to be minimal, although it may contribute to a diabetic 
phenotype. The second mutation, R252S, was observed in cardiomyopathy patients. This 
substitution lies immediately C-terminal to the homeodomain, and some evidence suggests 
the mutant may activate transcription more potently [76]. 
 
1.4 The role of Isl1 in development 
Isl1 expression was detected in adult pancreatic, retinal, and neuronal tissues [44, 78, 79]. 
However, it is expressed in a wide variety of tissues during development, where its role has 
been more comprehensively characterised [80]. Isl1 is crucial for embryonic development; 
Isl1 knockout mice embryos exhibit arrested development at E9.5, followed by necrosis 
around E11.5 [10]. Further evidence for the early requirement of Isl1 is the presence of Isl1 
expression in the zebrafish as early as gastrulation, the stage at which cells differentiate into 
the endoderm, mesoderm, and ectoderm [81]. 
 
In most instances, Isl1 functions to promote the differentiation of tissues during development. 
In human embryonic stem cells, the promoter of Isl1 is occupied by transcription factors 
crucial for maintaining pluripotency: Oct4 (Octamer-binding protein 4), Sox2, and homeobox 
protein Nanog [5]. In such cells, expression of Isl1 is repressed by this trio of transcription 
factors. Aberrant expression of Isl1 is associated with several types of cancer, with both 
upregulation and downregulation of expression being observed [82-85]. Isl1 has roles in the 
development of many organs. Each of these roles has been characterised to varying extents, 
as discussed below. 
 
1.4.1 Isl1 in motor neuron development 
The action of Isl1 in the development of motor neurons is the most well understood of its 
roles. Indeed, Isl1 is the first molecular indicator of spinal motor neuron differentiation [86, 
87]. Motor neuron development begins with the formation of the floor plate in the embryonic 
neural tube (Figure 1.7). Shh (Sonic Hedgehog) is secreted in the notochord at the ventral end 
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of the neural tube, creating a signalling cascade that triggers the differentiation of these cells 
into the floor plate [88, 89]. These cells then secrete more Shh, in a second signalling cascade 
[90]. Meanwhile, BMP (bone morphogenic protein) cytokines are secreted at the dorsal end 
of the neural tube, [88]. The diffusion of these signalling proteins along the dorsoventral axis 
establishes a gradient that dictates the specification of cells along the length of the neural tube 
(Figure 1.7B) [88].  
 
 
Figure 1.7: Schematic of the developing notochord. (A) Concentration gradients of 
Sonic hedgehog (Shh) and bone morphogenic proteins (BMP) establish cell populations 
along the neural tube. (B) Differentiated identities of neural tube neurons. SN: sensory 
neurons; V0-3: ventral interneurons; MN: motor neurons. Figure based on Figure 8 from 
[88]. 
 
Cells destined to become V2 interneurons express Ldb1 and Lhx3 (LIM homeobox protein 3) 
[30, 91]. In the band of cells immediately ventral to this population, Isl1 expression is also 
induced, which is sufficient to redirect cell fate towards a ventral motor neuron identity [10, 
86, 92, 93]. The exact mechanism through which Isl1 expression is induced remains 
unknown, although Onecut proteins have been shown to be necessary for maintaining its 
expression, and Phox2a (Paired mesoderm homeobox protein 2A) binds to Isl1 enhancer 
elements in developing neurons [94, 95]. Direct Shh signalling represses expression of Isl1, 
indicating that intermediate transcription factors must be produced prior to induction of Isl1 
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expression [96]. As only a twofold difference in Shh concentration is required to result in Isl1 
expression, this additional level of regulation may be necessary to correctly direct Isl1 
expression [97]. 
 
In cells destined to become motor neurons, Isl1 forms a ternary transcriptional complex with 
Lhx3 and Ldb1 (Figure 1.8A) [98-100]. This complex is characterised by sets of LIM:LID 
interactions, the self-association of Ldb1, and homeodomain-DNA interactions. When Isl1 is 
absent, Lhx3 and Ldb1 form a binary complex, promoting the expression of genes that induce 
differentiation into V2 spinal interneurons (Figure 1.8B) [13].  
 
 
Figure 1.8: Schematics of LIM-HD neuronal transcriptional complexes.  (A) 
Ternary Lhx3/Isl1/Ldb1 complex formed in cells destined to become motor neurons. Isl1LID 
interacts with Lhx3LIM, Isl1LIM interacts with Ldb1LID, and the homeodomains from Isl1 and 
Lhx3 bind DNA. The Ldb1 self-association domain (SA) facilitates higher order complex 
formation. (B) Binary Lhx3/Ldb1 complex formed in cells destined to become V2 
interneurons, in which Lhx3LIM interacts with Ldb1LID. 
 
The evidence for the existence of these complexes comes primarily from in vivo experiments 
using various mutants and chimeras [93, 98, 101]. Although structural information is 
available, or can be inferred by homology, for the individual domains and the LIM:LID 
subcomplexes, questions remain about the assembly of the ternary complex and how the 
different complexes target different DNA sequences to direct development. 
 
1.4.1.1 DNA-binding of LIM-HDs in spinal neuron development 
It is known that the ternary complex targets sites with a CATTAXXXAAATTA consensus 
sequence [99]. This sequence was initially identified in the promoters of key downstream 
targets of the ternary complex, and was later confirmed as a consensus sequence through 
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SELEX (selective evolution of ligands by exponential enrichment) experiments [98, 99]. The 
individual binding preferences of Lhx3 and Isl1 have also been explored. Lhx3 has a 
preference for binding to TAATTA sites, and this sequence is also bound by Lhx4, as shown 
in the crystal structure of Lhx4 bound to DNA (Figure 1.4) [102, 103]. Two different 
consensus sequences have been determined for Isl1: CATTAG from SELEX [99], and 
TAATAT from in vitro promoter binding studies [104]. It was suggested that the DNA 
binding preferences of Isl1 depend on the protein binding partners it is associated with [105]. 
 
1.4.1.2 Downstream targets of the motor neuron ternary complex 
Several known downstream targets of the Isl1/Lhx3/Ldb1 motor neuron complex have been 
shown to be essential for the next step towards motor neuron development. Isl1 and Lhx3 are 
both targeted by the complex, generating a positive feedback loop [106]. The ternary 
complex also represses expression of Chx10 (Visual system homeobox 2), a protein that is 
important in further V2 interneuron development [107]. Promoted targets include mir-218, 
Lmo4 (LIM domain only protein 4), Stam1 (Signal transducing adapter molecule 1), and 
Mnx1 (Motor neuron and pancreas homeobox protein 1) [98, 106, 108-110]. Lmo4 is 
involved in modulating the formation of the ternary complex, by competing for binding to 
Ldb1 [106, 111]. Stam1 is involved in axonal projections, and Mnx1 has been shown to 
repress genes related to interneuron development, helping direct cells towards a motor neuron 
identity [112]. Stat3 (Signal transducer and activator of transcription 3) was identified as a 
coactivator and a potential binding partner of the Lhx3/Isl1/Ldb1 transcriptional complex 
[113]. 
 
1.4.2 Isl1 is necessary for correct heart development 
The role of Isl1 in heart development was discovered when mouse Isl1 deletion mutants were 
shown to have impaired vascular development, especially in the formation of the dorsal aorta 
[10]. These developmental defects were thought to be the cause of the embryonic lethality of 
the mutant mice. Upon further study, Isl1 expression was found to be necessary for the 
correct formation and survival of the outflow tract, right ventricle, and both atria of the heart 
[114, 115].  
 
Heart development is an extremely intricate process (comprehensively reviewed in [116, 
117]). During early development of the heart, two distinct cell populations are established in 
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the cardiac mesoderm, called the first and second heart fields. The first heart field consists of 
cells that begin to differentiate early, to initially form the cardiac crescent, which later 
becomes the linear heart tube (Figure 1.9). Second heart field cells differentiate later, 
migrating into the developing heart tube after its initial formation (Figure 1.9B). In the 
mature heart, the left ventricle is made primarily from first heart field cells, but most other 
structures originate from both first and second heart field cells [118, 119]. Isl1 expression is 
used as a marker of cells from the second heart field, as it is expressed in all second heart 
field cells [114, 120-122]. It has also been observed in some cells from the first heart field, 
but does not appear to be required for their development [123]. 
 
 
Figure 1.9: Early stages of heart development. The first (red) and second (yellow) 
heart fields are shown. (A) The cardiac crescent is formed from first heart field cells with 
second heart field cells located below it. (B) The cardiac crescent forms the heart tube. 
Second heart field cells (where Isl1 is expressed) migrate into this structure and begin to 
differentiate alongside first heart field cells, with both contributing to most mature heart 
tissues. Figure based on Figure 1 from [116] and Figure 1 from [124]. 
 
Differentiated heart tissue shows no Isl1 expression, indicating that Isl1 plays a role only 
during the development of the heart, and not in its ongoing function [114]. The exact role of 
Isl1 in heart development is still unclear, but various downstream and upstream effectors 
have been identified that can help to establish the role Isl1 is playing in these tissues. In 
contrast to motor neuron development, there is evidence that Isl1 acts upstream of Shh 
signalling during heart development [125]. 
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Mef2c (Myocyte-specific enhancer factor 2C) was found to be a direct target of Isl1 in the 
anterior heart field, the tissue that later contributes to the outflow tract and right ventricle of 
the developing heart [126]. Mef2c null mutant mice show an almost identical phenotype to 
Isl1 null mutants, indicating that the deletion of Isl1 could be exerting an affect primarily 
through the lack of expression of Mef2c [127]. An enhancer element has been identified that 
activates expression of Mef2c when bound by Isl1, Tbx20 (T-box transcription factor 20), 
and GATA zinc finger transcription factors [114, 126, 128]. Tbx20 has also been implicated 
in motor neuron development, potentially cooperating with Isl1 to induce expression of Mnx1 
and Isl2 [128]. Fgf10 (fibroblast growth factor 10) and Nkx2.5 (Homeobox protein Nkx-2.5) 
are direct targets of Isl1, in concert with GATA binding protein 4 (Gata4) and Tbx proteins 
[128-130]. A potential interaction between Isl1 and Jmjd3 (Lysine-specific demethylase 6B), 
a histone demethylase protein, may also promote expression of downstream targets [131]. 
 
The expression of Isl1 itself appears to be regulated in heart tissues by forkhead transcription 
factors [132]. An evolutionarily conserved enhancer element from the Isl1 gene was shown to 
contain multiple binding sites for several different forkhead transcription factors [132]. Other 
proteins that directly promote Isl1 expression in developing heart tissues are Octamer-binding 
protein 1 (Oct1), β-catenin, and Cbp/p300-interacting transactivator 2 (Cited2) [133-136]. 
Isl1 can interact with Cited2, further driving cardiac differentiation [136]. 
 
Recently, the Isl1/Ldb1 complex was demonstrated to be relevant to heart development [137]. 
Given the ability of Isl1 to simultaneously interact with two binding partners through both its 
LIM and LID domains, together with the absence of Lhx3 expression in the developing heart, 
an alternate binding partner could form a ternary transcription factor complex with Isl1 and 
Ldb1 that targets genes associated with heart development [138]. One potential binding 
partner could be from the Ajuba family of LIM domain proteins, which regulate Isl1 activity 
in developing heart cells [139]. 
 
1.4.3 Development of the pancreas requires Isl1 
As noted above (Section 1.3), the discovery of Isl1 in pancreatic islets gave the protein its 
name [44]. During embryonic development, the pancreas forms as two buds along the gut 
tube, one of the first endodermic structures formed in embryogenesis (Figure 1.10) [140]. A 
series of signalling cascades then assign three different cell types to the growing pancreas: 
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endocrine cells, exocrine cells, and duct cells [141, 142]. The endocrine cells differentiate 
further into different types of islet cells, which are responsible for secreting pancreatic 
hormones like insulin, glucagon, and somatostatin. 
 
 
Figure 1.10: Formation of the pancreas.  Along the gut tube (gold) the pancreas 
forms as two buds, one dorsal (aqua) and one ventral (blue). As embryogenesis progresses, 
rotation of the gut tube occurs, allowing the ventral and dorsal pancreatic buds to merge into 
one structure. 
 
Pancreatic Isl1 deletion embryos exhibited two main pancreatic abnormalities: malformed 
dorsal pancreatic mesenchyme, and an absence of glucagon-expressing islet cells in the 
dorsal pancreatic epithelium [143, 144]. Once born, these mutants also show a reduction in 
islet cells [144]. Further studies revealed that Isl1 plays an important role in differentiating 
islet cells, immediately after they exit the cell cycle [44, 78, 143]. There are conflicting 
reports as to whether Isl1 plays a role in the expansion of this cell population, or only its 
maintenance [145-148]. Functionally, Isl1 was shown to regulate glucagon expression in 
mature islet cells [104].  
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More details about the mechanisms of action of Isl1 in pancreatic development remain 
elusive. Shh was shown to play a role in pancreatic development, and it appears to be 
responsible for initiating Isl1 expression in the developing pancreatic islets [149]. This may 
indicate a similar mechanism for inducing Isl1 expression as the one found in the developing 
central nervous system (Section 1.4.1). 
 
Several potential downstream targets of Isl1 in pancreatic cells have been identified. Paired 
box protein 6 (Pax6), another homeodomain transcription factor required for both the 
development of islet cells and the production of glucagon, is not detected when Isl1 
expression is knocked down, and deletion of either Isl1 or Pax6 results in a similar phenotype 
[150, 151]. Isl1 can also bind to an enhancer of MafA, a key transcription factor involved in 
the downstream development of pancreatic endocrine tissue [144, 152].  
 
Several candidates for pancreatic binding partners of Isl1 have also been identified. These 
include Neurogenic differentiation factor 1 (NeuroD1) [153], Single-stranded DNA-binding 
protein 3 (Ssbp3) [154], Protein inhibitor of activated STAT protein gamma (Pias4) [155], 
Pancreas/duodenum homeobox protein 1 (Pdx1) and Histone-lysine N-methyltransferase 
SETD7 (Set7/9) [145], as well as Ldb1 [156, 157]. Whether or not these proteins all interact 
directly with Isl1 is not clear. For example, NeuroD1 was implicated as an Isl1 interaction 
partner involved in regulating insulin expression [153], but studies by other groups did not 
see the same result [154, 156]. There is more confidence in the role of Ldb1 acting with Isl1 
in the pancreas, with evidence that the two act to regulate MafA expression [156]. Ssbp3 is 
also likely to be a genuine interaction partner of the Isl1/Ldb1 complex, as an interaction 
between Ssbp proteins and Ldb1 within such complexes has already been well characterised; 
however it is unknown whether there is a direct interaction between Isl1 and any Ssbp protein 
[158-160].  
 
1.4.4 Brain development requires Isl1 
To date, characterising the role of Isl1 in brain development has proved difficult, due to the 
complexity of the organ. Isl1 has been determined to play a role in the development of 
several structures in the brain. These include the pituitary gland, striatum, hypothalamus, and 
thalamus (Figure 1.11) [78, 161, 162]. 
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Figure 1.11: Schematic of the adult brain.  Regions of Isl1 expression are labelled in 
black, with other brain structures labelled in grey for reference. Image adapted from “Brain 
human sagittal section” by Patrick J. Lynch, medical illustrator; C Carl Jaffe (MD), 
cardiologist. 
 
Low levels of expression of Isl1 were initially identified in the adult brain, specifically in the 
pituitary gland and other endocrine tissues [78]. Further studies have revealed that Isl1 plays  
a role in both hormone expression in the mature pituitary gland, and in pituitary development 
[163]. Shh signalling has been found in the developing pituitary gland, but it was later 
observed that removing the Shh signalling had no effect on Isl1 expression, indicating a 
different signalling cascade to that seen in developing motor neurons [164, 165]. 
Interestingly, Shh signalling can induce Lhx3 expression in the developing pituitary, and 
there is evidence that Isl1 and Lhx3 are co-expressed in this tissue for a brief period of time 
[29, 166, 167]. 
 
Isl1 is crucial for the development of cholinergic neurons in the striatum of the brain [168-
170]. Expression of Lhx6 and Lhx7/8 are required for correct development of these neurons, 
and evidence from co-immunoprecipitation and chromatin immunoprecipitation (ChIP) 
studies suggests that Lhx/Isl1/Ldb complexes contribute to this process [171, 172]. Beyond 
these studies, there is limited knowledge of downstream targets of such a ternary complex, 
where Lhx3 is substituted with Lhx6 or Lhx7/8. 
20 
 
The role of Isl1 in the developing thalamus is similarly under-characterised. In the developing 
thalamus, expression of several LIM-HD proteins, including Isl1, is required for correct 
development [173]. Isl1 is expressed in the hypothalamus as well, where it may play a role in 
modulating hormones [174, 175]. However, there is limited knowledge of binding partners of 
Isl1 in these tissues, how Isl1 expression is induced, and how Isl1 influences the 
transcriptional environment. 
 
1.4.5 Isl1 is involved in development of the kidney and urinary tract 
Expression of Isl1 in the kidney was first detected shortly after the initial discovery of Isl1. 
This expression was observed specifically in tubules proximal to the glomerulus in adult rats 
(Figure 1.12) [176]. It has only been recently that the role of Isl1 in renal tissues has been 
investigated. Conditional Isl1 knockout mutant mice displayed developmental defects in the 
kidney and urinary tract, indicating Isl1 plays a developmental role in these tissues [177, 
178].  
 
 
Figure 1.12: Schematics of the kidney.  (A) Structure of the kidney and its connection 
to the ureter. (B) Schematic of a nephron. 
 
Isl1 expression was observed in developing tissues between E10.5 and E14.5, and when this 
expression was not present, Bone morphogenic protein 4 (Bmp4) levels were reduced [177]. 
Bmp4 plays a major role in development of the kidneys and urinary tract, and deletion of 
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Bmp4 results in a phenotype similar to that of Isl1 deletion [177, 179, 180]. It is likely that 
Isl1 stimulates Bmp4 expression in the developing kidney and urinary tract. Recently this 
stimulation was observed in developing genital tissue, where Isl1 was demonstrated to 
promote expression of Bmp4, Fgf10, and Wnt5a [181]. All three of these proteins form 
components of major developmental signalling cascades that could drive the differentiation 
of this tissue. 
 
1.4.6 Isl1 in the developing retina 
Isl1 expression was initially detected in the adult retina and was later detected in developing 
retinal cell populations [79, 175, 182, 183]. In these cells, Isl1 has been shown to act in 
combination with the homeodomain protein POU domain, class 4, transcription factor 2 
(Pou4f2) [184, 185]. Isl1 is necessary for maintaining the expression of Pou4f2, and the two 
proteins form complexes to regulate expression of genes relevant for retinal ganglion 
differentiation [186, 187]. 
 
1.4.7 Other roles of Isl1 in development 
Many additional instances of Isl1 influencing development (Table 1.2) have not been 
explored in as much depth as those discussed above. Note that in many cases it has not been 
established whether the regulatory relationships listed in Table 1.2 are direct or indirect. 
 
Table 1.2: Expression of Isl1 in development of a multitude of other tissues.  
Tissue  Role Knockout 
phenotype 
Targets of Isl1 
regulation 
Isl1 expression 
regulated by 
References 
Ear Inner ear 
development 
- - Lmo4 [188-190] 
Gut Expressed in 
stomach and 
intestinal 
cells 
Impaired lipid 
absorption, and 
glucose 
homeostasis 
- Foxa1, Foxa2  
 
[191-193] 
Jaw Growth of 
the lower jaw 
Extremely 
misshapen lower 
jaw 
Wif1, Dkk1  
Dkk2, β-
catenin 
Bmp4 [194-196] 
Limbs Hindlimb 
development 
Severe 
malformation of 
the hindlimb 
β-catenin - [195, 197] 
Muscle Head muscle 
development 
- - Bmp4 [198] 
Teeth Tooth type 
specification 
- Bmp4 Bmp4 [196, 199] 
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1.5 Known binding partners of Isl1 
Isl1 can be found associated with many different protein binding partners across different 
tissues, as discussed above. In many cases, it has not been established whether these 
interactions are direct protein-protein interactions, indirect interactions bridged by other 
proteins, or indirect interactions facilitated through DNA-binding. Summarised in Table 1.3 
are the most well-described binding partners of Isl1, and the tissues in which they interact. 
 
Table 1.3: Known protein interaction partners of Isl1.  
Binding partner Tissue of interaction References 
Lhx3 Developing spinal motor neurons [93, 99] 
Ldb1 Developing spinal motor neurons 
Developing heart tissue 
Pancreas 
[99] 
[137] 
[156, 157] 
Phox2a Developing cholinergic neurons (brain) [105] 
Pou4f2 Developing retina [187] 
Stat3 Developing spinal motor neurons 
Non-Hodgkin lymphoma 
[113, 200] 
[201] 
c-Jun Non-Hodgkin lymphoma [201] 
Tbx20 Developing heart 
Developing motor neurons 
[128] 
Ssbp3 Pancreas [154] 
Cited2 Developing heart [136] 
Pdx1 Developing pancreas [145] 
Set7/9 Developing pancreas [145] 
 
  
23 
 
1.6 Alternative forms of Isl1 
1.6.1 Isl1-β 
An isoform of Isl1, named Isl1-β, lacks residues 256-278, meaning it is missing the first 17 
residues of the LID [202]. The role of this isoform has yet to be elucidated. It is likely to be 
unable to form higher order complexes through the binding of the LID, which would affect 
many functions of Isl1, but this has not yet been investigated in depth. 
 
1.6.2 Phosphorylation of Isl1 
The same study that identified Isl1-β also identified a phosphorylation site in the sequence of 
Isl1 [202]. However, it remains to be seen if there is a specific phosphorylation site on Isl1 
that is relevant to its function. Additionally, the role of this modification has yet to be 
elucidated, though there is evidence it plays a role in insulin production in the liver [203]. 
 
1.6.3 Isl2 
As mentioned in Section 1.2.1, all mammals possess a paralogue of Isl1 called Isl2. Isl2 is 
very similar to Isl1 in terms of sequence and function, with the two murine sequences being 
72% identical [57]. The high degree of conservation between the two paralogues makes it 
difficult to study them independently, as most antibodies targeted to one paralogue will 
recognise both [30, 204]. The most distinct difference observed between the two paralogues 
is their expression patterns. For example, Isl2 is expressed later than Isl1 in motor neuron 
development [205], exhibits more prolonged expression during inner ear development [206], 
and is expressed in different areas of the developing mouse retina [207]. 
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1.7 Aims of this thesis 
As discussed in Section 1.4, Isl1 is necessary for the correct development of many different 
tissues, but in most cases there is little molecular insight into how the protein functions. This 
is especially the case with the many potential binding partners of Isl1 reported in the 
literature, where there is a lack of evidence to indicate whether interactions are direct, or 
mediated by DNA and/or other proteins. However, it is clear that the interplay of protein-
protein and protein-DNA interactions act to help Isl1 fulfil a function in a variety of different 
cellular contexts. By characterising the protein-protein and protein-DNA interactions Isl1 can 
make, this thesis aims to further our understanding of how Isl1 can fulfil such a broad range 
of functions, in temporally and spatially distinct settings.  
 
In order to do this, two broad aims were defined. Firstly, to search for novel direct protein 
binding partners of Isl1. Chapter 3 describes efforts to achieve this through the use of yeast 
two-hybrid library screening. Chapter 4 then analyses the potential binding partners 
identified, assessing the likelihood of the identified interactions being biologically relevant to 
the known functions of Isl1. 
 
The second broad aim was to investigate the molecular mechanisms associated with the 
DNA-targeting of the Lhx3/Isl1/Ldb1 ternary complex. Chapter 5 explores the DNA-binding 
behaviour of the Isl1 and Lhx3 homeodomains both in isolation and in combination. Chapter 
6 then pursues the structural characterisation of the Isl1/Lhx3 DNA-binding complex. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
A complete index of all chemicals and reagents referred to in this thesis can be found in 
Table 2.1. All solutions were prepared in ultrapure MilliQ
®
 water (MQW), unless otherwise 
specified. 
 
Table 2.1: Chemicals and reagents used throughout this thesis. 
Material Manufacturer 
(+/−)-2-Methyl-2,4-pentanediol (MPD) Hampton Research (Aliso Viejo, CA) 
1,6-hexanediol Sigma-Aldrich (St Louis, MO) 
25:24:1 phenol:chloroform:isoamyl alcohol Sigma-Aldrich (St Louis, MO) 
2-log ladder DNA ladder New England BioLabs (Ipswich, MA) 
3-amino-1,2,4-triazole (3-AT) Sigma-Aldrich (St Louis, MO) 
4-(2-hydroxylethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Biochemicals.com.au (Gymea, NSW) 
4,4-dimethyl-4-silapentane-1-sulfonic acid 
(DSS) 
Sigma-Aldrich (St Louis, MO) 
5-bromo-4-chloro-3-indolyl-α-D-
galactopyranoside (X-α-gal) 
Gold Bio Technology (St Louis, MO) 
Acetic acid Chem-Supply (Port Adelaide, SA) 
Acrylamide/Bis acrylamide 29:1, 40% w/v Biochemicals.com.au (Gymea, NSW) 
Adenine hemisulfate Sigma-Aldrich (St Louis, MO) 
Agarose Amyl Media (South Dandenong, VIC) 
Ammonium chloride (NH4Cl) Ajax Finechem (Taren Point, NSW) 
Ammonium persulfate Sigma-Aldrich (St Louis, MO) 
Ampicilin sodium salt Gold Bio Technology (St Louis, MO) 
Arginine Sigma-Aldrich (St Louis, MO) 
Barium chloride Merck (Darmstadt, Germany) 
2-(Bis(2-hydroxyethyl)amino)acetic acid 
(Bicine) 
Sigma-Aldrich (St Louis, MO) 
2-[Bis(2-hydroxyethyl)amino]-2- Amresco (Solon, OH) 
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(hydroxymethyl)propane-1,3-diol (Bis-Tris) 
β-mercaptoethanol Sigma-Aldrich (St Louis, MO) 
Boric Acid Sigma-Aldrich (St Louis, MO) 
Bolt
TM
 4-12% polyacrylamide gels Thermo Fisher Scientific (Waltham, MA) 
Bovine serum albumin (BSA) (acetylated) Sigma-Aldrich (St Louis, MO) 
Bovine serum albumin (BSA) (monomeric) Sigma-Aldrich (St Louis, MO) 
Bromophenol blue Sigma-Aldrich (St Louis, MO) 
Calcium chloride (CaCl2) Univar (Downers Grove, IL) 
Carbenicilin sodium salt Gold Bio Technology (St Louis, MO) 
Choramphenicol Gold Bio Technology (St Louis, MO) 
Complete supplement media (CSM) MP biomedical (Santa Ana, CA) 
cOmplete
TM
 EDTA-free protease inhibitor Sigma-Aldrich (St Louis, MO) 
Coomassie Brilliant Blue R-250 Life Technologies (Carlsbad, CA) 
Deoxyribonucleotide triphosphates (dNTPs) Boehringer Mannheim (Mannheim, 
Germany) 
Deuterium oxide (D2O) Sigma-Aldrich (St Louis, MO) 
D-Glucose Chem-Supply (Port Adelaide, SA) 
Difco yeast extract Bacto Laboratories (Mt Pritchard, NSW) 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (St Louis, MO) 
Disodium hydrogen phosphate (Na2HPO4) Ajax Finechem (Taren Point, NSW) 
Dithiothreitol (DTT) Gold Bio Technology (St Louis, MO) 
Ethanol Chem-Supply (Port Adelaide, SA) 
Ethylene ditetraacetic acid (EDTA) Ajax Finechem (Taren Point, NSW) 
Ficoll Sigma-Aldrich (St Louis, MO) 
Glass beads (5 mm diameter) Sigma-Aldrich (St Louis, MO) 
Glutathione Sepharose 4B resin GE Healthcare (Chicago, IL) 
Glycerol Chem-Supply (Port Adelaide, SA) 
Guanidine hydrochloride Biochemicals.com.au (Gymea, NSW) 
Hexammine cobalt chloride Sigma-Aldrich (St Louis, MO) 
Histidine Sigma-Aldrich (St Louis, MO) 
HydraGreen
TM ACTGene (Piscataway, NJ) 
Hydrochloric acid Univar (Downers Grove, IL) 
Igepal CA-630 Sigma-Aldrich (St Louis, MO) 
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Immobilon Western Chemiluminescent HRP 
substrate 
Merck (Darmstadt, Germany) 
Isoleucine Sigma-Aldrich (St Louis, MO) 
Isopropanol Univar (Downers Grove, IL) 
Isopropyl β-D-thiogalactopyranoside (IPTG) Progen (Heidelberg, Germany) 
Leucine Sigma-Aldrich (St Louis, MO) 
Lithium acetate (LiAc) Ajax Finechem (Taren Point, NSW) 
Lysine Sigma-Aldrich (St Louis, MO) 
Magnesium chloride (MgCl2) Ajax Finechem (Taren Point, NSW) 
Magnesium sulfate (MgSO4) Ajax Finechem (Taren Point, NSW) 
Manganese chloride (MnCl2) Sigma-Aldrich (St Louis, MO) 
Mark12
TM
 protein standard Thermo Fisher Scientific (Waltham, MA) 
MES (2-ethanesulfonic acid) powder Sigma-Aldrich (St Louis, MO) 
MES (2-ethanesulfonic acid) buffer  20 × Thermo Fisher Scientific (Waltham, MA) 
Methanol Chem-Supply (Port Adelaide, SA) 
Methionine Sigma-Aldrich (St Louis, MO) 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich (St Louis, MO) 
NuPAGE
®
 LDS Sample buffer (4X) Sigma-Aldrich (St Louis, MO) 
Peptone Affymetrix (Santa Clara, CA) 
Phenylalanine Sigma-Aldrich (St Louis, MO) 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich (St Louis, MO) 
Piperazine-N,N′-bis(2-ethanesulfonic acid) 
(PIPES) 
Sigma-Aldrich (St Louis, MO) 
Polyethylene glycol, MW 3350 (PEG 3350) Sigma-Aldrich (St Louis, MO) 
Polyethylene glycol, MW 4000 (PEG 4000) Hampton Research (Aliso Viejo, CA) 
Polyethylene glycol, MW 8000 (PEG 8000) Thermo Fisher Scientific (Waltham, MA) 
Polyethylimine (PEI) 50% solution Sigma-Aldrich (St Louis, MO) 
Polyethylimine (PEI) Mw 25,000, 
Transfection Grade 
Polysciences Inc (Warrington, PA) 
Potassium acetate Merck (Darmstadt, Germany) 
Potassium chloride (KCl) Ajax Finechem (Taren Point, NSW) 
Potassium dihydrogen phosphate (KH2PO4) Chem-Supply (Port Adelaide, SA) 
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Proline Sigma-Aldrich (St Louis, MO) 
Salmon sperm DNA Sigma-Aldrich (St Louis, MO) 
Skim milk powder Woolworths (Bella Vista, NSW) 
Sodium cacodylate Sigma-Aldrich (St Louis, MO) 
Sodium chloride (NaCl) Chem-Supply (Port Adelaide, SA) 
Sodium dihydrogen phosphate (NaH2PO4) Ajax Finechem (Taren Point, NSW) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (St Louis, MO) 
Sodium hydroxide (NaOH) Univar (Downers Grove, IL) 
Spermine tetrahydrochloride Sigma-Aldrich (St Louis, MO) 
Streptactin HRP (horseradish peroxidase) 
conjugate 
BioRad (Hercules, CA) 
Strontium chloride Sigma-Aldrich (St Louis, MO) 
SYPRO
TM
 Ruby Protein Gel Stain Thermo Fisher Scientific (Waltham, MA) 
Thiamine Sigma-Aldrich (St Louis, MO) 
Threonine Sigma-Aldrich (St Louis, MO) 
2-Amino-2-(hydroxymethyl)propane-1,3-diol 
(Tris) 
Chem-Supply (Port Adelaide, SA) 
tris(2-carboxyethyl)phosphine (TCEP) Soltec Biosciences (Gloucester, MA) 
Triton X-100 Sigma-Aldrich (St Louis, MO) 
Tryptone T Oxoid (Hampshire, England) 
Tryptopan Sigma-Aldrich (St Louis, MO) 
Tween-20 Amresco (Solon, OH) 
Tyrosine Sigma-Aldrich (St Louis, MO) 
Uracil Sigma-Aldrich (St Louis, MO) 
Valine Sigma-Aldrich (St Louis, MO) 
WesternC
TM
 protein standard BioRad (Hercules, CA) 
Yeast Extract Affymetrix (Santa Clara, CA) 
Yeast nitrogen base Bacto Laboratories (Mt Pritchard, NSW) 
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2.1.2 Enzymes 
All enzymes were used with the buffers provided by the manufacturer, and used according to 
manufacturers’ instructions. 
 
Table 2.2: Enzymes used throughout this thesis. 
Enzyme Manufacturer 
BamHI EC 3.1.21.4 New England BioLabs (Ipswich, MA) 
Dnase I EC 3.1.21.1 Sigma-Aldrich (St Louis, MO) 
DpnI EC 3.1.21.4 New England BioLabs (Ipswich, MA) 
EcoRI EC 3.1.21.4 New England BioLabs (Ipswich, MA) 
HRV-3C protease EC 3.4.22.28 Mackay & Matthews laboratory, University of 
Sydney 
Lysozyme EC 3.2.1.17 BioMatik (Cambridge, Ontario) 
Lyticase EC 3.2.1.4 Sigma-Aldrich (St Louis, MO) 
Phusion DNA polymerase EC 2.7.7.7 Dr Jason Low, University of Sydney 
QuickStick DNA ligase EC 6.5.1.1 Bioline (London, UK) 
RNase A EC 3.1.27.5 Sigma-Aldrich (St Louis, MO) 
RNase (DNase free) EC 3.1.27.5 Thermo Fisher Scientific (Waltham, MA) 
 
2.1.3 Media 
A full list of media used in this project can be found in Table 2.3. Luria-Bertani broth (LB) 
and yeast peptone dextrose broth (YPD) were prepared in distilled water; all other media 
were prepared in MilliQ
®
 water. All media were sterilised by autoclaving before use. Sterile 
glucose was prepared and autoclaved separately, and added to media after autoclaving where 
appropriate. For solid media, agarose was added to a final concentration of 1.5% w/v.  
 
EXPI293™ expression medium was purchased as a complete media (Life Technologies; 
Carlsbad, CA). 
 
Table 2.3: Media used throughout this thesis. 
Media Components 
LB 1% w/v peptone, 0.5% w/v yeast extract, 0.5% w/v NaCl 
SOC media 2% w/v tryptone, 0.5% w/v yeast extract, 2 mM NaCl, 2 
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mM KCl, 2 mM MgCl2, 2 mM MgSO4, 0.4% w/v 
glucose 
M9-L minimal medium 0.4% w/v glucose, 30 mg/L isoleucine, 150 mg/L valine, 
20 mg/L arginine, 30 mg/L lysine, 20 mg/L methionine, 
50 mg/L phenylalanine, 200 mg/L threonine, 30 mg/L 
tyrosine, 20 mg/L uracil, 20 mg/L histidine, 20 mg/L 
tryptophan, 20 mg/L adenine, 40 mg/L proline, 10 mg/L 
thiamine, 2 mM MgSO4, 0.1 mM CaCl2, 50 mM 
Na2HPO4, 25 mM KH2PO4, 1 mM NaCl, 20 mM NH4Cl 
YPD 2% w/v tryptone, 1% w/v yeast extract, 2% w/v glucose, 
0.2% w/v adenine 
Synthetic dextrose broth (SD) 0.65% w/v yeast nitrogen base, 0.4% w/v glucose, 1 × 
CSM 
EXPI293™ expression medium Gibco™ EXPI293™ expression medium (Thermo Fisher 
Scientific; Waltham, MA) 
 
20 µg/mL X-α-gal and additional nutrients were added to SD media as required. Additional 
components are listed in Table 2.4. 
 
Table 2.4: Additional nutrients present in selective yeast media. 
Media Additional components 
SD-L 2 g/L adenine, 2 g/L histidine, 2 g/L tryptophan 
SD-W 2 g/L adenine, 2 g/L histidine, 10 g/L leucine 
SD-L-W 2 g/L adenine, 2 g/L histidine 
SD-L-W-H 2 g/L adenine 
SD-L-W-H+0.5 mM 3-AT 2 g/L adenine, 0.5 mM 3-AT 
SD-L-W-H+2 mM 3-AT 2 g/L adenine, 2 mM 3-AT 
SD-L-W-H-A  None 
 
2.1.4 Oligonucleotides and plasmids 
Single-stranded oligonucleotides used for cloning and DNA binding studies were synthesised 
by IDT (Integrated DNA Technologies; Coralville, IA). A list of all oligonucleotides used for 
binding studies can be found in Appendix A. All oligonucleotides used for binding studies 
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were annealed to a complementary strand through heating to 90 °C for 10 min, followed by 
gradual cooling. 
 
The yeast plasmids used throughout this project were pGAD10 (LEU2, ampR) (BD 
Biosciences Clontech; Mountain View CA), pGADT7-RecAB (LEU2, ampR) (BD 
Biosciences Clontech;  Mountain View, CA) and NpGBT9 (TRP1, ampR or kanR) (Professor 
Merlin Crossley, University of Sydney). NpGBT9 is a derivative of pGBT9, in which the 
EcoRI and BamHI cut sites in the multiple cloning site have been swapped. Throughout this 
work, NpGBT9 will be referred to as pGBT9. 
 
Bacterial expression was conducted using a modified pMAL vector (Dr Ivan Nisevic, 
University of Sydney) or a modified pET-DUET vector (Herman Fung, University of 
Sydney). The pMAL vector encodes an MBP (maltose binding protein) tag with a 
downstream factor Xa cleavage site immediately upstream of the multiple cloning site. The 
modified pET-DUET vector encodes a GST (glutathione S-transferase) tag with a 
downstream HRV-3C cleavage site immediately upstream of the first multiple cloning site. 
Protein-encoding DNA fragments were subcloned into only the first multiple cloning site.  
 
pcDNA3.1, encoding either an N-terminal FLAG or HA tag, was used for all work in 
mammalian cells (Dr Jason Low, University of Sydney). The amino acid sequences of protein 
fusion tags can be found in Appendix B.  
 
2.1.5 Antibodies and peptides 
Antibodies used throughout this thesis are listed in Table 2.5. 
 
Table 2.5: Antibodies used throughout this thesis. 
Antibody Manufacturer Concentration used 
Rabbit α-FLAG mAb-HRP Cell Signaling Technology 
(Danvers, MA) 
1:4000 
Mouse α-HA mAb-HRP Cell Signaling Technology 
(Danvers, MA) 
1:40000 
 
Additionally, 3×FLAG peptide (APExBio; Houston, TX) was used during FLAG affinity 
purification. The sequence of this peptide is: MDYKDHDGDYKDHDIDYKDDDDK. 
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2.1.6 Organisms 
Table 2.6 lists the genotypes of bacteria and yeast used throughout this work. DH5α cells 
were used for cloning and plasmid propagation; HB101 cells were used for isolation of yeast 
plasmids and plasmid propagation; BL21 Gold (DE3) cells were used for protein expression.  
Escherichia coli (E. coli) strains were maintained in sterile LB media. Saccharomyces 
cerevisiae (S. cerevisiae) strains were maintained in YPD media. 
 
Table 2.6: Organism strain genotypes.  
Species Organism strain Genotype 
S. cerevisiae AH109 (BD Biosciences 
Clontech; Mountain View, CA) 
MATa, trp1-901, leu2-3, 112, ura3-52, 
his3-200, gal4Δ, gal80Δ, 
LYS2∷GAL1UAS-GAL1TATA-HIS3, 
GAL2UAS-GAL2TATA-ADE2, 
URA3∷MEL1UAS-MEL1TATA-lacZ, 
MEL1 
S. cerevisiae Y187 (BD Biosciences Clontech; 
Mountain View, CA) 
MATα, ura3-52, his3-200, ade2-101, 
trp1-901, leu2-3, 112, gal4Δ, met–, 
gal80Δ, URA3::GAL1UAS-GAL1TATA-
lacZ 
E. coli DH5α (Bethesda Research 
Laboratories, Gaithersburg, MD) 
F
–, Φ80lacZΔM15, Δ(lacZYA-argF), 
U169, recA1, endA1, hsdR17, (rK–, 
mK+), phoA, supE44, λ–, thi-1, 
gyrA96, relA1 
E. coli BL21 Gold (DE3) (Integrated 
Sciences, Chatswood, NSW) 
F
–
, ompT, hsdSB(rB–, mB–), gal, dcm, 
(DE3) 
E. coli Rosetta™ 2 (DE3) (Merck; 
Darmstadt, Germany) 
F
-
, ompT, hsdSB(rB
-
 mB
-
), gal, dcm, 
pRARE2 (Cam
R
), (DE3) 
E. coli HB101 (CGC, University of 
Minnesota) 
F
-
, mcrB, mrr, hsdS20(rB
-
 mB
-
), recA13, 
leuB6, ara-14, proA2, lacY1, galK2, 
xyl-5, mtl-1, rpsL20(Sm
R), glnV44, λ- 
 
A pre-transformed Mate & Plate Universal Mouse yeast library (Clontech; Mountain View, 
CA) was used for yeast two-hybrid mating screens. 
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Suspension-adapted HEK (human embryonic kidney) Expi293F
TM
 cells (Thermo Fisher 
Scientific; Waltham, MA) were used for mammalian cell work. 
 
2.2 Cloning 
All constructs produced during this thesis were sequenced at the Australian Genome 
Research Facility (Westmead, NSW) to confirm the correct sequence was present. A list of 
sequencing primers used can be found in Appendix C. Throughout this thesis, a slash will be 
used to signify protein fusions, with a colon being used to represent specific protein-protein 
or protein-DNA interactions. 
 
2.2.1 Gibson cloning 
Gibson cloning was used to produce new protein constructs or edit vectors (Table 2.7). 
 
Table 2.7: Constructs produced through Gibson cloning.  
Vector Insert Purpose 
pGBTK9 kanR Changing ampicillin resistance to kanamycin 
resistance (Section 2.3.3) 
pGBT9 LIMK1LIM Yeast two-hybrid analysis 
pGBT9 LIMK2LIM Yeast two-hybrid analysis 
pcDNA3.1-FLAG Isl1LIM Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Isl1∆LIM Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Isl1FL Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Ldb1LID/Isl1LIM Mammalian co-immunoprecipitation 
pcDNA3.1-HA Isl1LIM Mammalian co-immunoprecipitation 
pcDNA3.1-HA Isl1∆LIM Mammalian co-immunoprecipitation 
pcDNA3.1-HA Isl1FL Mammalian co-immunoprecipitation 
pcDNA3.1-HA Ldb1LID/Isl1LIM Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1FL Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1ND Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1NL Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1NK Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1LC Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1CC Mammalian co-immunoprecipitation 
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pcDNA3.1-FLAG Mkln1KC Mammalian co-immunoprecipitation 
pcDNA3.1-FLAG Mkln1FC Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1FL Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1ND Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1NL Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1NK Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1LC Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1CC Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1KC Mammalian co-immunoprecipitation 
pcDNA3.1-HA Mkln1FC Mammalian co-immunoprecipitation 
pGADT7-RecAB Mkln1FL Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1ND Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1NL Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1NK Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1LC Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1CC Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1KC Yeast two-hybrid analysis 
pGADT7-RecAB Mkln1FC Yeast two-hybrid analysis 
 
2.2.1.1 Polymerase chain reaction (PCR) 
Phusion polymerase was used for all PCRs. PCRs were conducted in Phusion buffer (10 mM 
Tris-HCl (pH 8.8), 50 mM KCl, 2.5 mM MgSO4, 0.1% Triton X-100, 0.2 mg/mL BSA), with 
0.5 µM forward and reverse primers, 0.5 mM dNTPs, and 37.5-75 ng template DNA. PCRs 
were conducted using a Biometra T3000 Thermocycler (Analytik Jena; Jena, Germany). 
PCRs were run for 35 cycles, using the following program: denaturation at 98 °C (15 s), 
annealing at 65 °C (20 s), extension at 72 °C (30 s/kb amplicon). 
 
2.2.1.2 PCR product purification 
After PCR, reaction mixtures were purified using an ISOLATE II PCR and Gel Kit (Bioline; 
London, UK). Samples were incubated with 10 mU DpnI to ensure removal of parental DNA, 
in CutSmart
®
 buffer (New England Biolabs; Ipswich, MA). Reactions were incubated for 1-
4 h at 37 °C.  
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2.2.1.3 Ligation 
Gibson assembly [208] was used to ligate amplified products into vectors. These reactions 
contained 50 ng vector, with threefold molar equivalents of insert. To this mixture was added 
Gibson Assembly Master Mix (New England Biolabs; Ipswich, MA). Reactions were 
incubated for at 50 °C, 4 h, in a Biometra T3000 Thermocycler, before being transformed 
into competent DH5α E. coli (Section 2.5.1). 
 
2.2.2 Restriction cloning 
Restriction cloning was used to subclone already cloned constructs into new vectors 
(Table 2.8). 
 
Table 2.8: Constructs produced through restriction cloning . 
Source Vector Destination Vector Insert 
pGAD10 pET-DUET LLHD1 
pGEX pET-DUET 2HDLL 
pGEX pET-DUET 2HDN 
pGEX pET-DUET NHD1 
pGEX pET-DUET NHD3 
pGEX pET-DUET LLHD3 
pGBT9 pGBTK9 Isl1LIM 
pGBT9 pGBTK9 Isl1∆LIM 
 
Source and destination vectors were digested by incubating the appropriate plasmids in 
CutSmart
®
 buffer with 20 U each of high fidelity BamHI and EcoRI (New England Biolabs; 
Ipswich, MA). These reactions were incubated for 4 h at 37 °C. 
 
Digested DNA was run on a 1.5% w/v agarose gel, supplemented with HydraGreen
TM
 
(1:60,000), made in TAE buffer (40 mM Tris pH 8.0, 20 mM acetic acid, 1 mM EDTA) for 
35 min, before desired species were visualised, excised, and purified using the ISOLATE II 
PCR and Gel Kit (Bioline; London, UK). Inserts were ligated into the desired destination 
vectors using Quick-Stick ligase (Bioline; London, UK). Vector and insert were combined in 
the provided buffer at both a 1:6 and a 1:3 ratio before enzyme was added. Reactions were 
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incubated for 30 min to allow ligation to occur. This reaction mix was used for 
transformations into DH5α E. coli cells (Section 2.5.1). 
 
2.3 Yeast handling procedures 
2.3.1 Preparation and transformation of competent yeast 
Yeast competency and transformation protocols were already established in the Matthews 
laboratory [209, 210]. AH109 yeast were grown in rich YPD media overnight with shaking 
(150 rpm) at 30 °C. Cells were pelleted by centrifugation (5 min, 1000 × g, room 
temperature). Cells were washed in 25 mL MQW, before being subjected to centrifugation (5 
min, 1000 × g, room temperature). Supernatant was removed, and cells resuspended in 
competency buffer (10 mM Tris (pH 8.0), 1 mM EDTA, 100 mM LiAc (pH 7.5)), in 
preparation for transformations. 
 
An aliquot of competent yeast (100 μL) was added to plasmid DNA (1 μL of each plasmid to 
be transformed or co-transformed, at a typical concentration of 500 ng/μL for each plasmid) 
and carrier salmon sperm DNA (10 μL). Sterile PEG/LiAc solution (600 μL; 10 mM Tris 
(pH 8.0), 40% PEG 4000, 100 mM LiAc, 1 mM EDTA) was added and the solution mixed 
gently. This mixture was incubated for 30 min with shaking (150 rpm) at 30 °C, before 
DMSO (70 μL) was added. Cells were heat shocked for 15 min at 42 °C, being mixed gently 
every 5 min. Following this, cells were chilled on ice water for 2 min. The mixture was 
subjected to centrifugation (5 min, 2000 × g, 4 °C), and the supernatant removed. The cell 
pellet was resuspended in resuspension buffer (300 μL; 10 mM Tris pH 8.0, 1 mM EDTA). 
This mixture was inoculated onto selective media appropriate for the plasmids being 
transformed (see Section 2.1.3 for complete media formulation): 
 SD-L, SD media with no leucine supplementation, for transformations with 
pGAD10/pGADT7-RecAB. 
 SD-W, SD media with no tryptophan supplementation, for transformations with 
pGBT9. 
 SD-L-W, SD media with no leucine or tryptophan supplementation, for co-
transformations with one pGBT9 plasmid and one of pGAD10 or pGADT7-RecAB 
plasmid. 
Plates were incubated for 65-72 h at 30 °C before being scored for colonies. 
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For high throughput applications, yeast transformations were carried out in sterilised 96-well 
plates, with a well volume of 2 mL. All the transformation solutions used were halved in 
volume, with two exceptions: the plasmid DNA, which was kept the same as in the original 
transformation protocol, and the final resuspension volume, which was increased to 750 µL 
per sample. An aliquot (50 μL) of this suspension was inoculated onto appropriate agar 
prepared in 24-well tissue culture plates. Plates were allowed to dry for 1-2 h under a bunsen 
burner flame after inoculation, to reduce the amount of residual liquid present. They were 
then incubated for 65-72 h at 30 °C before being scored for colonies. 
 
2.3.2 Yeast two-hybrid spot test assays 
Yeast two-hybrid spot test assay protocols were already established in the Matthews 
laboratory [209, 210]. Transformed yeast were grown overnight with shaking (150 rpm) at 
30 °C in selective SD-L-W media (1 mL). Cell densities were normalised using the optical 
density of the solution at 600 nm with a 1-cm pathlength (OD600). Two 1-in-10 serial 
dilutions were prepared from the normalised cell suspension, resulting in solutions with 
OD600 values of 0.2, 0.02 and 0.002. Aliquots (2 μL) of each sample were spotted onto each 
selection condition, as well as growth control SD-L-W plates. Selection conditions used from 
least to most stringent included: 
 SD-L-W-H  
 SD-L-W-H+0.5 mM 3-AT  
 SD-L-W-H+1 mM 3-AT  
 SD-L-W-H+2 mM 3-AT  
 SD-L-W-H+5 mM 3-AT 
 SD-L-W-H-A 
 
Section 2.1.3 contains full compositional details of these media (Table 2.4). 
 
2.3.3 Mating library screens 
Library mating screens were performed as laid out in the Clontech Matchmaker
®
 Gold Yeast 
Two-Hybrid System User Manual [211]. Briefly, AH109 yeast transformed with the selected 
bait plasmid were grown overnight, before being added to an aliquot (1 mL) of Y187 library 
yeast resuspended in fresh 2 × YPD media. This mix was incubated for 24 h at 30 °C with 
shaking (40 rpm). Cells were pelleted by centrifugation (5 min, 1000 × g, room temperature) 
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and resuspended in a smaller volume, before 150-mm selective media agar plates were 
inoculated with the mixture. Selection conditions were chosen to minimise auto-activation 
growth by the bait and are listed in Table 2.9. Plates were incubated for 3-5 days (30 °C), 
before colonies were picked for analysis. 
 
Table 2.9: Composition of screening plates used for different bait in mating 
screens. 
Bait construct Media composition 
Isl1LIM SD-L-W-H+0.5 mM 3-AT 
Ldb1LID/Isl1LIM SD-L-W-H 
Isl1ΔLIM SD-L-W-H+2 mM 3-AT 
SD-L-W-H+2.5 mM 3-AT 
 
Screens conducted before the commencement of this thesis used baits subcloned into pGBT9 
with ampicillin resistance (ampR). Screens conducted during the timeframe of this thesis used 
baits subcloned into pGBT9 with kanamycin resistance (kanR). This simplified downstream 
recovery of the prey plasmids (Section 2.3.5). 
 
2.3.3.1 Library screening quality control 
To assess the viability of each mating partner and ensure the efficiency of library screening, 
samples of the individual mating partners and the mated solution were taken, diluted (1:10, 
1:100, 1:1000, and 1:10000), and inoculated onto appropriate selective media (SD-L and SD-
W for single plasmid selection, SD-L-W for dual plasmid selection). After incubation at 30 
°C for 72 h the numbers of colonies for each condition were counted. Full details can be 
found in Appendix D. 
 
2.3.4 Extraction of plasmid DNA from mated yeast 
Over the course of this thesis, two protocols were used to extract plasmid DNA from yeast. 
The first used phenol:chloroform extraction to lyse cells and separate DNA from proteins and 
RNA [209], followed by isopropanol precipitation to purify DNA away from any remaining 
phenol. The second and more successful protocol used enzymatic digestion and alkaline lysis 
to lyse cells, in the presence of RNase to remove RNA. Both are described below. 
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2.3.4.1 Lysis by phenol:chloroform extraction with isopropanol precipitation 
Aliquots (10 mL) of SD-L media were inoculated with mated yeast and allowed to grow 
overnight at 30 °C, with shaking (200 rpm). Cells were pelleted by centrifugation (5 min, 
5000 × g, room temperature) before being resuspended in lysis buffer (200 µL; 10 mM Tris, 
pH 8.0, 2% v/v Triton X-100, 1% SDS, 100 mM NaCl, 1 mM EDTA). Glass beads (0.5 mm, 
amount corresponding to 200 µL volume) were added. An equal volume of 25:24:1 
phenol:chloroforom:isoamyl alcohol, 1 mM EDTA, equilibrated to pH 8.0, was added, and 
the samples vortexed at 3500 rpm for 3 min to encourage cell lysis and extraction of DNA. 
The samples were centrifuged (5 min, 11000 × g, room temperature) to separate the phases. 
Samples (200 µL) of each aqueous phase were taken for isopropanol precipitation. NaCl was 
added to a concentration of 350 mM, and isopropanol added to a concentration of 40% (v/v). 
After the addition of isopropanol, samples were immediately subjected to centrifugation 
(30 min, 11000 × g, 4 °C). The supernatant was removed, and the pellet washed with 70% 
ethanol. Samples were subjected to centrifugation (30 min, 11000 × g, 4 °C), the supernatant 
removed, and the pellets dried. Once dry, the pellets were resuspended in MilliQ
®
 water. 
HB101 bacteria were transformed using these DNA solutions. 
 
2.3.4.2 Lysis by enzymatic digestion and alkaline conditions 
Aliquots (10 mL) of SD-L media were inoculated with mated yeast and allowed to grow for 
24 h with shaking (180 rpm) at 30 °C. Cells were pelleted by centrifugation (15 min, 
1000 × g, room temperature) and resuspended in resuspension buffer (100 µL; 25 mM Tris, 
pH 8.0, 10 mM EDTA, 50 mM glucose, 0.1 mg/mL RNase A). To this was added an equal 
volume of 1000 U/mL lyticase and the sample incubated for 2 h at 37 °C. Lysis solution 
(200 µL; 0.2 M NaOH, 1% SDS) was added, and the samples incubated for a further 10 min 
at room temperature. Neutralisation buffer (280 µL; 3 M potassium acetate, 4 M guanidine 
HCl) was added to stop lysis, and the sample incubated on ice for 30 min, before being 
subjected to centrifugation (10 min, 10000 × g, 4 °C) to clarify the lysate. HB101 bacteria 
were transformed with these clarified lysates. 
 
2.3.5 Isolation and identification of prey plasmid 
HB101 bacteria were transformed with extracted yeast DNA to isolate the pGADT7-RecAB 
prey plasmid only from mated yeast samples. Initially this was done through leucine 
complementation on M9-L media [209], as the HB101 strain of E. coli has a deficiency in 
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leucine biosynthesis, which can be complemented by the presence of the LEU2 gene on the 
pGADT7-RecAB plasmid. In processing the screens conducted during the course of this 
thesis, this system was not necessary, as the ampicillin resistance gene was replaced with one 
for kanamycin (Section 2.2.1), so bait and prey plasmids carried differing antibiotic 
resistance genes (kanamycin and ampicillin, respectively). LB media supplemented with the 
appropriate antibiotic was sufficient to select for the prey plasmid. 
 
E. coli were transformed as described in Section 2.5.1. However, due to the low abundance of 
the prey plasmid in the transformation input solution, freshly prepared competent cells were 
required to achieve sufficient transformation efficiency. These were prepared according to the 
Inoue method [212]. Briefly, SOC media (50 mL) was inoculated with HB101 cells to an 
OD600 of 0.05 and incubated at 37 °C until the culture reached an OD600 between 0.40 and 
0.44, with shaking (150 rpm). The culture was cooled in ice water for 10 min, pelleted by 
centrifugation (15 min, 1000 × g, 4 °C), and resuspended in TB (8 mL; 10 mM PIPES, 
pH 6.7, 250 mM KCl, 15 mM CaCl2, 55 mM MnCl2). This solution was incubated on ice for 
15 min, before being subjected to centrifugation (15 min, 1000 × g, 4 °C) and resuspended in 
TB (2 mL). DMSO (140 µL) was added in dropwise while gently agitating the solution. Cells 
were subsequently transformed with the appropriate plasmids. This protocol was scaled up to 
400 mL of SOC culture when >40 transformations were required, with all reagents being 
used at scale. 
 
Successfully transformed colonies were observed after overnight incubation. Individual 
colonies containing the prey plasmid were grown overnight in LB liquid media (10 mL) 
supplemented with ampicillin to 100 μg/mL. Plasmid DNA was extracted using the BioLine 
Isolate II Plasmid Mini Kit and sequenced using primers that flanked the multiple cloning site 
to identify the prey gene of interest. Sequencing was conducted by the Australian Genome 
Research Facility (Westmead, NSW). Sequencing primer sequences can be found in 
Appendix C. 
 
2.3.6 Extraction of protein from transformed yeast 
Yeast were lysed according to the method described by von der Haar (2007) [213]. Briefly, 
cultures of yeast were grown in either SD-L or SD-L-W-H-A (1 mL) at 30 °C with shaking 
(150 rpm) until they reached maximum density (~24 h; roughly 1 × 10
8
 cells). Cells were 
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harvested and resuspended in lysis solution (200 µL; 0.1 M NaOH, 0.05 M EDTA, 2% SDS, 
2% β-mercaptoethanol), before being incubated for 10 min at 90 °C. 4 M acetic acid (5 µL) 
was added, and samples were vortexed for 30 s, before being incubated for a further 10 min 
at 90 °C. Lysis was halted through the addition of a neutralising loading buffer (50 µL; 
0.25 M Tris pH 6.8, 50% glycerol, 0.05% bromophenol blue). Samples were stored at -20 °C 
until analysed through SDS-PAGE and Western blotting (Section 2.4.5). 
 
2.4 Validation of interactions from screening through FLAG 
pulldowns 
2.4.1 Cell growth conditions 
Suspension-adapted HEK Expi293F
TM
 cells were used to produce proteins in a mammalian 
system. These cells were grown in Expi293
TM
 Expression Medium at 37 °C with shaking 
(130 rpm) and 5% CO2, until reaching a density of 2 × 10
6
 cells/mL, at which point they were 
transfected with two pcDNA3.1 plasmids encoding proteins of interest, fused to either a 
FLAG or a HA tag. 
 
2.4.2 Transfections 
Aliquots (1.9 mL) of cells were transfected with two plasmids each. An equimolar mix of 
plasmids totalling 3.8 µg was prepared in PBS (205 µL; Phosphate buffered saline; 137 mM 
NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4), before filter-sterilised PEI (7.6 µL; 
1 mg/mL) was added. The mixture was immediately vortexed for 10 s, before being 
incubated for 20 min at room temperature. This DNA mix was added to aliquoted cells, 
which were incubated in the same conditions as described previously (Section 2.4.1) for a 
further 65 h. Cells were harvested in three aliquots (two of 1 mL, one of 100 µL) by washing 
twice with PBS (1.9 mL), being subjected to centrifugation (5 min, 300 × g, 4 °C) between 
washes to pellet cells. Once washed, cells were frozen with liquid nitrogen, and pellets stored 
at -80 °C until needed. 
 
2.4.3 Expression checks 
An aliquot (corresponding to 100 µL of culture) of cell pellet was resuspended in NuPAGE
®
 
LDS Sample buffer and PBS, boiled for 5 min, and subjected to centrifugation through a 
0.8 mL Pierce
TM
 spin filter (Thermo Fisher Scientific; Waltham, MA) for 1 min at 6000 × g 
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at room temperature, to remove viscous material. Samples were analysed for protein 
expression through Western blotting with appropriate antibodies (Section 2.4.5). 
 
2.4.4 Cell lysis and FLAG-affinity immunoprecipitation 
Cell pellet aliquots (corresponding to 1 mL of culture) were resuspended in lysis buffer 
(500 µL; 50 mM  Tris, pH 7.9, 150 mM NaCl, 1% (v/v) Triton X-100, 1 × cOmplete
®
 
EDTA-free protease inhibitor, 0.2 mM DTT), before being lysed with a probe sonicator 
(3 cycles, each 20 s, 10-20% amplitude, 0.5 s duty cycle). Lysates were incubated on ice for 
30 min to allow chromatin to precipitate before being clarified through centrifugation 
(20 min, 16000 × g, 4 °C). Clarified lysates were incubated with pre-equilibrated anti-FLAG 
Sepharose 4B beads (20 µL; BioTool, Houston, TX) overnight at 4 °C with rotation (10 rpm). 
Beads were washed five times with chilled wash buffer (1 mL; 50 mM Tris pH 7.5, 150 mM 
NaCl, 0.5% (v/v) Igepal CA-630, 0.2 mM DTT), with samples being subjected to 
centrifugation (5 min, 1000 × g, 4 °C) to sediment the beads each time. Bound proteins were 
eluted with FLAG elution buffer (20 µL; 10 mM HEPES pH 7.5, 150 mM NaCl, 300 µg/mL 
3×FLAG peptide), with samples being incubated for 30 min before being subjected to 
centrifugation (5 min, 300 × g, 4 °C) and the supernatant removed. Three elution steps were 
carried out for each sample, with the eluates being pooled for Western blot analysis. 
 
2.4.5 Western blot analysis 
Samples, along with WesternC standards (3 µL; BioRad; Hercules, CA) were subjected to 
SDS-PAGE on Bolt
TM
 4-12% Bis-Tris Plus gels run in 1 × MES buffer (Table 2.1) at 180 V 
for 27 min. Samples were transferred from the gel to PVDF membranes through 
electroblotting at 20 V, 1 h, in transfer buffer (25 mM Bicine, 25 mM Bis-Tris pH 7.2, 1 mM 
EDTA, 10% methanol). The gel was stained through conventional Coomassie staining to 
confirm that protein transfer to the membrane was successful. The membrane was washed 
five times with PBS-T (~30 mL; 137 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, 0.1% Tween), rocking for 5 min at room temperature each time. After washing, the 
membrane was blocked with 5% skim milk in PBS-T (~30 mL), incubating for 1 h with 
rocking at room temperature, before being incubated overnight with rocking at 4 °C with the 
desired HRP-conjugated antibody/antibodies in PBS-T/milk (antibody dilutions as specified 
in Table 2.5), and with StrepTactin-HRP Conjugate (1:20000) for visualisation of the 
WesternC ladder. The membrane was washed five times with PBS-T in the same conditions 
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as above. Blots were developed using Immobilon™ Western Chemiluminescent HRP 
Substrate, according to the manufacturer’s instructions, and were scanned using a LI-COR C-
DiGit Blot Scanner (LI-COR Biotechnology; Lincoln, NE). 
 
2.5 Production of homeodomain containing protein constructs 
2.5.1 Bacterial transformations 
Transformation protocols were adapted from previously used protocols in the Matthews 
laboratory [209, 210, 214]. Plasmid DNA (100 ng) was added to sterile KCM buffer (50 μL; 
0.1 M KCl, 30 mM CaCl2, 50 mM MgCl2) or sterile TFB buffer (17 µL; 100 mM KCl, 10 
mM MES, pH 6.2, 45 mM MnCl2, 10 mM CaCl2, 3 mM hexammine cobalt chloride). 
Resuspended competent E. coli cells (50 μL) were added, and the mixture incubated for 
30 min at 4 °C. The mixture was incubated at 42 °C for 30 s (for HB101 cells) or 60 s (for all 
other strains), before being transferred to ice water for 2 min. Sterile SOC media was added 
(200 μL) and the solution was incubated for 1 h at 37 °C with shaking (150 rpm). The 
transformation mixture was inoculated onto LB agar plates containing appropriate selection 
conditions to ensure retention of the plasmid. 
 
2.5.2 Protein overexpression 
Overexpression protocols were adapted from previously used protocols in the Matthews 
laboratory [209, 214]. Several colonies of BL21 Gold PLysS (DE3), transformed with the 
appropriate plasmid, were inoculated into LB broth (10 mL per litre of expression culture) 
supplemented with both 100 μg/mL carbenicilin and 34 μg/mL chloramphenicol, and 
incubated overnight at 37 °C with shaking (150 rpm). This culture was used to inoculate fresh 
media (1 L) to an OD600 of 0.05, and the resulting culture was incubated at 37 °C with 
shaking (120 rpm), until an OD600 of 0.7 was reached. Protein expression was induced 
through the addition of IPTG (Isopropyl β-D-thiogalactopyranoside) to a concentration of 0.4 
mM. Cultures were incubated further to allow protein expression to proceed. For the 
constructs NHD1, NHD3, 2HDN, and 2HD23, expression cultures were incubated for an 
induction period of 3 h at 37 °C, before being harvested. For 2HDLL, LLHD3, and LLHD1, 
the induction period was 16-20 h at 25 °C. After the induction period, cultures were harvested 
by centrifugation (30 min, 5000 × g, 4 °C) to sediment cells. Supernatant was removed, and 
pellets were snap frozen with liquid nitrogen and stored at -80 °C, for future lysis and 
purification. 
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2.5.3 Protein Purification 
Purification protocols for all constructs followed the same procedure, based on previously 
established protocols from the Matthews laboratory [209, 214]. Due to differences in 
isoelectric point, buffers used throughout the purification of LLHD1 contained 20 mM Bis-
Tris, pH 6.6, rather than 20 mM Tris, pH 8.0. 
 
2.5.3.1 Cell lysis 
Cell pellets were resuspended in lysis buffer, at a density of ~1 g cells/10 mL lysis buffer 
(20 mM Tris, pH 8.0, 300 mM NaCl, 1 mM PMSF, 1 mM β-mercaptoethanol, 10 µg/mL 
lysozyme, 10 µg/mL DNase). Once resuspended, cells were lysed using a French Press, pre-
chilled at 4 °C, under a pressure of 10000-12000 psi. Soluble material was separated from 
insoluble material through centrifugation (40 min, 30000 × g, 4 °C). 
 
2.5.3.2 PEI precipitation of nucleic acids 
A solution of 10% PEI in lysis buffer was added dropwise to the clarified lysate at 4 °C with 
stirring, until a concentration of 0.8% was reached. This solution was incubated for a further 
15 min at 4
 
°C with stirring, before being subjected to centrifugation (20 min, 10000 × g, 
4 °C) to sediment precipitated nucleic acids and PEI. 
 
2.5.3.3 Glutathione affinity purification of target protein 
The supernatant recovered from PEI precipitation was applied to pre-equilibrated Glutathione 
Sepharose 4B resin (1 mL per L of expression culture) and incubated for 1 h at 4 °C with 
rotation (~40 rpm), to maximise binding to the resin. The resin was washed with 10 column 
volumes of wash buffer (20 mM Tris, pH 8.0, 50 mM NaCl, 10% glycerol, 1 mM PMSF, 
1 mM β-mercaptoethanol) to remove contaminants. The resin was washed with cleavage 
buffer (10 column volumes; 20 mM Tris, pH 8.0, 50 mM NaCl, 1 mM PMSF, 1 mM β-
mercaptoethanol). The resin was resuspended in 3 column volumes of cleavage buffer 
supplemented with HRV-3C protease, and proteolytic cleavage allowed to progress overnight 
at 4 °C with rotation (3 rpm). 
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2.5.3.4 Cation exchange chromatography 
Cation exchange chromatography was used to further purify target proteins from contaminant 
proteins, as well as reducing any remaining nucleic acid contamination. A UnoS1 cation 
exchange column (BioRad; Hercules, CA) was used on a BioLogic DuoFlow FPLC system 
(BioRad; Hercules, CA) for this. Cation exchange chromatography was conducted in 20 mM 
Tris pH 8.0 (2HDN, 2HD23, 2HDLL, NHD1, NHD3, LLHD3) or 20 mM Bis-Tris pH 6.6 
(LLHD1), supplemented with 1 mM DTT. A 0.05-1 M NaCl linear gradient was applied to 
elute proteins. 
 
2.5.4 Protein concentration, dialysis and storage 
Proteins were concentrated using Vivaspin
®
 Centrifugal Concentrators (GE Healthcare; 
Chicago, IL) with a 3 kDa or 10 kDa molecular weight cut-off (MWCO), blocked with 1% 
Tween. Concentrators were subjected to centrifugation at 2000-3000 × g in a spin bucket 
centrifuge. Protein concentrations were measured using the absorbance at 280 nm (A280), as 
measured by an ND-1000 NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA). Extinction coefficients for all proteins are listed in Table 2.10 as estimated through 
ProtParam [215]. 
 
Table 2.10: Extinction coefficients of purified proteins.  
Protein Extinction coefficient (ε) (M-1 cm-1) 
2HDN 20970 
2HD23 19480 
2HDLL 37930 
NHD1 6990 
NHD3 13980 
LLHD1 21430 
LLHD3 30940 
 
Proteins were either dialysed for experimental use immediately after purification, or frozen in 
liquid nitrogen, and stored at -80 °C for future use. Dialysis was conducted overnight at 4 °C 
with stirring, using SnakeSkin™ 3.5 kDa molecular weight cut-off dialysis tubing (Thermo 
Fisher Scientific; Waltham, MA), except in the case of 2HDLL, where 10 kDa molecular 
weight cut-off dialysis tubing was used. 
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2.6 Homeodomain characterisation and DNA binding studies 
2.6.1 Far-UV Circular dichroism (CD) 
Freshly dialysed protein samples at 5-6 µM in buffer (20 mM sodium phosphate 
monobasic/dibasic, pH 7.4, 50 mM NaCl, 1 mM DTT) were used. Measurements were 
recorded using a Jasco J-815 spectropolarimeter equipped with a peltier-controlled sample 
holder (JASCO; Easton, MD), using 1-mm pathlength stoppered quartz cells. All reported 
temperatures refer to the sample temperature. For individual spectra, three scans were 
collected at 20 °C with a data pitch of 0.5 nm, a scanning speed of 20 nm/min, a digital 
integration time of 1 s, and a bandwidth of 1 nm and averaged. For spectra recorded over the 
course of a thermal denaturation/melt experiment, two scans per temperature point were 
collected, with a 1-nm data pitch, a digital integration time of 0.5 s, and a bandwidth of 1 nm. 
Spectra were recorded in increments of 2 °C, with the temperature increasing at a rate of 
2 °C/min, with a 1 min delay time before collecting data. More simple melts were also 
recorded, measuring data only at 208 nm, 222 nm, and 247 nm. For these measurements, 
samples were heated at a rate of 1 °C/min, collecting data points every 2 °C. A bandwidth of 
2 nm was used, with a digital integration time of 4 s. Data were corrected for buffer 
contribution and smoothed by the Savitzky Golay method [216] using Spectra Manager 
version 2.08 (JASCO; Easton, MD). 
 
2.6.2 Nuclear magnetic resonance (NMR) 
Freshly dialysed protein samples at 100 µM (NHD1) or 70 µM (NHD3) in buffer (20 mM 
sodium phosphate monobasic/dibasic, pH 7.0, 100 mM NaCl, 1 mM DTT) were 
supplemented with 5% D2O and 2 µM DSS. An 800 MHz Bruker Avance 3 spectrometer, 
fitted with a cryogenic TCI probehead (Bruker BioSpin; Billerica, MA) was used to record 
one dimensional 
1
H spectra of samples at 25 and 37 °C, with 128 scans taken for each 
acquisition. These spectra were processed using TOPSPIN 3.5PL7 (Bruker BioSpin; 
Billerica, MA). 
1
H shifts were directly referenced to DSS at 0 ppm. 
 
2.6.3 Fluorescent electrophoretic mobility shift assay (EMSA) 
Protein was dialysed into EMSA buffer (10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM 
MgCl2, 1 mM DTT) overnight, and used to construct a twofold dilution series with a top 
concentration of 6.8 μM. These protein samples were incubated for 45 min on ice with a 
specified concentration of fluorescein-labelled oligonucleotide, either 1 nM (M100) or 5 nM 
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(all other oligonucleotides), in reaction buffer (10 mM HEPES pH 7.7, 50 mM KCl, 2.5 mM 
MgCl2, 10 mM DTT, 67 μg/mL acBSA, 4% Ficoll), in a final reaction volume of 30 μL. 
Acrylamide gels (8%) made in TBE buffer (5 mM Tris pH 7.8, 9 mM boric acid, 0.25 mM 
EDTA) were pre-run in 0.5 × TBE buffer for 1 h at 110V, before samples were loaded and 
subjected to electrophoresis at 110V for 3 h at room temperature. Gels were imaged using a 
Typhoon fluorescence imager (GE Healthcare; Chicago, IL). 
 
2.6.4 Microscale thermophoresis (MST) 
Protein was dialysed into reaction buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM 
DTT). A 1:2 dilution series of protein was prepared, with a top final concentration of 75 µM. 
Fluorescein-labelled oligonucleotide was added to these solutions, to a concentration of 
50 nM, in a total volume of 30 µL. Samples were loaded into capillary tubes before 
undergoing microscale thermophoresis in a Monolith NT.115 instrument (NanoTemper 
Technologies; Munich, Germany). Thermophoresis was conducted at 95% LED power, and 
MST power at both 20% and 40%. 
 
2.6.5 Isothermal titration calorimetry (ITC) 
Protein and oligonucleotides being studied were dialysed individually into the same reservoir 
of buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM TCEP) and their concentrations 
measured. A MicroCal i200 ITC calorimeter (Malvern Panalytical; Malvern, UK) was used to 
record data, injecting an oligonucleotide of choice into the cell, which contained a solution of 
the protein of choice (either 9.3 µM NHD3 or 9 µM NHD1). Injections of oligonucleotide 
into buffer (not containing protein) were used to correct for any changes in temperature not 
arising from protein-DNA interactions. Twenty injections of 2 µL each were recorded, with 
120 s between injections and an injection speed of 0.5 µL/s. Data were analysed using Origin 
7.0, using the ITC data analysis software package (Malvern Panalytical; Malvern, UK). 
 
2.6.6 Size exclusion chromatography with multi-angle laser light scattering 
(SEC-MALLS) 
SEC-MALLS protocols were adapted from previously used protocols from the Matthews 
laboratory [209, 210]. Freshly dialysed protein samples were adjusted to a concentration of 2-
3 mg/mL in buffer (20 mM sodium phosphate monobasic/dibasic, pH 7.0, 100 mM NaCl, 1 
mM DTT). Protein solution (150 µL) was applied at 0.5 mL/min to a Superose 12 10/300 GL 
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column (GE Healthcare; Chicago, IL) on an Äkta Basic, fitted with in-line MiniDAWN™ 
TREOS multi angle light scattering and Optilab T-rEX differential refractive index detectors 
(both from Wyatt Technology, Santa Barbara, CA). ASTRA 6.1 from Wyatt software was 
used to normalise data and calculate the average molecular weight of the species of interest in 
the sample. 
 
2.6.7 X-ray crystallography 
Proteins were dialysed into EMSA buffer overnight (10 mM HEPES pH 7.7, 50 mM KCl, 
2.5 mM MgCl2, 1 mM DTT). The protein concentration was measured, and an equimolar 
amount of oligonucleotide (Table 6.1) added. The protein-DNA mix was concentrated 
(Section 2.5.4) until the volume had reduced to a volume corresponding to 15-20 mg/mL. 
The protein-DNA mix was subjected to centrifugation (5 min, 10000 × g, room temperature) 
to sediment any aggregates. A Freedom EVO 100 liquid dispensing robot (Tecan; 
Männedorf, Switzerland) was used to dispense 100-µL aliquots of crystallisation solutions 
into 96-well MRC plates (Molecular Dimensions; Suffolk, UK), before a Mosquito positive 
displacement liquid handling robot (TTP Labtech Ltd.; Cambridge, UK) was used to generate 
drops containing 200 nL mother liquor mixed with either 200 nL protein-DNA or 200 nL 
DNA-only samples. Crystal trays were incubated at 18 °C, and observed for signs of 
crystallisation beginning 24 h after initial inoculation. 
 
Initial screens for protein-DNA crystals were conducted using commercial screens: PEG Rx, 
PEG Ion, Salt Rx, Index HT, Natrix HT, and Crystal Screen suites from Hampton Research 
(Aliso Viejo, CA), and JCSG+ HT and PACT HT suites from Molecular Dimensions 
(Suffolk, UK). These crystallisation screens were used to find conditions favourable for 
crystallisation of the desired species. 
 
Four-gradient screening trays used for optimisation of crystallisation conditions were 
dispensed using the Freedom EVO 100 liquid dispensing robot. For each gradient, four 
solutions were prepared representing the most extreme conditions being screened. These 
solutions were then combined at different ratios using the Freedom EVO 100 liquid 
dispensing robot in order to produce screening gradients. 
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2.6.7.1 Preparation of crystals 
Crystals were recovered from crystallisation drops and transferred into cryoprotection 
solution of the same composition as the crystallography solution, but with an additional 25% 
glycerol present. They were either dissolved or cryo-cooled in liquid nitrogen and stored in 
liquid nitrogen until being exposed to X-rays. 
 
2.6.7.2 Characterisation of crystals 
Crystals were analysed by SDS-PAGE to determine whether or not protein was present in the 
crystal. To achieve this, crystals were recovered from crystallisation wells and dissolved in 
NuPAGE
®
 LDS Sample buffer, before being loaded onto Bolt
TM
 4-12% polyacrylamide gels 
and subjected to SDS-PAGE. Mark12
TM
 protein standard (2 µL) was included to estimate 
protein size. Proteins were visualised using SYPRO Ruby, according to the manufacturer’s 
instructions. Briefly, the gel was fixed (7% acetic acid, 50% methanol), before being stained 
with SYPRO
TM
 Ruby gel stain. The gel was destained (7% acetic acid, 10% methanol) before 
being visualised using a Typhoon fluorescence imager (GE Healthcare; Chicago, IL). 
Cryoprotected crystals were sent to the Australian Synchrotron for X-ray diffraction 
experiments, on the MX2 beamline, using an ADSC Quantum 315r detector. 
 
2.6.8 Small angle X-ray scattering (SAXS) 
SAXS experiments were conducted at the Australian Synchrotron SAXS beamline (Clayton, 
VIC), using a 1M Pilatus detector and a 900-mm camera length. Experiments were recorded 
in both static mode using a 96-well plate autoloader, and in line with size exclusion 
chromatography, using a Superose 12 10/300 GL column (GE Healthcare; Chicago, IL) with 
a 1 mL/min flow rate. 
 
Protein (2HDLL) and DNA (M100c20b) samples were dialysed overnight into  buffer 
(20 mM sodium phosphate monobasic/dibasic, pH 7.4, 100 mM NaCl, 1 mM DTT), before 
concentrations were adjusted to a desired range. For complex samples, DNA and protein 
were mixed together in a 1:1 ratio. For SEC-SAXS, one sample each of protein (2.55 
mg/mL), DNA (3 mg/mL), and protein-DNA (3.9 mg/mL) was injected. For static SAXS, 1:2 
serial dilutions were constructed, diluting the sample in a matched buffer, for a total of 6 
samples per species. Concentrations for protein-DNA samples ranged between 125 µg/mL 
and 4 mg/mL; concentrations for DNA-only samples ranged between 30 µg/mL and 1 
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mg/mL. A single 2HDLL-only sample was analysed, at a concentration of 2.55 mg/mL. 
Samples were subjected to centrifugation (10000 × g, 5 min, room temperature) to sediment 
any aggregates, and degassed, before being subjected to SAXS.  
 
Data were processed using scatterBrain version 2.82 (Australian Synchrotron; Clayton, VIC) 
and PrimusQT (ATSAS, EMBL Hamburg; Hamburg, Germany). Modelling was conducted 
using MONSA (ATSAS, EMBL Hamburg; Hamburg, Germany). Further information, 
including references for analysis programs can be found in Appendix E. 
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3 Screening for novel Isl1-interacting proteins 
through yeast two-hybrid library screening 
3.1 Introduction 
As discussed in Chapter 1, Isl1 plays a role in the development of many tissues. It is likely 
that Isl11 is acting in combination with other developmentally relevant transcription factors, 
where those factors vary according to tissue type, giving rise to diverse functions of Isl1. This 
chapter describes the use of yeast two-hybrid library screening to discover novel binding 
partners for Isl1 that could help to broaden our knowledge about the modes of action of Isl1 
in different tissues. 
 
3.2 The Yeast two-hybrid system for probing interactions 
The yeast two-hybrid system has been established as a simple and efficient way of screening 
for direct protein-protein interactions [217]. It utilises the yeast transcription factor GAL4, 
which contains independently folding DNA binding (DBD) and activation (AD) domains as 
part of the same polypeptide chain. In a yeast two-hybrid experiment, two potential binding 
partners are subcloned into plasmids encoding either the GAL4DBD or the GAL4AD (Figure 
3.1). An interaction between the two resulting fusion proteins will bring the domains of 
GAL4 into proximity, promoting the expression of reporter genes downstream of the GAL 
promoter. If there is no interaction between the binding partners, the GAL4AD will not be 
brought close to the GAL4DBD, and will not induce gene expression. Stronger interactions 
will promote higher levels of expression of the downstream genes than weaker interactions 
and will persist under high stringency conditions. 
 
53 
 
 
Figure 3.1: Schematic representation of the yeast two-hybrid system.  
Schematics of the plasmids used: (A) pGBT9 was used for all bait constructs; (B) pGAD10 
was used for prey constructs made in the Matthews laboratory, and the prey library used 
pGADT7-RecAB. (C) Molecular mechanism behind yeast two-hybrid.  
 
These interaction screens are conducted in auxotrophic strains of Saccharomyces cerevisiae.  
These yeast strains have been modified to grow only on media that contains specific 
nutrients, or when they are transformed with plasmids that encode genes to complete specific 
nutrient biosynthesis pathways. For example, the plasmids encoding the bait protein (pGBT9) 
and prey protein (pGAD10/pGADT7-RecAB) also encode one nutrient biosynthesis gene 
each for tryptophan (TRP1) and leucine (LEU2) respectively. Various strains of S. cerevisiae 
have been engineered to knock out either one or both of these genes, so that maintaining 
these yeast on media lacking leucine (-L) and/or tryptophan (-W) will select for only those 
yeast possessing the plasmids. 
 
Further, these yeast strains have been modified such that the histidine biosynthesis gene HIS3 
is under the control of a GAL promoter. Hence, when in the absence of histidine, only the 
yeast expressing a pair of proteins that interact will be able to grow, as the presence of the 
interaction will bring the GAL4AD into proximity of the GAL4DBD, bound to a GAL promoter, 
enabling expression of the HIS3 gene.  
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3.2.1 Classifying yeast two-hybrid interactions according to strength 
Many S. cerevisiae strains optimised for yeast two-hybrid analysis contain multiple reporter 
genes under the control of GAL promoters. In the work described here, three reporter genes 
were used: HIS3, ADE2, and LacZ. Each gene is under the control of a different GAL4 
responsive promoter: GAL1, GAL2, and MEL1 respectively. By varying the composition of 
the selective media used, the strength of an interaction can be estimated (Table 3.1). 
 
Table 3.1: Selective media used for yeast two-hybrid screening.  Exact media 
compositions can be found in Section 2.1.3. 
Media Nutrients of note Use 
SD-L-W Excludes tryptophan and leucine Growth control 
SD-L-W-H 
Excludes tryptophan, leucine, and 
histidine 
Detects interactions of any 
strength 
SD-L-W-H 
+0.5 mM 3-AT 
Excludes tryptophan, leucine, and 
histidine. Includes 0.5 mM 3-AT 
Eliminates weakest 
interactions 
SD-L-W-H 
+2 mM 3-AT 
Excludes tryptophan, leucine, and 
histidine. Includes 2 mM 3-AT 
Detects medium and strong 
interactions 
SD-L-W-H-A 
Excludes tryptophan, leucine, histidine, 
and adenine 
Detects only strong 
interactions 
 
3.2.1.1 Assessing interaction strength using ADE2 
The product of the ADE2 gene is an enzyme in the adenine biosynthesis pathway in yeast. In 
general, weak interactions between bait and prey are insufficient to simultaneously activate 
expression of both HIS3 and ADE2, making it useful as a selectable marker for identifying 
strong interactions (Table 3.1). 
 
3.2.1.2 Colourimetric assessment of interactions using LacZ 
LacZ encodes a galactosidase enzyme that can be used as a colourimetric marker when 
combined with media containing X-α-gal (5-Bromo-4-chloro-3-indoxyl-α-D-
galactopyranoside): an interaction between the bait and prey will result in production of an α-
galactosidase, which cleaves the X-α-gal, forming galactose and an indole that spontaneously 
dimerises to form a blue product [218, 219]. A more intense blue appearance correlates with 
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increased expression of the galactosidase, and so indicates a stronger interaction. Blue 
colouration may not always be seen, as the MEL1 promoter is more weakly bound by GAL4 
than the GAL1 and GAL2 promoters [220]. 
 
3.2.1.3 Discerning weak and moderate interactions using HIS3 expression 
The HIS3 gene can also be used to indicate the strength of an interaction, through addition of 
the competitive inhibitor 3-AT (3-amino 1,2,4-triazole). 3-AT inhibits the protein product of 
the HIS3 gene, and so inhibits growth. Adding increasing amounts of 3-AT will allow 
moderately strong interactions to be distinguished from weak interactions, as only stronger 
interactions will induce higher levels of HIS3 expression, overcoming the effect of 3-AT. The 
levels of 3-AT used throughout this work are described in Section 2.1.3 and Table 3.1. 
 
3.3 Yeast two-hybrid library screens were conducted using Isl1 as 
bait 
The yeast two-hybrid system was originally developed to screen for novel binding partners in 
a library format. This is achieved through mating compatible strains of yeast (one with the 
allele MATa and the other with the allele MATα), where one strain is transformed with the 
bait plasmid encoding the protein of interest, and where the other strain is transformed with a 
library of potential binding partners subcloned into a prey vector [221]. When the two strains 
of yeast mate, the resulting hybrid yeast will contain both the bait protein plasmid and one 
prey plasmid from the library. The progeny can then be screened on nutritionally selective 
media to select for bait-prey interactions. 
 
In this thesis, yeast two-hybrid mating screens were used to identify putative Isl1-interacting 
proteins. These screens used constructs of Isl1 fused to the GAL4DBD as bait, and a 
commercial library of pre-transformed yeast as prey.  
 
3.3.1 Three constructs of Isl1 were chosen as baits for screening 
Full length Isl1 protein could not be used for screening, as it has been found by the Matthews 
laboratory to show high levels of auto-activation in the yeast two-hybrid system [222]. That 
is, yeast transformed with pGBT9 encoding full length Isl1 and pGAD10 encoding only the 
GAL4AD, are able to grow on media lacking histidine and adenine. To avoid this problem, 
three constructs containing portions of the Isl1 protein were chosen for screening: Isl1LIM, 
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Isl1∆LIM, and Ldb1LID/Isl1LIM (Figure 3.2). These constructs had previously been subcloned 
into the pGBT9 vector (Amy Nancarrow, University of Sydney), and as part of my Honours 
work in 2014 were shown to have little to no auto-activation (Figure 3.2B) [209]. Library 
screens were conducted on selective media designed to eliminate auto-activation, and so 
minimise the occurrence of false positives where yeast growth occurs in the absence of an 
interaction between Isl1 and a bait protein. 
 
 
Figure 3.2: Schematic representations of Isl1 constructs used for library 
screening. (A) Domains of Isl1 bait constructs. (B) Previously determined auto-activation 
levels of Isl1 bait constructs, using yeast co-transformed with an empty pGAD10 plasmid and 
an Isl1-encoding pGBT9 plasmid. Each set of three spots contains a 1:10 serial dilution of 
yeast, from OD600 0.2 to 0.002. 
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3.3.2 Construction of the Clontech Mate & Plate Library 
A Clontech Normalised Universal Mouse Mate & Plate library was purchased in 2014 for 
conducting these screens, providing enough material for performing five screens. Two of 
these screens were conducted in 2014, with the other three being undertaken during the 
course of this thesis [209]. 
 
The commercial library was generated through isolating RNA from mouse tissues and 
producing complementary DNA (cDNA) from this, using primers that anneal to the poly-
adenylation signal on mature mRNAs (Figure 3.3) [223]. In this way, the library was 
designed to be biased towards proteins being expressed in the source tissue. Following cDNA 
production, a normalisation step was undertaken to reduce the prevalence of abundant 
transcripts. Normalisation used a duplex specific nuclease that selectively cleaves double 
stranded DNA [223]. The pool of cDNAs was heated to separate the two strands of each 
transcript, and then slowly cooled. More abundant transcripts should anneal at higher 
temperatures due to their higher concentration in solution. Those transcripts were digested by 
the duplex specific nuclease, while low abundance transcripts should have remained single 
stranded and have been protected from digestion. All remaining cDNAs were then cloned 
into a prey vector (pGADT7-RecAB) using restriction digestion cloning that cuts at sites 
introduced into the cDNA during the conversion of mRNA into cDNA. The resulting library 
of plasmids was transformed into a MATα strain of S. cerevisiae, Y187. 
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Figure 3.3: Schematic of the production of the cDNA library used for 
interaction partner screening.  
 
3.3.3 Mating screens against Isl1 were conducted successfully 
The bait construct of interest was first transformed into AH109, a MATa strain of yeast. This 
bait strain was mated to Y187 yeast containing the library prey. The mated yeast were then 
inoculated onto agar plates using nutritional selection to search for bait-prey interactions. In 
total, five screens were conducted, with two each against Isl1LIM and Isl1∆LIM, and one against 
Ldb1LID/Isl1LIM. Two of these screens (one against Isl1LIM and one against Ldb1LID/Isl1LIM) 
were conducted in 2014, as part of my Honours project; however, the resulting pools of prey 
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were only partially processed in that time [209]. As further processing of these screens 
contributed to this thesis, all five screens will be discussed. 
 
All screening experiments were conducted correctly. This was judged both by the appearance 
of colonies on the screening plates after incubation, and by titrations of all strains of yeast to 
quantify viability of both binding partners, mating efficiency, and screening efficiency 
(reported in Appendix D). While some inconsistencies in mating efficiencies were 
encountered, these tests indicate that more than 20 million clones were screened in each 
mating screen performed. 
 
 Initially, one screen against each Isl1 construct was planned. However, due to significant 
sample loss occurring during the processing of the first Isl1LIM pool of interactors, and 
concerns that the nutritional selection was too harsh in the first Isl1∆LIM screen, additional 
screens were carried out for these two constructs (Table 3.2). 
 
Table 3.2: Comparison of yeast isolated from mating screens.  
Isl1 construct used as bait Selective media used Colonies observed 
Ldb1LID/Isl1LIM SD-L-W-H 74 
Isl1LIM screen A SD-L-W-H+0.5 mM 3-AT >1000 
Isl1LIM screen B SD-L-W-H+0.5 mM 3-AT >1000 
Isl1ΔLIM screen A SD-L-W-H+2.5 mM 3-AT 35 
Isl1ΔLIM screen B SD-L-W-H+2 mM 3-AT 200 
 
The variation in the number of colonies observed during the initial screening was taken as an 
indication that the screening process was effective. As would be expected, screening with the 
known protein-protein interaction domain Isl1LIM, returned a much larger number (> tenfold) 
of potential interactors than screening with the same LIM domains bound to a known binding 
partner, Ldb1, which should prevent the primary peptide-binding face from making 
interactions (Section 1.2.2.1, Table 3.2).  
  
Due to the large number of colonies observed in the Isl1LIM screens, a fraction of the total 
number of yeast colonies were isolated for identification: 180 from Screen A, and 260 from 
Screen B. The colonies isolated from these screens were chosen based on largest size and 
most intense colour, as these should represent the strongest bait-prey interactions. 
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3.4 Prey plasmids were isolated and prey proteins identified 
The methodology selected for identifying the interacting prey was to isolate the intact 
plasmids from the yeast for sequencing, identification, and downstream applications. This 
required extraction of plasmid DNA from the yeast, and amplification in bacteria before final 
isolation of the plasmid.  
 
Several different methods were trialled to obtain high concentration, pure plasmid from hits 
(Section 2.3.4). Compared to E. coli, S. cerevisiae has at least a tenfold lower copy number 
for plasmids [224], and plasmid recovery proved technically challenging.  The protocol used 
required either a large amount of yeast culture, or a very high efficiency of plasmid 
extraction, to maximise plasmid yield from yeast. 
 
The final procedure used was adapted from Singh & Weil, and involved lysing yeast through 
alkaline lysis methods after enzymatic digestion of the outer cell wall of the yeast, followed 
by clarification of the lysate [225]. This fraction was then transformed into freshly prepared 
competent HB101 E. coli, prepared according to the Inoue method [212]. The combination of 
these two methods consistently resulted in successful recovery of the prey plasmids for 
sequencing and identification. 
 
The vast majority of isolated prey plasmids were easily identified through Sanger sequencing, 
using primers that annealed to sequence upstream and downstream of the prey-coding region. 
However, there were 32 prey constructs that could not be identified successfully by this 
approach. This was especially the case for the Isl1ΔLIM screens, where sequencing of 27 out of 
235 prey plasmids resulted in anomalous sequencing data (Figure 3.4). In those cases, the 
plasmids were discarded, as they most likely represented plasmids with anomalous sequence 
features, and likely did not contain protein coding sequence. 
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Figure 3.4: Comparison of good quality and anomalous sequencing data of 
library prey plasmids.  Top: sequencing chromatogram from a typical Isl1ΔLIM prey 
plasmid (Isl1ΔLIM hit G7). Bottom: Example of a sequencing chromatogram from a prey 
plasmid containing an unidentifiable prey gene (Isl1ΔLIM hit G5), estimated to be from the 
same region as in the top panel. Note that this region is upstream of the prey-coding region. 
 
3.5 Not all identified prey encoded proteins 
Once sequence information was available, each prey construct could be categorised according 
to sequence type. Through BLAST (Basic Local Search Alignment Tool) searching, it was 
found that many of the prey-encoded sequences that did not correspond to any known protein 
(Table 3.3). These prey constructs were most commonly found to contain cDNA 
corresponding to the 3’-untranslated regions (UTRs) of proteins. This is most likely an 
artefact from the production of the cDNA library, which used a poly-dT primer to anneal to 
cellular mRNAs via the 3’-polyadenylation signal (Section 3.3.2). 3’-UTRs are commonly 
found between the stop codon of an open reading frame and the polyadenylation signal. 5’-
degradation of the RNAs during the construction of the library could additionally explain 
why such a large proportion of identified prey constructs (up to 56% in a given screen) 
contained only 3’-UTR sequence without any protein-coding region. As these hits did not 
appear to represent novel binding partners for Isl1, they were not further investigated. 
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Table 3.3: Proportion of isolated prey encoding proteins across library 
screens. 
Screen Ldb1LID/Isl1LIM 
Isl1LIM 
screen A 
Isl1LIM 
screen B 
Isl1ΔLIM 
screen A 
Isl1ΔLIM 
screen B 
Prey isolated 74 180* 260* 35 200 
Prey identified 74 105 258 31 177 
Prey encoding 
proteins in frame 
27 (36%) 73 (70%) 150 (58%) 5 (16%) 23 (12%) 
Prey encoding 
frameshifted 
proteins 
8 (11%) 14 (13%) 33 (13%) 8 (25%) 57 (29%) 
Prey not encoding 
proteins 
38 (51%) 18 (17%) 75 (29%) 18 (56%) 94 (47%) 
Non-redundant 
in-frame proteins 
11 25 46 4 21 
* Screen grew >1000 colonies. Strongest interactions were isolated for identification. 
 
3.5.1 Investigation of frameshifted proteins 
A significant proportion of hits (30% overall) encoded protein-coding sequences that were 
out of frame from the upstream GAL4 protein sequence (Table 3.3). Documentation from 
Clontech indicated that yeast are tolerant to ribosomal frameshifts, meaning that during 
translation the mRNA can shift by one base in either direction with respect to the ribosome 
[211, 226]. This phenomenon would make it possible for these frameshifted sequences to be 
expressed correctly, even though they are encoded in a different reading frame to the 
upstream GAL4 sequence. However, it was important to establish whether this was the case 
for this set of sequences. 
 
The pGADT7-RecAB plasmid encodes a hemagglutinin (HA) tag immediately downstream 
of the GAL4AD, upstream of the multiple cloning site (MCS) in which the prey protein coding 
sequence is inserted, allowing detection of the expressed protein in an anti-HA Western blot. 
Several plasmids were chosen that contained protein-coding sequence that would result in a 
significant size difference of the expressed protein, depending on whether the protein 
sequence expressed was in frame with the GAL4 sequence or not (Table 3.4). 
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Table 3.4: Expected size of potentially frameshifted prey.  Predicted size of the 
protein product unique to each clone is given for each reading frame, in kDa. For each prey, 
the frame that corresponds to a known protein is underlined. Note that these sizes include the 
size of the upstream sequence, which includes the HA tag, GAL4AD, and SV40 NLS (simian 
virus 40 nuclear localisation sequence) (~22 kDa). 
Prey ID Frame 1 size (kDa) Frame 2 size (kDa) 
(GAL4 frame) 
Frame 3 size (kDa) 
E4 24.4 29.6 23.5 
E7 22.9 24.6 44.9 
M7 25.8 23.8 34.6 
P10 23.5 28.2 33.3 
T8 22 24.1 39.2 
U5 22.5 29.2 27 
 
The plasmids selected were isolated as part of the Isl1LIM screening process and showed 
evidence of strong interactions with the Isl1LIM construct. The plasmids were co-transformed 
into yeast along with IslLIM and grown in either media selecting for the presence of plasmids 
(SD-L-W), or media selecting for a strong interaction between bait and prey (SD-L-W-H-A), 
to determine if inducing protein expression selected for protein produced in a particular 
frame. The protein was then extracted (Section 2.3.6) and subjected to anti-HA Western blot 
analysis, to observe the size of the expressed prey protein (Figure 3.5).  
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Figure 3.5: Anti-HA Western blots of protein extracts from yeast.  Yeast were 
co-transformed with pGBT9-Isl1LIM and a library pGADT7-RecAB (E4, E7, M7, P10, or 
U5), and grown to saturation in selective media, before protein was extracted. Total protein 
extracts were subjected to anti-HA Western blot analysis. (A) Blot of extracts of yeast grown 
in SD-L-W media, selecting for the presence of plasmids. (B) Blot of extracts of yeast grown 
in media selecting for plasmid presence (SD-L-W; right lane for each sample) or for a strong 
interaction (SD-L-W-H-A; left lane for each sample). 
 
Samples U5 and E7 did not show levels of expression detectable by Western blot, so 
conclusions were drawn from the other four samples. All extracts from media selecting for a 
strong interaction showed a more intense band, signifying increased levels of protein 
expression (Figure 3.5B). This may occur as the growth conditions would favour yeast that 
are able to produce more of the ADE2 gene product, potentially because they have higher 
levels of expression of the prey protein, inducing more expression of the ADE2 gene.  
 
Comparing the sizes of the detected proteins between preys, it appears that E4 and P10 
expressed proteins of very similar sizes (around 30 kDa), with the proteins being expressed in 
M7 and T8 being close in size, but slightly smaller (around 25 kDa). Of the three potential 
coding frames, only frame 2 fulfils all these criteria, with E4 and P10 being 1.4 kDa different 
in size (29.6 and 28.2 kDa respectively), M7 and T8 being 0.3 kDa different in size (23.8 and 
24.1 kDa respectively), and the two pairs being ~5 kDa different in size (Table 3.4). Given 
that Frame 2 is expected, these data indicate that no ribosomal frameshifts are occurring. As 
all these protein sequences that interacted with Isl1LIM appear to represent nonsense peptides, 
and not a protein-protein interaction that occurs in vivo, hits found to encode frameshifted 
proteins were not pursued further. 
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3.6 Primary validation of putative interactors to check for prey 
auto-activation 
Identifying false positives and non-specific interactions is an essential step of any screen for 
novel interaction partners. Yeast two-hybrid experiments can have a high false positive rate 
due in part to the nature of the artificial fusion proteins used in screening. For this reason, 
validation experiments formed a crucial step in the workflow. Of the 398 protein-encoding 
hits from the five screens carried out (Table 3.3), 147 were found to be unique, with the other 
149 being duplicates. Additional validation steps were carried out with the pool of 147 
putative interactors to test the likelihood that these interactions were both specific and 
relevant to Isl1. Note that these 147 included hits that encoded different truncation constructs 
of the same protein.  
 
First, yeast two-hybrid analysis was used to check for auto-activation of the putative 
interactors. Co-transformations, rather than mating, followed by spot test assays, were 
conducted for this purpose (Section 2.3.1). Co-transformed yeast were inoculated onto a 
range of different media (Table 3.1), to test both for auto-activation of the prey construct, and 
also to probe the strength of putative interactions (Figure 3.6). 
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Figure 3.6: An example of yeast two-hybrid assays to assess auto-activation.  
Yeast co-transformed with one pGBT9 plasmid and one pGAD plasmid were inoculated onto 
(A) Growth control media (SD-L-W). (B) Selective media (SD-L-W-H+ 0.5 mM 3-AT), and 
allowed to grow for 3 days. Each set of three spots contains a serial 1:10 dilution of yeast, 
from OD600 0.2 to 0.002. Prey 12B and 15A were classified as genuine interactors as they 
displayed no growth when screened against the empty pGBT9; 7, 30C, and 38A were 
considered false positives. 
 
This process eliminated 12 false positives, as the growth pattern shown with the prey alone 
for these hits was the same as the growth pattern shown in the presence of both the bait and 
the prey. It also allowed categorisation of the remaining hits according to strength of 
interaction (Table 3.5). All hits that encoded different truncation constructs of the same 
protein behaved consistently. Different trends were observed for each Isl1 construct screened, 
with the pool of potential LIM domain interactors being the largest, and having the greatest 
proportion of strong interactions. These trends confirmed observations made during the 
recovery of hits from initial screening (Section 3.3.3). 
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Table 3.5 Distribution of interaction strengths according to the Isl1 
construct used as bait.  Percentages listed are as a proportion of the non-redundant hits 
for each Isl1 construct.  
Construct Strong Medium Weak False positive 
Isl1LIM 95% (53) 4% (2) 2% (1) 0 
Isl1ΔLIM 4% (1) 36% (9) 24% (6) 36% (9) 
Ldb1LID/Isl1LIM 0 13% (1) 50% (4) 38% (3) 
 
3.7 Further assessing false positives and non-specific interactions 
After eliminating false positives originating from prey auto-activation, the remaining pool of 
73 putative interactors may still contain some false positives, and is also likely to contain 
non-specific interactors. For this reason, further steps were taken to assess the likelihood of 
each prey protein representing a biologically relevant interaction. 
 
3.7.1 The CRAPome database was used to screen for non-specific binders 
The growing number of large-scale protein-protein interaction screens being published in the 
literature has enabled the creation of resources that identify common hits from screens that 
are unlikely to represent relevant interactions. CRAPome (Contaminant Repository for 
Affinity Purification) is one such resource, which predominantly uses mass spectrometry 
screening data [227]. Hits that occur with a high frequency in the CRAPome dataset are 
considered to represent non-specific interacting proteins. Of the 73 remaining proteins from 
screening, there was a relatively small number of proteins that appeared in the CRAPome 
dataset at a high frequency (Figure 3.7), suggesting that the yeast two-hybrid prey pool does 
not contain interactions representing common contaminating proteins. 
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Figure 3.7: Prevalence of putative Isl1-interacting proteins in CRAPome 
database. 66 out of 73 non-redundant identified putative interactors had entries in 
CRAPome. The maximum possible score in CRAPome is 411, representing a protein being 
detected in every screen in the database.  
 
Interestingly, the four highest CRAPome scoring proteins from the pool of potential 
interactors were all ribosomal proteins. This reflects a trend found across interaction mapping 
studies in which ribosomal proteins are commonly found as false positives [227]. No prey 
constructs were discarded at this stage, as very few were present in the CRAPome dataset at 
high frequencies, and they would likely prove useful comparisons when checking for the 
specificity of the interaction with Isl1. 
 
3.7.2 Subcellular localisation can be used to assess likelihood of an 
interaction occurring 
Screening hits for subcellular localisation can be a useful indicator for whether it is likely that 
biologically relevant interaction partners have been detected. Isl1 is primarily localised in the 
nucleus of cells, meaning the most likely interaction partners will be those also located in the 
nucleus (Figure 3.8) [228]. 
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Figure 3.8: Analysing subcellular localisations of Isl1 -interacting proteins.  
(A) Subcellular distribution of Isl1, adapted from Human Protein Atlas 
(www.proteinatlas.org). (B) Predicted subcellular localisations of potential Isl1-interacting 
proteins identified across all screens. 
 
Based on either known or predicted localisations, 44% of the total pool of protein hits were 
proteins that localise in the nucleus (Table 3.6) [229]. Given that nuclear proteins are 
predicted to comprise 10-20% of the total mammalian proteome [230], this statistic indicates 
that the screening process enriched for nuclear proteins in the set of putative interactors. This 
trend was strongest in the Isl1LIM interaction pool. However, given the small sizes of the 
Isl1ΔLIM and Ldb1LID/Isl1LIM interaction pools, it is difficult to say whether this trend is 
significant. 
 
Table 3.6: Subcellular localisations of non-redundant protein hits.  Note that 
several proteins occurred in more than one screen; these are only counted once in the overall 
pool. 
Isl1 bait construct Nuclear proteins Non-nuclear proteins % nuclear proteins 
Isl1LIM 29 26 53% 
Isl1ΔLIM 3 14 18% 
Ldb1LID/Isl1LIM 1 5 17% 
Overall 32 41 44% 
 
It should be noted that in many cases the localisations assigned to putative interacting 
proteins are predictions only (no experimental data available). Thus, potential interacting 
proteins were not eliminated from the pool of samples based solely on subcellular 
localisation. 
(A) (B)
Isl1 expression not detected
Isl1 expression detected
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3.7.3 Using yeast two-hybrid to check for specific binders reveals many 
non-specific interactors 
A straightforward method of determining if a prey protein interacts specifically with Isl1 is to 
screen the prey against other potential binding partners. Yeast two-hybrid assays were used 
for screening all potential interactors against Isl2, the close homolog of Isl1, and additional 
other proteins as explained below. 
 
3.7.3.1 Non-specific interactions in the Isl1LIM prey pool 
A set of 54 prey constructs representing each Isl1LIM-interacting protein identified were tested 
for specificity of binding to Isl1LIM by screening against LIM domains from other proteins, 
including Isl2, LIM domain only protein 4 (Lmo4, another LIM domain transcription factor), 
and LIM kinase 2 (Limk2, a cytoplasmic LIM protein). Hits that interacted with Lmo4LIM 
may represent biologically relevant, but less specific, binding partners. Hits that interact with 
Limk2LIM are more likely to represent non-specific interactions that are not biologically 
relevant to the function of Isl1. 
 
Of the pool tested, 42 Isl1LIM-interacting prey constructs showed strong interactions with 
Limk2LIM, with many also showing strong interactions with Lmo4LIM (Table 3.7). All prey 
constructs except two showed a strong interaction with Isl2LIM. Those were Meprin A subunit 
beat (Mep1b) and Muskelin (Mkln1), which only showed evidence of weak interactions with 
any of the tested non-Isl1 LIM domains, highlighting them as potentially specific Isl1LIM 
interaction partners. 
 
Table 3.7: Screening putative interactors for interaction specificity.  
Breakdown of putative interactors by Isl1 construct, showing strengths of interactions with 
Isl1-like proteins. 
  Limk2 interaction strength 
 Strong  Moderate  Weak No interaction 
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Strong 15 0 0 3 
Moderate  5 0 0 2 
Weak  20 0 0 7 
No interaction  2 0 0 0 
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Overall, nine of the Isl1LIM-interacting pool showed strongest binding to Isl1LIM, with 
minimal binding to the other LIM domains screened. These were: Ddx20, Dfna5, Lace1, 
Mep1b, Mkln1, Nup50, Rps18, Sparcl1, and Zfand1. 
 
3.7.3.2 Checking the interaction interface of Ldb1LID/Isl1LIM-interacting prey 
A set of six hits from the original Ldb1LID/Isl1LIM screen were tested for specificity: 
Isoaspartyl peptidase (Asrgl1), Coatomer subunit beta (Copb1), COP9 signalosome complex 
subunit 5 (Cops5), Mkln1, Transient receptor potential channel 1 (Trpc1), and Ubiquitin D 
(Ubd). Of these, Asrgl1, Cops5, and Mkln1 had also been isolated in the Isl1LIM screening. 
This was taken as an indication that these proteins may not be interacting with the 
Ldb1LID/Isl1LIM complex as a whole, but might compete with Ldb1LID for binding of Isl1LIM. 
Accordingly, Ldb1LID/Isl1LIM-interacting hits were screened against Isl1LIM, Isl2LID, and 
Lmo4LIM, to check both for specificity of binding to Ldb1LID/Isl1LIM, and for which part of 
the Ldb1LID/Isl1LIM construct was facilitating the interaction. 
 
Asrgl1, Cops5, and Trpc1 were found to interact strongly with Isl1LIM and Lmo4LIM, 
indicating that they most likely interact with LIM domains, but not specifically with Isl1 
(Figure 3.9). Therefore, they were not pursued further. Copb1, Mkln1, and Ubd were found to 
interact weakly with Lmo4, but showed varied interaction strengths with Isl1LIM. Copb1 
showed weak binding, Ubd showed moderate binding, and Mkln1 showed strong binding to 
Isl1LIM.  
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Figure 3.9: Yeast two-hybrid spot test validations for specificity of 
Ldb1LID/Isl1LIM interacting proteins.  Yeast were co-transformed with one pGBT9 
plasmid and one pGAD plasmid and grown on a range of selective media to screen for 
interactions. pGBT9 plasmids used were: empty pGBT9 (E), Isl1LIM, Lmo4LIM, and Isl2LID. 
pGAD plasmids used were: empty pGAD10 (E), and pGADT7-RecAB plasmids encoding 
the prey proteins Ubd, Trpc1, Mkln1, Cops5, Copb1, and Asrgl1. 
 
Whereas Mkln1 did appear in Isl1LIM screening, Copb1 and Ubd did not, although they 
showed an interaction with Isl1LIM in the above specificity validations. This absence may be 
explained by the fact that the interactions of these two proteins with Isl1LIM are relatively 
weak, and so would not have been isolated in the Isl1LIM screening process, which focussed 
on the strongest interactions detected. As Copb1 interacted equally strongly with 
Ldb1LID/Isl1LIM, Isl1LIM, and Lmo4LIM, it was not pursued further. This leaves Mkln1 and Ubd 
as the remaining likely Ldb1LID/Isl1LIM-interacting proteins, although it appears likely that 
they are binding only to Isl1LIM.  
 
3.7.3.3 Determining Isl1∆LIM prey interaction specificity 
Isl1∆LIM-interacting hits were screened against full length Isl2 and Isl2LID (Figure 3.10). As 
the C-terminus of Isl1(other than the LID) has an unknown domain structure, further 
screening against homologous domains could not be conducted. None of the 17 proteins 
tested showed an interaction with Isl2LID. Most of the Isl1∆LIM-interacting proteins showed 
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similarly strong interactions with full length Isl1 and Isl2, indicating no preference for 
interacting with a particular Islet protein.  
 
 
Figure 3.10: Representative yeast two-hybrid spot test validations for 
specificity of Ldb1LID/Isl1LIM interacting proteins.  Yeast were co-transformed with 
one pGBT9 plasmid and one pGAD plasmid, and grown on a range of selective media to 
screen for interactions. pGBT9 plasmids used were: empty pGBT9, Isl1FL, Isl2FL, and Isl2LID. 
pGAD plasmids used were: empty pGAD10, and pGADT7-RecAB plasmids encoding the 
prey proteins Rnf167, Scpep1, Spata7, Tigd2, Usp8, and Zdhhc20. 
 
3.7.3.4 Fhl1 
Screening with Isl1LIM resulted in a total of 51 hits encoding 3 different truncations of the 
protein Four and a half LIM domains protein 1 (Fhl1), making it the most represented 
protein.  In fact, Fhl1 represented 14% of the total pool of Isl1LIM hits, and 23% of the total 
protein-encoding pool of Isl1LIM hits. Being represented in such high numbers in the sample 
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pool may indicate a particularly strong interaction, or simply that Fhl1 is an abundant 
transcript in the library. 
 
Unlike other protein hits, the different Fhl1 fragments identified varied by less than 5 
residues (or 15 bp). The shortest construct of Fhl1 found was 19 amino acids in length, and 
the longest was 23, both containing the very C-terminal portion of the Fhl1 protein. 
Specificity validation experiments showed that Fhl1 interacted very strongly with both 
Isl2LIM and Limk2LIM, suggesting that it is a non-specific LIM-binding sequence (further 
discussed in Section 3.8.2). 
 
3.8 Discussion 
The data presented in this chapter identified several proteins that represent potentially 
biologically relevant interaction partners for Isl1. Chapter 4 will further address which of 
these interactions are likely to be biologically relevant. This discussion will focus on the 
methodology used to generate this pool of potential Isl1-interactors. Listed in Table 3.8 are 
the prey constructs that were seen to interact with Isl1 most strongly out of the proteins that 
they were tested against for specificity (Section 3.7.3). 
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Table 3.8: Potential Isl1-interacting proteins from yeast two-hybrid 
screening. 
Screen Isl1∆LIM Isl1LIM Ldb1LID/Isl1LIM 
Protein Art3 Ddx20 Mkln1 
 BC035947 Dfna5 Ubd 
 Cops5 Lace1  
 Cyc1 Mep1b  
 Kctd9 Mkln1  
 Lrrc51 Nup50  
 Ly6c1 Rps18  
 Ms4a5 Sparcl1  
 Nectin3 Zfand1  
 Nkiras1   
 Oscp1   
 Rnf167   
 Scpep1   
 Spata7   
 Tigd2   
 Usp8   
 Zdhhc20   
 
3.8.1 Analysing the methodology used 
Overall, the methodology employed here was successful in identifying potential new binding 
partners for different regions of Isl1. Yeast two-hybrid assays are an established methodology 
used for screening protein-protein interactions, and so rigorous screening protocols and 
controls are known.  
 
False positives are well-known to occur in yeast two-hybrid screens. However, they can be 
minimised in library screening through several strategies. One strategy is minimisation of the 
auto-activation of the bait by, for example, choosing an appropriate stringency of selective 
media, and selecting the orientation of bait and prey with respect to the activation and DNA 
binding domains of GAL4. Generally, the construct fused to the DNA binding domain will 
show higher auto-activation than the construct fused to the activation domain [231, 232]. This 
phenomenon is especially true for transcription factors [233], and for this reason Isl1 bait 
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constructs used were fused to the DNA binding domain, so that auto-activation could be 
assessed and then minimised in the library screening. This approach is reflected in the 
primary validations performed herein, where only 12 hits out of 147 were found to be auto-
activation false positives (Section 3.6). 
 
Many modern large-scale yeast two-hybrid interaction screening studies do not conduct 
validation experiments by the same methodology because hits are identified not by isolation 
of plasmids and sequencing as was carried out here, but by using PCR with primers that flank 
the prey insert region [234, 235]. Amplicons can thus be sequenced directly to identify the 
prey constructs. However, although this identification strategy is more efficient than plasmid 
extraction and sequencing, it does not provide material that can be used in yeast two-hybrid 
validation experiments. Note that validation with an orthogonal method is a strong indication 
of a genuine interaction (see Section 4.3.2 for an example). However, in the context of large-
scale library screening, it is difficult to find an orthogonal technique that can be conducted 
efficiently, especially when dealing with large pools of putative interactors [235]. 
 
3.8.2 Intrinsic flaws in the initial library used 
More than half of the total sample pool were found to not contain protein sequence in frame 
with the GAL4 domain upstream (364/674 samples). These samples appear to be the result of 
methodological flaws in the production of the yeast library used for screening. As described 
earlier, the cDNA library used for screening was produced from mRNA extracted from 
mouse tissue samples (see Section 3.3.2 and Figure 3.3). This methodology introduced two 
types of product into the library that led to false positives: non-protein coding RNA 
sequences, and protein sequences that were inserted into the bait vector in the wrong frame to 
that of the upstream GAL4 protein sequence (see Section 3.5). Each of these product types 
can result in nonsense proteins in the context of GAL4-fusion constructs. 
 
Non-coding RNA sequences isolated through the screening process primarily encoded 3’-
untranslated regions of genes. These cDNAs may have arisen from partially degraded 
mRNAs, where the 5’ end of the mRNAs had degraded to a point such that all protein-coding 
sequence was removed, leaving only the 3’ untranslated regions, which could still 
successfully be incorporated into the library as the 3’ polyadenylation signals used to 
generate cDNA were still intact. They may also have arisen during the production of cDNA, 
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through off-target binding of the primers. Although the presence of 3’ UTR-encoding prey is 
not ideal, the same artefact introduces truncations of protein-encoding mRNAs into the 
library, which can help to determine the minimal binding domain of an interacting protein. 
This will be further explored in Chapter 4 (Section 4.3).   
 
A particular potential hit that was likely to have been affected by truncations of protein-
encoding mRNAs was Fhl1 (Section 3.7.3.4). The consistently short length of Fhl1 encoded 
by hits could indicate a very precisely defined minimal binding domain, but it may also 
indicate that a larger portion of Fhl1 disrupts the observed interaction. Investigation of the 
domain structure of Fhl1 revealed that the last LIM domain ends in the middle of the prey 
Fhl1 peptide (Figure 3.11). It seems likely that the Fhl1 peptides found in library screens 
represent a conformation that would not normally exist in vivo, as it would natively form part 
of a LIM fold. This interaction with Isl1LIM was consequently considered as not biologically 
relevant. 
 
 
Figure 3.11: Domain structure of Fhl1.  Longest portion found during screening is 
aligned below. 
 
There is no method of selecting the reading frame of the cDNA as it is inserted into the 
pGADT7-RecAB vector, which means there is only a 1-in-3 chance that the coding sequence 
being inserted will be in the correct reading frame. Theoretically, yeast are tolerant to 
ribosomal frameshifts, meaning that out of frame sequences could still be able to produce the 
correct protein product [226, 236]. However, work here shows no evidence for ribosomal 
frameshifts (Section 3.5.1). Consequently, at least 2/3 of the sequences in the prey library 
would not represent an actual protein sequence, and with the possibility of nonsense protein 
sequences giving rise to false positives (e.g., through expression of short peptides), this 
statistic represents a significant inefficiency of cDNA library design. This problem was 
exemplified in this work by the ~30% of hits encoding out of frame sequences (Section 3.5), 
highlighting the need for appropriate validation procedures. One possible benefit of this 
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inefficiency is that although these hits clearly do not represent biologically relevant binding 
partner, they could prove useful in the development of peptide inhibitors to the bait. 
 
3.8.3 Considering the pool of prey 
Most hits found during screening were isolated from screening with the Isl1LIM construct, 
which is consistent with the presence of a well characterised protein-protein interaction 
domain in that construct [45]. This set of interactions has an established pipeline for 
characterisation [53, 55, 57, 58]. However, the interactions with Isl1∆LIM and Ldb1LID/Isl1LIM 
may represent interesting interactions with potentially novel mechanisms of interaction. As 
the C-terminus of Isl1 remains undescribed in terms of function, it would be of great interest 
to investigate interactions occurring in this region. 
 
Many of the prey constructs that interacted strongly with Isl1LIM were discovered to interact 
strongly with Limk2LIM and/or Lmo4LIM (Section 3.7.3). It is possible that those hits represent 
several novel LIDs that target a broad array of LIM domains, in a similar way to the primary 
LIM cofactor Ldb1, which interacts with LIM domains from all LIM-HD and Lmo proteins 
[54]. Given the low levels of conservation in LID sequences, it is entirely possible that these 
proteins, though having very low levels of sequence similarity, bind to LIM domains via the 
same mechanism. However, these interactions could be artefacts of the screening process. In 
particular, the hydrophobic nature of unbound LIM domains may have enriched the sample 
pool for non-specific interaction partners. As the yeast two-hybrid system takes many 
proteins out of their native environment, many prey constructs can contain exposed 
hydrophobic regions (especially if the construct comprises part of a normally folded domain) 
that in these conditions could interact strongly with hydrophobic Isl1LIM [54]. This kind of 
false positive is unlikely to be detected using the primary validation with empty pGBT9, as 
described above, as the GAL4DBD is a well-folded domain with few exposed hydrophobic 
regions (Section 3.6) [233, 237]. 
 
The Isl1∆LIM screening pool had a particularly large proportion of hits that did not encode 
proteins. The reason for this remains unclear. The two characterised features of the Isl1∆LIM 
construct are the homeodomain and the LID. While the homeodomain is positively charged, 
it is more likely to interact with DNA than protein sequence, and the LID is intrinsically 
disordered, and only forms a stable structure when bound to specific LIM binding partners. 
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Neither of these structures should be prone to non-specific protein-protein interactions, so the 
presence of so many nonsense peptide hits is anomalous. 
 
The remaining pool of prey were further considered to assess whether they represent a likely 
biologically relevant interaction with Isl1. Those investigations form the basis of Chapter 4. 
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4 Assessing potential Isl1 interactors 
4.1 Introduction 
After eliminating false positives, and screening for interaction specificity, 27 candidates for 
specific interaction with Isl1 remained. These are listed in Table 4.1. In this Chapter their 
likelihood of being biologically relevant interactions was assessed by considering what was 
known about those proteins in the literature, and the physical properties of the constructs that 
were identified as hits. Following this assessment a strong candidate was further assessed 
experimentally through attempts to define a minimal binding domain and validate the 
interaction by an orthogonal method. 
 
Table 4.1: Isl1-interacting proteins remaining after validations.  If a protein was 
isolated in screens with different Isl1 constructs, the total number of clones isolated is given 
in brackets.  
Protein 
Isl1-interacting 
construct 
Number of 
clones 
isolated 
Length of 
protein isolated 
Ecto-ADP-ribosyltransferase 3 
(Art3) 
Isl1∆LIM 1 Full protein 
BC035947 Isl1∆LIM 1 Unknown 
COP9 signalosome complex 
subunit 5 (Cops5) 
Isl1∆LIM 3 (11) 38-334 
Cytochrome C1 (Cyc1) Isl1∆LIM 1 (3) 296-335 
BTB/POZ domain-containing 
protein KCTD9 (Kctd9) 
Isl1∆LIM 1 309-339 
Leucine-rich repeat-containing 
protein 51 (Lrrc51) 
Isl1∆LIM 1 Full protein 
Lymphocyte antigen 6C1 (Ly6c1) Isl1∆LIM 1 74-131 
Membrane-spanning 4-domains, 
subfamily A, member 5 (Ms4a5) 
Isl1∆LIM 1 Full protein 
Nectin-3 (Nectin3) Isl1∆LIM 1 54-549 
NF-kappa-B inhibitor-interacting 
Ras-like protein 1 (Nkiras1) 
Isl1∆LIM 1 Full protein 
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Oxidored-nitro domain-containing 
protein 1 (Oscp1) 
Isl1∆LIM 1 Full protein 
E3 ubiquitin-protein ligase RNF167 
(Rnf167) 
Isl1∆LIM 1 Full protein 
Retinoid-inducible serine 
carboxypeptidase (Scpep1) 
Isl1∆LIM 1 Full protein 
Spermatogenesis-associated protein 
7 homolog (Spata7) 
Isl1∆LIM 2 200-582 
Tigger transposable element-
derived protein 2 (Tigd2) 
Isl1∆LIM 1 25-525 
Ubiquitin carboxyl-terminal 
hydrolase 8 (Usp8) 
Isl1∆LIM 1 941-1080 
Palmitoyltransferase ZDHHC20 
(Zdhhc20) 
Isl1∆LIM 1 64-380 
Probable ATP-dependent RNA 
helicase DDX20 (Ddx20) 
Isl1LIM 1 458-825 
Gasdermin-E (Dfna5) Isl1LIM 2 238-512 
AFG1-like ATPase (Lace1) Isl1LIM 1 428-480 
Meprin A subunit beta (Mep1b) Isl1LIM 1 398-704 
Nuclear pore complex protein 
Nup50 (Nup50) 
Isl1LIM 1 39-464 
40S ribosomal protein S18 (Rps18) Isl1LIM 5 63-152 
SPARC-like protein 1 (Sparcl1) Isl1LIM 14 335-650 
AN1-type zinc finger protein 1 
(Zfand1) 
Isl1LIM 4 189-268 
Muskelin (Mkln1) Isl1LIM, 
Ldb1LID/Isl1LIM 
1 
4 
113-735 
Ubiquitin D (Ubd) Ldb1LID/Isl1LIM 1 Full protein 
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4.2 Assessing the literature 
The candidates under consideration are broken into groups according to which screen or 
screens they were identified as hits: Isl1∆LIM only, Isl1LIM only, Ldb1LID/Isl1LIM only, and 
both Isl1LIM and Ldb1LID/Isl1LIM (Mkln1). 
 
4.2.1 Isl1∆LIM interactors 
Of the 17 proteins found as potential binding partners to Isl1∆LIM, nine immediately seem 
unlikely, due to their notated functions and localisations in the cell. Art3 is extracellular, 
Ly6c1, Ms4a5, Nectin3, Oscp1, Rnf167, and Zdhhc20 all function in the plasma membrane, 
Scpep1, Rnf167, and Zdhhc20 are localised to the lysosome, and Spata7 localises to the 
microtubule network in cilia [238-246]. It seems unlikely that Isl1 could interact with these 
proteins as part of its role in regulating gene expression. Interactions with proteins localised 
to the lysosome may still be biologically relevant, as they could be involved in the 
degradation of Isl1. However, the lysosome is primarily involved in the degradation of larger 
assemblies, and it is more likely that Isl1 degradation would occur through the ubiquitin 
degradation pathway [247, 248]. Indeed, the ubiquitin ligase Rlim/Rnf12 has been identified 
as catalysing the ubiquitination of LIM-HD proteins that bind to the common LIM-HD/Lmo-
binding protein Ldb1, although not specifically Isl1 [249, 250]. 
 
Several proteins found in the pool of putative Isl1∆LIM interactors, such as Lrrc51, BC035947, 
and Tigd2 have not been characterised at all, making it difficult to comment on whether these 
proteins could be of further interest or not. The remaining five proteins (Kctd9, Usp8, Cops5, 
Cyc1, and Nkiras1) are discussed below individually. 
 
4.2.1.1 Kctd9 
Although Kctd9 was predicted to be an extracellular protein, is has been characterised as an 
E3 ubiquitin ligase [251]. It forms homopentamers through its BTB/POZ domain, and can 
form a larger complex alongside cullin proteins, potentially acting as the substrate 
recognition subunit of the E3 complex [251]. An interaction between Kctd9 and Isl1 would 
be of interest, as it may reveal a specific proteasomal degradation pathway for Isl1. However, 
it should be noted that the construct isolated during screening consists of only the C-terminal 
30 residues, and 17 of these residues are predicted to contribute to one of the ordered 
pentapeptide repeats (Figure 4.1). Consequently, the interaction with Isl1 should first be 
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tested with a larger portion of the protein. Whether this interaction can occur with Kctd9 in a 
pentameric state should also be investigated, to establish if this interaction could occur in 
vivo. 
 
 
Figure 4.1: Domain structure of Kctd9. Fragment of Kctd9 isolated from yeast two-
hybrid screening is shown beneath. 
 
4.2.1.2 Usp8 
Usp8 is also involved in the ubiquitination system, but has been shown to cleave conjugated 
ubiquitin from proteins, rather than tagging proteins for proteasomal degradation [252]. The 
clone of Usp8 isolated in the screening process encodes a truncated product of Usp8, 
containing only the last 140 amino acids (residues 941-1080) (Figure 4.2). The characterised 
structure of Usp8 shows that this truncation would likely eliminate two beta sheets and a zinc 
coordination site (Figure 4.2B), as well as disrupting the hydrophobic core of the fold in that 
region (Figure 4.2C) [253]. The truncation would likely leave the remaining protein only 
partially folded, with exposed hydrophobic surfaces, so is likely to represent an interaction 
artefact rather than a native interaction between Usp8 and Isl1. 
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Figure 4.2: Structure of Usp8.  (A) Domain structure of Usp8, with the fragment of 
Usp8 isolated from yeast two-hybrid screening shown beneath. (B) and (C) show the solved 
structure of the C-terminal catalytic domain (PDB:2GFO). (B) Residues found in the 
Isl1∆LIM-interacting construct are shown in blue, remaining residues are shown in green. (C) 
Surface representation of Isl1∆LIM-interacting Usp8, where red represents hydrophobic 
surfaces, with (left) and without (right) non-Isl1∆LIM-interacting residues (yellow). 
 
4.2.1.3 Cops5 and Cyc1 
Cops5 and Cyc1 were both isolated in multiple screens, but only Isl1∆LIM binding appears to 
be real based on the following data. Cops5 was isolated in screens with all three Isl1 
constructs used, but it was discarded in the Isl1LIM and Ldb1LID/Isl1LIM pools because of high 
auto-activation levels (Figure 4.3A). Repeated testing of auto-activation levels of Cops5 gave 
variable results. Although some experiments showed low levels of auto-activation, most 
showed high levels of auto-activation. This suggests that the binding seen with Cops5 may 
represent an artefact, and not a genuine interaction with Isl1∆LIM.  
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Figure 4.3: Cops5 and Cyc1 yeast two-hybrid spot tests.  . Each set of three spots 
contains a serial 1:10 dilution of yeast, from OD600 0.2 to 0.002. (A) Validation spot test 
assays of Cops5 against Ldb1LID/Isl1LIM, Isl1LIM and Isl1∆LIM, with two iterations of Isl1LIM 
testing. (B) Validation spot test assays of Cyc1 against Ldb1LID/Isl1LIM and Isl1∆LIM. 
 
Cyc1 was isolated in the Ldb1LID/Isl1LIM screen, but upon further testing did not show an 
interaction with Ldb1LID/Isl1LIM. Yeast two-hybrid spot test assays show a moderately strong 
interaction with Isl1∆LIM (Figure 4.3B). However, given the well-established role of Cyc1 in 
the mitochondrial electron transport chain, it also seems unlikely as an biologically relevant 
interaction partner for Isl1 [254].  
 
4.2.1.4 Nkiras1 
Nkiras1 plays a role in regulating NF-κB signalling, by preventing the degradation of NF-
kappa-B inhibitor beta [255, 256]. This interaction could be of interest, as NF-κB signalling 
is a major signalling pathway involved in development. Of note, the clone isolated during 
screening encodes the full length Nkiras1 protein, making the observed interaction more 
likely to indicate a true binding event. 
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4.2.2 Isl1LIM interactors 
The Isl1LIM pool of interactors represents the interactions most likely to be biologically 
relevant, as the LIM domains are known protein interaction domains, and the proteins 
remaining in this pool all showed evidence of strong and specific interactions with Isl1.  
 
4.2.2.1 Sparcl1/Ecm2/Sc1 
Secreted protein, acidic and rich in cysteine-like 1 (Sparcl1) is a glycoprotein named for its 
similarity to an earlier discovered protein Sparc (Secreted protein, acidic and rich in cysteine) 
[257, 258]. Due to its similarity to Sparc, Sparcl1 has been speculated to play a role in 
regulating the extracellular matrix, potentially through acting as a collagen chaperone [259]. 
Sparcl1 contributes to proliferation and survival of cells, although the mechanism by which 
this occurs is unknown [260]. In line with this role, Sparcl1 expression was correlated with 
several kinds of cancer, including prostate and colorectal cancers [261, 262].  
 
That Sparcl1 was recovered 14 times from the Isl1LIM screen highlights it as a protein of 
interest (Table 4.1). However, although Sparcl1 shows a strong interaction with Isl1LIM in 
yeast two-hybrid assays, it seems unlikely that this interaction would occur in vivo. Sparcl1 is 
exported from the cell in order to regulate the extracellular matrix. This makes it unlikely as a 
biologically relevant interaction partner candidate for Isl1, as they likely would never co-
localise. Like many extracellular proteins, Sparcl1 also contains many disulfide bonds and is 
heavily post-translationally modified [263]. These modifications should not be present in the 
intracellular environment of the yeast two-hybrid assay. These reasons make it probable that 
the interaction observed between Isl1 and Sparcl1 is an artefact of the experimental system 
used.  
 
4.2.2.2 Ddx20/Dp103/Gemin3 
DEAD-box helicase DDX20 (Ddx20) is a protein with several roles in the cell [264]. It was 
first discovered as part of a complex involved in spinal muscular atrophy [265]. This complex 
interacts with a broad range of RNAs and is involved in the assembly of small nuclear 
ribonucleoproteins (snRNPs) [265-267]. The DEAD-box motif in Ddx20 provides the RNA 
binding function required for this complex [268]. Beyond this, Ddx20 has also been shown to 
play a role as a transcriptional regulator, through binding to Egr (Early growth response) 
protein family members, to be important in ovarian development, and to play a role in cell 
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signalling pathways involving NF-κB and p53 [269-272]. Deletion of Ddx20 is lethal, with 
fertilised eggs failing to progress past the two-cell stage (blastocoel), indicating that it plays a 
major role in early embryonic development [272]. 
 
Both Isl1 and Ddx20 localise to the nucleus and are involved in transcriptional regulation. 
Deletion of either of these proteins results in lethality at an early stage of embryonic 
development. These common attributes suggest that an interaction between Isl1 and Ddx20 
may be biologically relevant, and is worth further investigation. 
 
4.2.2.3 Zfand1 
AN1-type zinc finger protein 1 (Zfand1) is a largely uncharacterised protein. It is named for 
the presence of two AN1-type zinc fingers near its N-terminus. The AN1-type zinc finger is 
found in proteins associated with stress responses, across animals and plants [273]. The 
structure of the AN1-type zinc finger from the yeast protein Cuz1 (Cdc48-associated 
UBL/zinc finger protein-1) was recently solved [274]. Cuz1 is a homolog of Zfand1, and is 
involved in targeted protein degradation through the ubiquitin conjugation pathway [275]. 
The Cuz1-proteasome association was found especially in cases of exposure to metalloids, 
indicating a role in stress response.  
 
Recently, Zfand1 was shown to also regulate proteasomal protein degradation in response to 
stress, specifically from the metalloid arsenite [276]. This group of chemicals, which contain 
oxidised arsenic, have been shown to be carcinogenic, as a result of inhibiting DNA repair 
[277]. 
 
As Zfand1 is predicted to localise to the nucleus, the interaction between Isl1 and Zfand1 
could be of further interest. However, the interaction between Isl1 and a larger portion of 
Zfand1 must first be tested, as the clones isolated from screening all encode truncation 
products of Zfand1 containing only the C-terminal 78 amino acids (Figure 4.4). This 
truncation begins in the middle of the ordered C-terminal region, which is predicted to adopt 
a ubiquitin-like fold [276]. It is difficult to assess whether this truncation product reflects how 
the protein would behave and fold in vivo without further structural data.  
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Figure 4.4: Domain structure of Zfand1. Fragment of Zfand1 isolated from yeast 
two-hybrid screening is shown beneath.  
 
4.2.2.4 Dfna5/Gsdme/Dfna5h 
Non-syndromic hearing impairment protein 5 (Dfna5), also known as Gasdermin-E (Gsdme), 
was initially identified in a mutant form as a gene responsible for causing hereditary deafness 
[278, 279]. Dfna5 has since been found to play a role in the DNA damage response, and its 
expression is downregulated through promoter methylation in several types of cancer [280-
282]. These observations suggest that Dfna5 plays a role as a tumour suppressor. In support 
of this idea, further investigation has linked Dfna5 to pro-apoptotic pathways [283, 284]. 
Dfna5 is cleaved by caspase 3 in the apoptotic cascade, into N- and C-terminal fragments 
(Figure 4.5). The N-terminal fragment then translocates to the plasma membrane through the 
action of a membrane targeting sequence, where it may potentially oligomerise to form a pore 
that promotes cell lysis [284]. 
 
 
Figure 4.5: Domain structure of Dfna5. Fragment of Dfna5isolated from yeast two-
hybrid screening is shown beneath. 
 
Whether or not an interaction between Isl1 and Dfna5 is biologically relevant is difficult to 
predict, considering that Dfna5 appears to be a multi-functional protein. A Dfna5:Isl1 
interaction could form part of a cascade to regulate gene expression in response to either 
DNA damage signals or pro-apoptotic signals. Whereas the N-terminal fragment of Dfna5 
has been investigated, the role of the C-terminal fragment has not been explored - this is 
especially relevant as the construct of Dfna5 isolated interacting with Isl1LIM lacks the first 
237 residues (approximately half) of the protein. 
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4.2.2.5 Lace1/Afg1l 
AFG1-like ATPase (Afg1l), also known as Lactation elevated protein 1 (Lace1), was 
originally discovered as a protein that was highly upregulated in expression in lactating 
mouse breast tissue [285]. Lace1 is a homolog of the yeast Afg1 protein, a mitochondrial 
protein involved in proteolysis of electron transport chain proteins [286]. Lace1 was recently 
shown to play a similar role, promoting degradation of the subunits in complex IV of the 
electron transport chain [287]. There is also evidence that Lace1 promotes apoptosis through 
association with the tumour suppressor protein p53, and sequestering it to the mitochondria 
[288]. 
 
Given that Lace1 functions primarily in the mitochondria, an interaction with Isl1 appears 
unlikely in cells, as there is no evidence for the presence or function of Isl1 in mitochondria. 
However, this protein is still poorly characterised; if it can sequester p53 to the mitochondria, 
it is unlikely that it is always localised to the mitochondria, and so may at some stage co-
localise with Isl1. 
 
4.2.2.6 Mep1b 
Meprin A subunit beta (Mep1b) is a membrane protein with a large extracellular region. It 
normally functions as a proteolytic homo-oligomeric enzyme, breaking down target proteins 
[289]. This raises several impediments to a biologically relevant interaction with Isl1 as its 
localisation in membranes, along with a large extracellular component, reduces the likelihood 
of co-localisation with Isl1. That Mep1b normally exists as a membrane bound homo-
oligomer means that the context of the yeast two-hybrid assay may affect the structure of 
Mep1b. In yeast two-hybrid experiments, Mep1b should not be localised to a membrane, 
meaning regions of the protein that would normally be buried may be exposed, permitting the 
formation of non-native interactions. Overall, it seems unlikely that Isl1 and Mep1b would 
interact in vivo. 
 
4.2.2.7 Rps18 and the ribosomal interaction 
Ribosomal proteins have previously been identified as commonly occurring false positives in 
yeast two-hybrid screens [231]. The five ribosomal proteins identified from the Isl1LIM screen 
as potential interactors were Rpl9 from the large ribosomal subunit, and Rps18, Rps23, 
Rps26, and Rps29 from the small ribosomal subunit. Whereas only Rps18 was classed as a 
specific interactor from yeast two-hybrid experiments (Section 3.7.3), Isl1 would be near all 
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of these proteins during translation. Figure 4.6 shows these proteins highlighted in a recent 
structure of the intact ribosome, derived from electron microscopy [290]. 
 
 
Figure 4.6: Electron microscopy model of an intact mouse ribosome. Shown 
are two orientations: (A) front and (B) rotated 180°. RNA is shown in light orange, proteins 
from the screen are shown in blue, and other ribosomal proteins are shown in dark orange 
(PDB: 5LKS). 
 
Although the putative Isl1-interacting proteins are somewhat clustered, other ribosomal 
proteins in the vicinity have not been identified as Isl1 interactors. If these interactions occur 
in vivo, they are most likely to be transient interactions, which are only in effect during the 
translation of Isl1. These interactions could potentially aid in the folding of Isl1 as it is 
translated, especially considering that these ribosomal interactions are seen with the LIM 
domains of Isl1, which are located at the N-terminus of the protein. In this way, transient 
interactions with the ribosome could prevent off-target binding of the nascent Isl1 LIM 
domains, until the C-terminal LID is translated and can displace the ribosomal proteins. 
Although speculative, there is evidence that interactions of this type can form between 
nascent translating proteins and the ribosome, and that these interactions can be important in 
ensuring correct folding of the translating protein [291, 292]. However, none of the ribosomal 
proteins identified as putative interactors are close to the exit tunnel of the ribosome. It would 
be difficult for a translating protein to interact with any of these specific ribosomal proteins 
because they would not be sufficiently close. Additionally, the yeast two-hybrid environment 
removes all of the contextual ribosomal interactions that would be occurring in the cell. In 
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particular, Rps18 normally contacts the 16S rRNA, making it likely that the presence of this 
rRNA would block any interaction with Isl1LIM, or influence the folding of Rps18 in a way 
that disrupts the Rps18:Isl1 interaction [290]. Because of this, it seems probable that the 
interaction between Isl1 and Rps18 would not occur in vivo. 
 
4.2.2.8 Nup50 and the nuclear pore interaction 
The protein nucleoporin 50 (Nup50) forms part of the nuclear pore complex and is directly 
involved in protein import into the nucleus [293, 294]. An interaction between Isl1 and 
Nup50 could be central to the import of Isl1 into the nucleus. The canonical nuclear import 
pathway relies on importin proteins binding target proteins via a nuclear localisation 
sequence (NLS), before travelling through the nuclear pore [295]. This process primarily 
involves transient interactions between the importin protein and the nuclear pore complex, 
with no interactions occurring between the nuclear pore and the cargo protein. Interestingly, 
Nup50 may be an exception to this general rule, as Nup50 was shown to displace NLSs from 
importin proteins [293, 296]. This type of activity is generally considered a means by which 
the nuclear pore can help to detach imported proteins from the nuclear import chaperone. A 
Nup50:Isl1 interaction would then most likely involve an Isl1 NLS. 
 
To date no NLS has been formally identified in Isl1. There is evidence that helix 3 of the 
canonical homeodomain can act as an NLS (Section 5.10.4.2), but the interaction with Nup50 
involved Isl1LIM, not a construct containing the homeodomain [297]. Residues 7-14 in Isl1 
(PPKKKRLI) resemble a common NLS motif [295]. However, the Isl1LIM construct used for 
yeast two-hybrid screening is missing the first four amino acids of this potential NLS, so it is 
likely that the interaction detected here between Isl1 and Nup50 involves additional regions 
of Isl1LIM. Overall, an interaction between Nup50 and Isl1 could be of further interest, as it 
may reveal a mechanism for Isl1 transport into the nucleus. 
 
4.2.3 Ldb1LID/Isl1LIM interactors 
Compared to the other two Isl1 constructs screened, there were very few Ldb1LID/Isl1LIM-
interacting proteins isolated and identified. This suggests that the LIM domains of Isl1 are 
normally bound by one partner at a time. 
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The only protein found to interact solely with Ldb1LID/Isl1LIM was Ubiquitin D/Fat10, a small 
protein that is structurally similar to diubiquitin [298]. Like canonical ubiquitin, Fat10 can be 
conjugated to target proteins, promoting their degradation by the proteasome [299, 300]. To 
date, one E1 ubiquitin ligase has been identified that can bind both canonical ubiquitin and 
Fat10 [301]. Fat10 has been functionally linked to the immune response, with overexpression 
of Fat10 promoting apoptosis of the cell [298, 300, 302, 303]. 
 
An interaction between Isl1, Ldb1, and Fat10 could be possible, as Fat10 has been shown to 
localise to the nucleus [300]. However, neither Isl1 nor Ldb1 has been demonstrated to act as 
a ubiquitin conjugation enzyme, or as part of the ubiquitin degradation pathway. In the 
absence of other data, it is likely that this interaction is not biologically relevant. 
 
4.2.4 Mkln1 
Muskelin (Mkln1) was identified in the screens for both Isl1LIM and Ldb1LID/Isl1LIM. 
Interestingly, yeast two-hybrid experiments testing for specificity showed that there was no 
interaction between Mkln1 and Ldb1LID, and Mkln1 showed an equally strong interaction 
with Isl1LIM and Ldb1LID/Isl1LIM. This raises the possibility that Mkln1 in these experiments 
competes with Ldb1LID for binding to Isl1LIM, or binds a different surface on the LIM 
domains.  
 
Mkln1 was first identified as playing a role in maintaining the structure of the cytoskeleton, 
and in cell adhesion [304]. However, it has also been well characterised as part of a complex 
containing Ran-binding protein M (RanBPM), which is involved in transcriptional regulation 
[305, 306]. Further investigation has revealed that the localisation of Mkln1 depends on its 
protein binding partners [307, 308]. Mkln1 is predicted to contain an N-terminal discoidin 
domain, a central LisH (lissencephaly-1 homology) domain immediately followed by a 
CTLH (C-terminal to LisH) domain, and a C-terminal kelch repeat β-propeller domain 
(Figure 4.7) [304, 306, 309]. Both the discoidin domain and the LisH domain have been 
implicated as protein dimerisation domains. It has been shown that Mkln1 can exist in the cell 
as a monomer, dimer, or tetramer, with these different states associated with differing 
subcellular localisations [309-311]. 
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Figure 4.7: Domain structure of Mkln1.  (A) Schematic of the domain organisation of 
Mkln1. (B) Structure of the Mkln1 discoidin domain. (PDB: 4PQQ) (C) Structure of the 
discoidin domain (red) and a portion of the LisH domain (yellow), showing LisH 
dimerisation (PDB: 4OYU). 
 
The structures of the isolated discoidin domain (Figure 4.7B) and the discoidin domain with a 
portion of the LisH domain have been determined (Figure 4.7C) [311, 312]. There is limited 
structural information available about the CTLH domain, but it is consistently found in 
proteins downstream of a LisH domain, suggesting that it is required for correct folding or 
function. 
 
The interaction between Isl1 and Mkln1 was selected for further validation, both because of 
its identification in both Isl1LIM and Ldb1LID/Isl1LIM screens, and because the literature 
indicates that an interaction with Isl1 is plausible, in terms of both function and localisation. 
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4.3 Validating the interaction with Muskelin  
Mkln1 was isolated 5 times over the course of yeast two-hybrid screening, with each clone 
encoding a different portion of the Mkln1 protein (Figure 4.8). 
 
 
Figure 4.8: Schematic of Mkln1 truncations identified throughout yeast two-
hybrid screening.  Clones 1D, 6E, 15A, and 27A were identified in the Ldb1LID/Isl1LIM 
screen; A9 was identified in Isl1LIM screening. 
 
These constructs all contained the C-terminal CTLH, and kelch repeat domains, indicating 
that the region of interaction with Isl1 was likely to lie in this region. Constructs were 
designed to test this and to further narrow down the minimal Isl1-binding region of Mkln1 
(Figure 4.9). Constructs were designed around domain boundaries, in the hopes of preserving 
correct folding. As the kelch repeats collectively form a β-propeller structure, they were 
treated as one domain. Full amino acid sequences of both Mkln1 and Isl1 constructs used can 
be found in Appendix F. 
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Figure 4.9: Truncation constructs of Mkln1 produced to validate interaction 
with Isl1. 
 
These truncation constructs were screened for interactions with Isl1 in yeast two-hybrid 
experiments and in co-immunoprecipitation experiments using protein produced in 
mammalian cells, to probe the interaction in conditions that more closely represent the native 
environments for the two proteins in vivo.  
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4.3.1 Yeast two-hybrid shows an interaction between Isl1 and the CTLH 
region of Mkln1  
Yeast two-hybrid analysis was used to test interactions between Isl1LIM, Ldb1LID/Isl1LIM, and 
the various Mkln1 constructs produced. Full length Isl1 was not tested due to the high levels 
of auto-activation produced by the full length Isl1 construct. These experiments showed 
evidence of strong interactions between Isl1 constructs and the Mkln1 constructs NK, LC, 
and CC, and a weaker interaction with the original 1D clone (Figure 4.10). Other constructs 
showed some growth under the weakest selection conditions for interactions with Isl1LIM, but 
this was at similar level to the negative control and was not evident under more stringent 
selection conditions. 
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Figure 4.10: Spot tests of Mkln1 constructs against Isl1 constructs.  Yeast were 
co-transformed with one pGBT9 plasmid and one pGAD plasmid, and grown on a range of 
selective media to screen for interactions. . Each set of three spots contains a serial 1:10 
dilution of yeast, from OD600 0.2 to 0.002. pGBT9 plasmids used were: empty pGBT9, 
pGBT9-Isl1LIM, and pGBT9-Ldb1LID/Isl1LIM. pGAD plasmids used were: empty pGAD10, 
pGADT7-RecAB containing the library screen clone 1D, and pGADT7-RecAB containing 
the Mkln1 truncation constructs NL, NK, LC, CC, KC, and FC. Lower right presents a 
scoring table for interactions, with red representing no interaction, and darker shades of green 
representing stronger interactions. 
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The interactions of Mkln1NK, Mkln1LC, and Mkln1CC with Isl1LIM and Ldb1LID/Isl1LIM cannot 
be classified in terms of strength of binding from this experiment, as all combinations showed 
growth under the most stringent selection conditions. The full length Mkln1 construct (1D), 
which showed a weaker interaction than any of the truncations, was found to contain a 
frameshift in the sequence at the very beginning of the Mkln1 coding region, meaning the 
protein produced is most likely not full length Mkln1 (as discussed in Section 3.5.1). 
 
Overall, the yeast two-hybrid experiments indicated that the CTLH domain region of Mkln1 
is necessary for the interaction with Isl1. It remains unclear whether this region interacts with 
the Isl1 LIM domains on a different face to that of the conventional LID binding face. 
 
4.3.2 Co-immunoprecipitation results do not clearly indicate a minimal 
binding region of Mkln1 
An orthogonal system was utilised to further validate the interaction between Isl1 and Mkln1. 
Isl1 and Mkln1 constructs were subcloned into two versions of pcDNA3.1: one encoding an 
N-terminal FLAG tag and the other encoding an N-terminal HA tag. Gibson cloning was 
used for this purpose and to simultaneously correct the frameshift found in the construct 1D, 
hereafter referred to as Mkln1FL. 
 
After constructs were subcloned, HEK Expi293F
TM
 cells were co-transfected with 
combinations of two plasmids for protein expression. Each pair of plasmids transfected 
consisted of one encoding a FLAG-tagged bait and one encoding an HA-tagged prey. Both 
orientations of Isl1 and Mkln1 as bait and prey were used. 
  
Three days after co-transfection, cells were harvested. Western blotting was used to confirm 
the expression of both bait and prey proteins, through the simultaneous use of anti-FLAG and 
anti-HA antibodies (Figure 4.11). The majority of constructs showed expression, with the 
consistent exception of Mkln1FC. It is possible that Mkln1FC was expressed, but was not 
detectable through Western blotting in the conditions used as it was too small for the transfer 
conditions used.  
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Figure 4.11: Expression of FLAG- and HA-tagged proteins from HEK293 
cells. (A) Representative anti-FLAG/anti-HA Western blot, showing expression of 14 co-
transfections. (B) Expected sizes of FLAG- and HA-tagged constructs. HA-tagged Mkln1 
constructs and FLAG-tagged Isl1 constructs are marked with blue and red asterisks, 
respectively. 
 
Immunoprecipitation was performed using an anti-FLAG antibody immobilised on beads, 
with immunoprecipitates being eluted from the beads by adding 3× FLAG peptide to compete 
off the FLAG-tagged protein and any binding partners. Samples of co-immunoprecipitation 
input and eluate were subjected to anti-FLAG/anti-HA Western blotting to detect both bait 
and prey, and evidence for any interactions between the two (Figure 4.12). A representative 
experiment is shown in Figure 4.12A, with a summary of all the experiments in Figure 4.12C. 
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Figure 4.12: Detecting the interaction between Isl1 and Mkln1 using co -
immunoprecipitation.  (A) Representative Western blot of co-immunoprecipitation 
experiments. I: input; E: elution. HA-tagged Mkln1 constructs are marked with blue asterisks. 
(B) Expected size of FLAG bait and HA prey. (C) Summary of co-immunoprecipitation 
results. Ambiguous result indicates either a weak band was detected (For example Isl1LIM 
against Mkln1KC in (A)), or a band was not consistently detected in replicated 
experiments/both orientations. No data indicates expression of one or both partners was not 
observed, meaning that the interaction could not be tested. 
 
Most Mkln1:Isl1 combinations showed no interaction by co-immunoprecipitation (Figure 
4.12C). Consistent with the yeast two-hybrid data, the Isl1∆LIM construct did not interact with 
any Mkln1 construct, and the Mkln1 constructs ND and NL did not interact with any Isl1 
construct. In further agreement, Isl1LIM and Ldb1LID/Isl1LIM both interacted with Mkln1FL, 
Mkln1LC, and Mkln1CC, although the interaction between Isl1LIM and Mkln1CC was only 
observed with FLAG-Isl1 and HA-Mkln1, not the reverse orientation (i.e., with the tags 
swapped). In contrast to the yeast two-hybrid results, however, Mkln1NK did not interact with 
either Isl1LIM or Ldb1LID/Isl1LIM, although no data could be obtained for Mkln1NK against 
Ldb1LID/Isl1LIM. Additionally, HA-Mkln1KC was shown to weakly bind to FLAG-Isl1LIM by 
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co-immunoprecipitation, where no interaction was observed using yeast two-hybrid analysis 
(Figures 4.10, 4.12A and C). 
 
An unexpected result from the co-immunoprecipitation data was the lack of any interaction 
detected between any Mkln1 construct and Isl1FL. Given that expression of Isl1FL was 
observed consistently, and that using FLAG-Isl1FL effectively enriched for Isl1FL, it seems 
unlikely that this was due to technical issues such as poor expression levels. It is possible that 
the intramolecular Isl1LIM:Isl1LID interaction may occlude the Mkln1 binding site (Section 
1.3). This would seem unlikely given that Isl1LID binds across the same interface as Ldb1LID, 
which does not obstruct the Mkln1 interaction, but it is possible, as Isl1LID and Ldb1LID do 
have different kinetics of binding [313]. 
 
Overall the co-immunoprecipitation results, while in partial agreement with the yeast two-
hybrid results, did not clearly define a minimal binding region for the Isl1:Mkln1 interaction. 
 
4.3.3 Classifying the Isl1/Mkln1 interaction 
Taking the yeast two-hybrid and co-immunoprecipitation results together, it is likely that 
there is a genuine interaction between the two proteins, as there were interactions detected 
between Isl1 and Mkln1 in both systems. This interaction is likely to involve the LisH and 
CTLH domains, and may also require the Kelch repeats. More work is required to determine 
which regions are involved in binding, and which are required for correct folding, as there 
were no characterisation experiments performed to confirm whether the Mkln1 constructs 
used were correctly folded. 
 
 It is conceivable that the experimental conditions found in the co-immunoprecipitation 
scenario impacted the interaction, preventing it from forming between certain combinations 
of constructs [314]. This could be due to steric constraints introduced by the presence of tags, 
or by the immobilisation of proteins using affinity beads. It is also possible that endogenous 
proteins from the HEK293 cells bound to either of the interaction partners in preference to 
the interaction being tested and prevented that interaction from taking place, as there were no 
purification steps performed to separate the proteins of interest from the rest of the soluble 
cell lysate. 
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Another factor to consider is the tendency for Mkln1 to form dimers and tetramers: it may be 
that the interaction with Isl1 can only occur with one oligomeric form of Mkln1, and that the 
truncation constructs used prevent Mkln1 from adopting this state [311]. 
 
Further experimentation to determine the nature of this interaction, as well as its biological 
relevance, should be conducted to confidently show a bona fide interaction between these two 
proteins. However, this was not possible within the time frame of this thesis. 
 
4.4 Discussion 
The data presented in this chapter identified several proteins that represent potential 
biologically relevant interaction partners for Isl1. What follows is a summary of the likely 
biological relevance of these identified interactions, followed by an evaluation of the success 
of the screening process. 
 
4.4.1 Assessing the pool of remaining prey 
Of the 27 prey proteins that were found to represent specific Isl1-interacting proteins in yeast 
two-hybrid analysis, 12 are plausible interactors based on known functional information 
about these proteins (Section 4.2, Table 4.2). 
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Table 4.2: Classification of identified proteins according to likelihood of 
biological relevance of the interaction. 
Isl1 bait Unlikely to interact Insufficient information 
to comment on 
Likely to interact 
Isl1LIM Sparcl1 
Mep1b 
Rps18 
Zfand1 
Lace1 
Mkln1 
Ddx20 
Dfna5 
Nup50 
Isl1∆LIM Art3 
Ly6c1 
Ms4a5 
Nectin3 
Oscp1 
Rnf167 
Zdhhc20 
Scpep1 
Spata7 
Usp8 
Cops5 
Cyc1 
Lrrc51 
BC035947 
Tigd2 
Kctd9 
Nkiras1 
Ldb1LID/Isl1LIM  Ubd Mkln1 
  
Of these 12 proteins, only Lrrc51, Ubd, Nkiras, and Mkln1 have been tested in their full-
length form. The others were recovered from the screens as truncated constructs. The first 
step in further validating these interactions should be obtaining the full-length protein and re-
testing the interaction with Isl1, both in yeast two-hybrid assays, and in an orthogonal system 
such as co-immunoprecipitation. 
 
Mkln1 is a putative interactor of interest, being the only validated prey protein that could 
interact with more than one Isl1 construct. Further, the mammalian co-immunoprecipitation 
data did indicate an interaction between Isl1 and Mkln1. However, the conflicting data for the 
minimal binding region of Mkln1 needs to be resolved, and additional in vivo data is needed 
to confirm the biological relevance of the interaction. 
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Confirmation of the co-localisation of Isl1 with these potential interaction partners in cells is 
an important future experiment. Evidence for co-localisation would build confidence in the 
biological relevance of these interactions. Once minimal binding domains have been 
established, and binding sites characterised, it would also be possible to test the functionality 
of these interactions by mutating the binding sites and then observing resulting phenotypes in 
cell lines or animal models. 
 
4.4.2 Assessing the success of library screening for identifying new binding 
partners 
There are several ways of assessing whether the screening performed here was an overall 
success. One is to assess the number of novel binding partners identified compared to the 
total number of hits analysed. Another is to compare the interactors identified from these 
screens with known binding partners for Isl1 in the literature. Both assessments are discussed 
below.   
 
4.4.2.1 Assessing the number of novel binding partners identified 
Several proteins were identified that could represent novel, specific, and biologically relevant 
binding partners for Isl1. However, only 6% of the total sample pool obtained from yeast 
two-hybrid library screening was found to represent specific interactions with Isl1 (Figure 
4.13). If this number is expanded to include less specific interactions, including interactions 
with the close homolog Isl2 or other nuclear LIM proteins, which could still be biologically 
relevant, it reaches 22%. This means the majority of hits from screening did not represent 
potential binding partners for Isl1. This inefficiency draws attention to the problems 
associated with library screening, and for this particular system used, as was discussed in the 
previous chapter (Section 3.8.1).  
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Figure 4.13: Breakdown of the categorisation of hits isolated  in yeast two-
hybrid library screening.  (A) All screens combined. (B) Hits according to Isl1 bait.  
 
4.4.2.2 Known Isl1-interacting proteins in the pool of detected interactors 
The identification of known Isl1-interacting proteins in the screens should function as 
positive controls, indicating that the screening was thorough and that the baits were behaving 
as they would in vivo. 
 
One glaring absence from the pool of interacting proteins is Ldb1, the major cofactor of all 
LIM-HD proteins, including Isl1 (Section 1.2.2.1). Ldb1 was expected to be present in the 
pool of Isl1LIM-interacting proteins. The interaction between Ldb1LID and Isl1LIM is well 
characterised, and has been previously observed in yeast two-hybrid assays in the Matthews 
laboratory [51, 54]. Ldb2 was identified from Isl1LIM screening, which should offer some 
reassurance. However, Ldb2 was among the prey that had protein sequence encoded out of 
frame with the upstream GAL4 sequence, and M7 was an Ldb2-encoding hit that was 
screened to check for whether a frameshift was occurring during protein expression (Section 
3.5.1). As no frameshift was observed, Ldb2 cannot be considered as a positive control. 
106 
 
Other LIM-HD proteins like Lhx3 and Lhx4 should also have been present in the Isl1∆LIM-
interacting pool. While the LID in Isl1 does not interact with as many proteins as does 
Ldb1LID, Isl1LID is known to interact with Lhx3 and Lhx4 with reasonable affinity [54, 57, 
313]. Neither of these proteins was identified in the Isl1∆LIM screens.  
 
Given the known strength of these interactions, the absence of Ldb1, Lhx3, and Lhx4 in the 
prey pool suggests that they were not screened against Isl1. As these proteins are present at 
low abundance in cells, it is possible that they were not successfully subcloned into the 
pGADT7-RecAB yeast library, or that the yeast containing these plasmids did not 
successfully mate with the bait strain. If this were the case, repeated screening should allow 
the identification of these proteins, and may also reveal more novel binding partners. 
 
An alternative explanation is that transcripts for Ldb1, Lhx3, and Lhx4 were not present in 
the mRNA pool used to generate the library used for screening. While the cDNA library used 
is marketed as universal, the transcripts are derived from adult mice [315]. As the LIM-HD 
proteins play many roles in embryonic development, it is possible that they are not expressed 
at sufficiently high levels in adult mice to ensure that they were present in the cDNA library. 
Certainly, Lhx3 and Lhx4 are expressed at very low levels in the adult mouse. However, 
Ldb1 is expressed at levels comparable to those of Zfand1, which was identified four times 
during screening [316]. 
 
The use of an adult-derived cDNA library reveals a larger issue with the work presented here. 
While many LIM-HD proteins are expressed both during development and in the fully 
developed adult mouse, there are many key developmental proteins that are only expressed 
during embryonic development. These would be ideal targets to test for interaction with Isl1, 
as Isl1 is implicated in the embryonic development of numerous tissues. However, these 
proteins are not present in the cDNA library used. This represents a significant flaw in the 
approach used here. This flaw was not noticed until the absence of Ldb1 was confirmed, 
leaving insufficient time to repeat the experiments with an embryonic mouse cDNA library, 
and highlights the issue that the output of any library screen is dependent on the composition 
of the library. 
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4.4.3 Future work to map the interaction partners of Isl1 
Although yeast two-hybrid screening may not have been successful in generating a 
comprehensive map of Isl1 interacting proteins, it still provided useful avenues for further 
study. Many of the proteins identified as putative binding partners need further validation, 
through the use of mammalian expression and co-immunoprecipitation. Ddx20, Dfna5, 
Nup50, Kctd9, and Nkiras1 would be good targets for this, as they are the most likely 
candidates to represent biologically relevant interactions (Table 4.2). 
 
Assuming the Isl1:Mkln1 interaction is validated through co-localisation studies, it would be 
interesting to determine the structure of the Isl1:Mkn1 complex. Once minimal binding 
domains have been identified, the relevant domain constructs could be produced. 
Recombinant Mkln1 was previously expressed in bacteria, in sufficient yields for 
crystallography studies [311]. Isolated Isl1LIM would prove difficult to obtain, given the 
propensity for unbound LIM domains to aggregate in solution, but co-expression and 
purification of the two proteins could provide soluble complex. Ldb1LID/Isl1LIM can be 
produced in sufficient yields using bacterial expression [54], suggesting this approach would 
likely be successful. One key question that would be answered by structure determination of 
the complex is whether the Isl1 LIM domains can simultaneously bind multiple proteins 
(Mkln1 and Ldb1LID), or if Mkln1 competes off Ldb1LID. This information would give 
valuable insights into the complexity of transcriptional regulation by Isl1. 
 
There are also several proteins already proposed in the literature as Isl1 interactors that need 
more thorough examination, including Pou4f2, Phox2a, Neurod1, and Stat3 (Section 1.5) 
[113, 187, 317].  None of these complexes have been confirmed to feature a direct interaction 
with Isl1. Stat3 is of particular interest, as it has been shown to cooperate with the motor 
neuron complex, in which Isl1 is bound to Ldb1 and Lhx3 via its LIM and LID regions 
respectively (Section 1.4.1, Table 1.3). If a direct interaction was detected between Isl1 and 
Stat3, it could reveal a new binding interface on Isl1. 
 
Additional interaction partners for Isl1 could be discovered through alternate techniques, 
which in combination with the yeast two-hybrid screens presented here would help improve 
confidence of their biological relevance. Recent interaction mapping studies have shown the 
potential of co-immunoprecipitation coupled with mass spectrometry (co-IP/MS) analysis in 
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detecting interactions in a high throughput manner [318-321]. While yeast two-hybrid 
methodology is well established in the Matthews laboratory, co-IP/MS analysis would have 
been a good alternate technique to identify new Isl1-interacting proteins. Compared to yeast 
two-hybrid library screening, the co-IP methodology can be easily applied to a range of 
different samples, such as different cell lines or mouse tissues, as there is no need to procure 
or produce cDNA libraries. There are also many software suites available for analysing the 
results of such experiments in a high throughput manner. However, the main barrier to a co-
immunoprecipitation approach is the requirement for a suitable antibody against the target 
protein. Although many antibodies against Isl1 are available, these antibodies are primarily 
used for immunofluorescence or Western blotting, and require testing to confirm that they are 
suitable for co-immunoprecipitation before a large scale interaction screen could be 
conducted. Preliminary experiments to this end were attempted for this project, and 
demonstrated the need for validation of the antibody. None of the three antibodies tested was 
sufficiently specific for co-immunoprecipitation (data not shown). 
 
4.4.4 Conclusion 
Overall, the aim of identifying novel binding partners to Isl1 was achieved, but use of more 
efficient methodology would have allowed for further investigation of relevant proteins, and 
potentially the identification of more binding partners. As it stands, there are several novel 
putative binding partners of Isl1 identified in this work. Further work could address the 
nature of these interactions, whether they are biologically relevant, and their consequences 
for development. 
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5 Investigating the mechanisms behind the 
action of the motor neuron complex 
 
5.1 Introduction 
This chapter describes efforts to understand the interactions between homeodomains and 
DNA that are associated with the motor neuron complex, as described in Section 1.4.1. All 
protein constructs were cloned prior to the commencement of this thesis, unless otherwise 
specified (Section 5.2). Expression and purification protocols had been established, but were 
further optimised during the course of this thesis to enable production of sufficient amounts 
of high purity protein for downstream characterisation and structural studies (Section 5.3). 
 
5.2 Construct design 
Various constructs of Isl1, Lhx3, and Ldb1 were generated for this project, including 
truncation mutants of single proteins as well as fusion constructs comprising domains of two 
proteins. These constructs were designed with the aim of understanding which regions are 
important for imparting affinity and specificity to the protein-DNA interactions that occur in 
vivo. Full construct sequences can be found in Appendix G. 
 
5.2.1 Single homeodomain constructs 
Constructs encoding the isolated homeodomains from Isl1 and Lhx3, named NHD1 and 
NHD3 respectively, had already previously been cloned (Tom Drury, University of Sydney). 
The canonical homeodomain is 60 residues long, including the N-terminal arm that is 
important for interacting with DNA. However, difficulties were encountered observing DNA 
binding using 60 residue homeodomain constructs (Tom Drury, unpublished data), so the 
constructs used throughout this thesis were 80 residues long, with extended N- and C- termini 
[214]. 
 
Additional single homeodomain constructs, containing upstream protein-protein interaction 
domains, were also produced to better mimic the motor neuron complex in vivo (Figure 
5.1A). These constructs were named LLHD3, which encoded Isl1LID fused to Lhx3LIM+HD, 
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and LLHD1, which encoded Ldb1LID fused to Isl1LIM+HD
 
(Figure 5.1B). LLHD3 was 
produced during my Honours work in 2014, and LLHD1 was produced for this thesis. 
 
 
Figure 5.1: Single homeodomain constructs used in the project.  (A) Schematic 
model of the motor neuron complex found in development. (B) Single homeodomain 
constructs used throughout the project. (C) Molecular weights of single homeodomain 
constructs with various protein fusion tags. 
 
5.2.2 Fusion homeodomain constructs 
Four homeodomain fusion constructs were used over the course of the work described in this 
thesis. All homeodomain fusion constructs used contained Isl1HD at the N-terminus, followed 
by a varied region, with Lhx3HD at the C-terminus (Figure 5.2). The construct 2HDLL 
contains native sequence that would naturally occur between the two homeodomains when in 
complex — the C-terminal LID of Isl1, and the N-terminal LIM domains of Lhx3.  
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Figure 5.2: Homeodomain fusion constructs used throughout the project.  Isl1 
is shown in pink and Lhx3 in purple; red line indicates glycine/serine linker, in place of 
native protein sequence. 
 
The constructs 2HDN, 2HD17, and 2HD23 were designed to contain 23-residue disordered 
linkers between the two homeodomains, in place of the native protein-protein interaction 
domains. In 2HDN, the linker contains a portion of sequence from Isl1 (the sequence between 
the end of the homeodomain and the beginning of the LID), and a portion of sequence from 
Lhx3 (the sequence between the end of the LIM domains and the beginning of the 
homeodomain). In 2HD23, all of this sequence is replaced with a glycine/serine linker. In 
2HD17, the 6 residues N-terminal to Lhx3HD are derived from native Lhx3 sequence in case 
those residues play a role in DNA binding or folding. 2HDLL was cloned by Tom Drury 
(University of Sydney). The remaining three constructs were produced during my Honours 
work in 2014 [209]. 
 
These constructs were generated to determine if any of the protein sequence between the 
homeodomains and their adjacent LIM or LID domains has an effect on DNA binding. In 
addition, 2HD17 and 2HD23 were produced in case 2HDN proved difficult to work with. For 
example, if the native linker in 2HDN was prone to cleavage by proteases, the glycine/serine 
linkers in 2HD17 and 2HD23 should be less prone to proteolysis.  
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5.3 Optimisation of homeodomain expression and purification 
Initially, production of the homeodomain constructs gave poor protein yield, with low 
reproducibility (Figure 5.3). Some optimisation of protein expression was conducted during 
my Honours work, but more was needed to develop protocols that reliably yielded sufficient 
protein for a variety of experiments.  
 
 
Figure 5.3: Variability of 2HDN purification.  Two examples of glutathione affinity 
purification of 2HDN using non-optimised protocols. FT: flow-through; W1: first wash; BC: 
before cleavage; AC: after cleavage; E1-E5: elution fractions 1-5. (A) Example of 
purification from 2015 with low yield. (B) Example of a purification from 2014 with high 
yield. Note that GST (glutathione S-transferase) and 2HDN cannot be resolved using SDS-
PAGE in the conditions used. 
 
Initial expression conditions used homeodomain constructs subcloned into vectors encoding 
either an N-terminal GST tag (2HDN, 2HD17, 2HD23, LLHD3) or maltose binding protein 
(MBP) tag (2HDLL, NHD1, NHD3), under the control of a lacUV promoter. The use of an 
MBP tag for 2HDLL, NHD1, and NHD3 was to improve protein solubility and overall yield, 
so the remaining constructs (2HDN, 2HD17, 2HD23 and LLHD3) were subcloned into the 
same vector for this thesis in the hope of improved expression levels. However, this 
modification did not lead to higher yields (Figure 5.4). 
 
114 
 
 
Figure 5.4: Amylose affinity purifications of homeodomain constructs with 
an N-terminal MBP tag.  (A) Purification of MBP-2HDN; (B) Purification of MBP-
2HD23. 
 
Inconsistencies in culture growth were observed with all constructs. For example, cultures 
would often not grow, or take more than four hours to reach a density suitable for induction 
of protein expression. These inconsistencies could indicate toxicity resulting from leaky 
expression of the protein constructs, as small amounts of the DNA-binding homeodomains 
could bind to bacterial DNA, interfering with cell growth or metabolism. 
 
Constructs were subsequently subcloned (for this thesis) into a pET-DUET expression vector 
encoding an N-terminal GST fusion under the control of a T7 promoter, to reduce possible 
leaky expression (Section 2.1.4). The possible effects of leaky expression and protein toxicity 
were tested by comparing the time taken for test cultures, each containing the same plasmid 
in a different E. coli strain, to reach an OD600 (optical density at 600 nm) of 0.7 from the same 
starting density (Table 5.1). Previous experiments used ampicillin to maintain the plasmid, 
but degradation of that antibiotic can lead to inconsistent bacterial growth and loss of the 
plasmid. Accordingly, carbenicillin was used instead as it is more resistant to degradation 
[322, 323].  
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Table 5.1: Testing for leaky expression and toxicity.  Three strains of E. coli (BL21 
(DE3), BL21 Gold (DE3) (pLysS), and Rosetta 2 (pLysS)) were transformed with an 
expression vector encoding GST-2HDLL, under the control of a T7 promoter. Cultures (10 
mL) supplemented with 100 µg/mL carbenicillin (and 34 µg/mL chloramphenicol for pLysS 
strains) were inoculated with transformed bacteria with an initial OD600 of 0.05, and 
incubated with shaking  until reaching an OD600 of 0.7 ± 0.05. The time taken to reach this 
OD600 is reported in minutes (N = 2). 
Temperature 
(°C) BL21 (DE3) BL21 Gold (DE3) (PLysS) Rosetta 2 (PLysS) 
25 360 280 295 
37 205 160 160 
 
pLysS strains contain a plasmid that expresses T7 lysozyme, which inhibits T7 polymerase 
produced from the DE3 prophage, reducing leaky expression [324]. Both strains that 
contained a pLysS plasmid reached an OD600 of 0.7 in similar time. The slower growth of the 
BL21 (DE3) cultures suggests that leaky expression is occurring in that strain and impacting 
the growth of the bacteria.  
 
Final expression protocols for all homeodomain constructs consisted of the following: 
transformed BL21 Gold (DE3) (PLysS) E. coli were grown at 37 °C in LB supplemented 
with 100 µg/mL carbenicillin, 34 µg/mL chloramphenicol, and 0.2% w/v glucose, until 
reaching an OD600 of 0.7, at which point protein expression was induced by the addition of 
0.4 mM IPTG (Isopropyl β-D-thiogalactopyranoside) (Section 2.5.2). Cultures expressing 
proteins containing LIM and LID domains were incubated at 25 °C for 16-20 hours post-
induction, rather than at 37 °C for three hours post-induction for HD-only constructs. 
 
Purification protocols were adapted from already established protocols [214]. However, 
nucleic acid contamination was observed in partially purified protein during this thesis work, 
so a PEI (polyethylenimine) precipitation step was introduced to precipitate nucleic acids 
prior to affinity chromatography (Figure 5.5). This new step achieved the goal of removing 
nucleic acid contamination without compromising protein yield. It was also observed that 
elution fractions from glutathione resin contained fewer contaminants when the lysate had 
been subjected to PEI precipitation prior to GSH-affinity chromatography. 
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Figure 5.5: Removal of nucleic acid contamination by PEI precipitation.  
Elution fractions from the purification process of 2HDLL were analysed by agarose 
electrophoresis and visualised by staining with HydraGreen
TM
. 
 
The final optimised protocol consisted of cell lysis by French press, nucleic acid precipitation 
by PEI, GSH-affinity chromatography, and cation exchange chromatography (Section 2.5.3). 
All homeodomain-containing constructs could be purified to a high standard using this set of 
protocols (Figure 5.6, Appendix H). 
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Figure 5.6: Examples of purifications of homeodomain constructs. Further 
examples can be found in Appendix H. (A) 2HDLL purification, showing cation exchange 
elution fractions 19-23 on SDS-PAGE, and elution profile. (B) NHD3 purification, showing 
cation exchange elution fractions 22-27 on SDS-PAGE, and elution profile. (C) NHD1 
purification, showing cation exchange elution fractions 21-26 on SDS-PAGE, and elution 
profile. 
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5.4 Isolated homeodomains are folded in solution 
In order to confirm that the homeodomain constructs produced were in a form that could bind 
to DNA, far-UV circular dichroism (CD) and nuclear magnetic resonance (NMR) were used 
to investigate the folded state of the proteins.  
 
The far-UV CD spectra observed are typical of folded proteins with maxima below 200 nm 
(Figure 5.7). The double minima observed (around 208 and 222 nm) are characteristic of 
alpha-helices and are consistent with the 3-helix fold of the canonical homeodomain, with 
additional disordered residues. There was no appreciable difference between the signals 
recorded for NHD1 and NHD3, suggesting that they are in very similar states in terms of 
secondary structure. 
 
 
Figure 5.7: Far-UV CD spectra of single homeodomains.  (A) Spectra for NHD1 
(red) and NHD3 (blue), collected at 20 °C. (B) Typical spectra characteristic of alpha helices 
(green), beta sheets (blue), and random coil (red) Figure taken from [325].  
 
1
H 1D NMR spectra taken for each of NHD1 and NHD3 showed sharp dispersed peaks 
characteristic of folded protein (Figure 5.8). In particular, peaks below 1 ppm and around 
7 ppm are good indicators of ‘foldedness’. Once more, the spectra are very similar, indicating 
NHD1 and NHD3 are likely to have similar tertiary structure. 
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Figure 5.8: 
1
H 1D NMR spectra. NHD1 is shown in red and NHD3 is shown in blue. 
Peaks in the 7-10 ppm and 1-3 ppm range are characteristic of folded protein. 
 
5.4.1 Investigation of protein fold stability of individual homeodomains 
1
H 1D NMR was used to assess the stability of the fold of both NHD1 and NHD3. Spectra 
were recorded for each protein at both 25 °C and 37 °C. The spectra at the higher temperature 
for both proteins showed a disappearance and broadening of peaks characteristic of partial 
unfolding (Figure 5.9). This was particularly noticeable in the aromatic region between 8 and 
9 ppm. 
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Figure 5.9 Comparison of NMR spectra taken at 25 °C and 37 °C.  (A) NHD1 
spectra; (B) NHD3 spectra. 
 
The apparent unfolding with higher temperature was subsequently monitored using far-UV 
CD over the temperature range 10 °C to 90 °C. Both homeodomains appeared folded at ≤ 25 
°C. The proteins exhibited a similar thermal denaturation profile, with an apparent Tm 
(melting temperature) at ~42 °C (Figure 5.10), as indicated by the disappearance of the 
signals at 208 and 222 nm, and a shift to typical unfolded spectra (see random coil, Figure 
5.7B). Collectively these data indicate that Lhx3HD and Isl1HD have similar properties in 
terms of protein folding and stability. 
121 
 
 
Figure 5.10: Far-UV CD melting profiles of single homeodomains.  Lowest 
temperatures are shown in red; higher temperatures progress through a rainbow, with highest 
temperatures in purple. (A) Spectra of NHD1. (B) Spectra of NHD3 taken at 2 °C increments 
from 10 °C to 90 °C (according to sample temperature), heating at 2 °C/min. (C) Plot of 
temperature against proportional CD signal at 208 nm and 222 nm for both NHD1 and 
NHD3. 
 
5.5 Using electrophoretic shift assays to probe in vivo DNA 
binding 
Electrophoretic mobility shift assays (EMSAs) were initially used to monitor DNA binding of 
Isl1HD and Lhx3HD. EMSAs can be used to observe protein-DNA interactions over a range of 
affinities, as well as to observe multiple binding events. Additionally, the appearance of a 
shifted band in a gel can give indications of binding kinetics [326]. However, the EMSA is 
not a true equilibrium experiment, and so cannot be used for precise measurements of 
thermodynamics or kinetics. All homeodomain constructs were tested against sequences 
sourced from promoters that are associated with the appropriate developmental complex in 
vivo: GSU, GA, and Hb9 (Table 5.2).  
122 
 
Table 5.2: Binding sequences used for EMSA binding studies.  A fluorescein 
moiety was present at the 5’ end of each sequence. Note that all oligonucleotides used were 
double-stranded. Putative homeodomain binding site is shown in bold. 
Name Gene Oligonucleotide sequence Bound by 
Isl1GA GA (proglucagon) ACCGCGTAATATCTG Isl1[327] 
Lhx3GSU GSU (glycoprotein 
hormone subunit α) 
ACTTAGCTAATTAAATGTG Lhx3[102, 328] 
M100 Hb9 (homeobox 
protein 9) 
CGGCCATTAGCCAAATTACGGC Isl1/Lhx3 in 
complex [99] 
 
5.5.1 Lhx3HD binds with specificity, but Isl1HD does not 
NHD3 was tested for its ability to bind M100, Isl1GA, and Lhx3GSU (Figure 5.11). Of those 
three potential interactions, NHD3 was seen to bind with high affinity only to the Lhx3GSU 
oligonucleotide, as shown by the clear shifted band present in the EMSA (Figure 5.11C). 
There is no clear gel-shift for the other two interactions (Figure 5.11A and B). However, 
disappearance of the free DNA indicates some binding between NHD3 and Isl1GA and 
M100. The concentration range at which this occurs, between 500 nM and 5 µM, suggests 
non-specific binding (discussed further in Section 5.10.1)  [329]. 
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Figure 5.11: Fluorescent EMSA titrations of NHD3.  * denotes the unbound 
oligonucleotide band. Concentrations range from 80 pM-5 µM NHD3, proceeding in a 
twofold concentration series. The leftmost lane of each set contains no protein. (A) M100. 
(B) Isl1GA. (C) Lhx3GSU.  
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Under the same electrophoresis conditions, NHD1 did not show a clear shifted band with any 
sequence tested (Figure 5.12). While the disappearance of the free oligonucleotide at higher 
concentrations of protein similarly suggests non-specific DNA binding, it is markedly weaker 
than the binding seen with NHD3. The behaviour of both proteins binding to DNA was 
reproducible, indicating a difference in the typical DNA binding behaviour of NHD1 and 
NHD3. 
 
 
Figure 5.12: Fluorescent EMSA titrations of NHD1.  * denotes the unbound 
oligonucleotide band. Concentrations range from 40 nM-5 µM NHD1, proceeding in a 
twofold concentration series. The leftmost lane of each set contains no protein. (A) M100. 
(B) Isl1GA. (C) Lhx3GSU.  
 
5.5.2 Lhx3HD and Isl1HD do not bind co-operatively when separated 
There exist in the literature several examples of homeodomains binding cooperatively in 
transcriptional complexes [330, 331]. To investigate whether this was the case for Isl1 and 
Lhx3, the purified NHD1 and NHD3 were tested for binding to M100 by EMSA in isolation 
and in combination (Figure 5.13). 
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Figure 5.13: Assessing cooperative binding between Isl1 HD and Lhx3HD to the 
M100 sequence. * denotes the unbound oligonucleotide band. The leftmost lane of each 
set contains no protein. Concentration range proceeds in a tenfold concentration series. From 
left to right: 0-5 µM NHD1, 0-5 µM NHD3, and 0-5 µM NHD1 and equimolar NHD3 (total 
0-10 µM protein).  
 
There was slightly more binding seen in the combined NHD1+NHD3 series, due to the 
overall higher number of DNA-binding protein molecules in solution, but as this minor 
increase was not more than the sum of the single homeodomain binding experiments, there 
was no evidence for cooperative binding in this experiment. Cooperative binding would 
manifest as a significantly earlier gel-shift of the DNA, and a higher shifted band being 
visible (representing two homeodomains bound to the same DNA oligonucleotide). This 
result suggests that Isl1HD and Lhx3HD do not directly influence each other’s DNA binding 
behaviour. 
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5.6 Seeking an explanation for the observed binding behaviour of 
Isl1HD 
In contrast with the above data, published literature has shown Isl1 binding to DNA using 
EMSAs (further discussed in Section 5.10.2) [104, 327]. However, many of these studies 
observed binding in the presence of whole nuclear extracts, containing potential binding 
partners for Isl1 that could confer tighter binding than would be observed using the isolated 
homeodomain [126, 130]. Other studies have used Isl1 fused to other protein motifs such as 
TrpE, HA (hemagglutinin), and GST [44, 332], but to date no studies have shown the isolated 
homeodomain of Isl1 binding directly to DNA. Given that many of these studies used larger 
portions of Isl1 than just the homeodomain, the binding behaviour of Isl1HD constructs 
containing additional protein domains was investigated. The binding behaviour of Lhx3HD 
was also assessed for comparison. 
 
5.6.1 The presence of upstream LIM:LID interaction regions has no direct 
effect on binding of Isl1HD or Lhx3HD 
In order to more closely mimic the biological context of these proteins within the ternary 
Lhx3/Isl1/Ldb1 complex, constructs were produced containing native sequence of Isl1 and 
Lhx3, from the LIM domains to the homeodomains (Figure 5.2). As these proteins are 
normally found in complexes, and the LIM domains tend to aggregate in the absence of a 
binding partner (Section 1.2.2.1), an N-terminal tethered LID sequence from a binding 
partner was also included, to form LLHD1 and LLHD3 (see Section 5.2.1 for more details). 
EMSAs were used to assess the binding of LLHD3 and LLHD1 to the same oligonucleotides 
as were tested with NHD3 and NHD1 (Figure 5.14). 
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Figure 5.14: EMSA titrations of homeodomain constructs with N-terminal 
LIM domains. * denotes the unbound oligonucleotide band. The leftmost lane of each set 
contains no protein. (A) LLHD3 against M100. LLHD3 concentrations range from 80 pM-5 
µM, in a twofold concentration series. (B) LLHD3 against Lhx3GSU. LLHD3 concentrations 
range from 80 pM-5 µM, in a twofold concentration series. (C) LLHD1 against M100, 
Isl1GA, and Lhx3GSU. LLHD1 concentrations range from 5 nM-5 µM, in a tenfold 
concentration series. 
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LLHD3 showed clear binding to Lhx3GSU, and weaker binding to M100, but LLHD1 
showed no binding to any oligonucleotide tested. These binding profiles are essentially 
identical to those seen for NHD3 (Figure 5.11) and similar for NHD1, but with less 
apparently non-specific binding (Figure 5.12). Thus, the presence of the LIM:LID interaction 
region does not affect binding of Lhx3HD, and if it does affect the binding of Isl1HD, it appears 
to be in an inhibitory manner. 
 
5.6.2 The presence of a dimerising domain can affect DNA binding 
preferences of homeodomains 
The influence of an N-terminal dimerisation domain was also investigated to mimic some of 
the previous studies that reported DNA binding activity of Isl1 (Section 5.6). This was 
achieved by omitting the HRV-3C cleavage step during purification of the homeodomain 
constructs (Section 2.5.3), to obtain GST-HD constructs with the ability to dimerise through 
GST, which has a dimerisation affinity with a dissociation constant (Kd) of ~ 1 µM [333]. 
GST-fused NHD1 and NHD3 were again tested against the same three oligonucleotides in 
EMSAs (Figure 5.15). 
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Figure 5.15: Behaviour of GST-fusion NHD1 and NHD3.  * denotes the unbound 
oligonucleotide band. The leftmost lane of each set contains no protein. Protein 
concentrations range from 40 nM-5 µM, proceeding in a twofold dilution series. (A) 
NHD1/GST-NHD1 against M100. (B) NHD1/GST-NHD1 against Isl1GA. (C) NHD1/GST-
NHD1 against Lhx3GSU. (D) NHD3/GST-NHD3 against M100. (E) NHD3/GST-NHD3 
against Isl1GA. (F) NHD3/GST-NHD3 against Lhx3GSU. 
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DNA binding of GST-NHD1 is slightly tighter than NHD1, but not by a substantial amount 
(Figure 5.15A-C). In contrast, binding of GST-NHD3 to DNA shows a very different pattern 
of behaviour to NHD3 (Figure 5.15D-F). Binding to Lhx3GSU was severely reduced, while 
binding to M100 was increased. Increased binding to M100 could be explained by the 
oligonucleotides ability to bind two homeodomains simultaneously, whereas Lhx3GSU can 
only bind one. However, the reduced binding to Lhx3GSU is not readily reconciled.  
 
5.7 Fusion constructs of Isl1 and Lhx3 behave differently to the 
individual homeodomains 
2HDN and 2HDLL were used to further probe the binding behaviour of the homeodomains 
from Isl1 and Lhx3 when in combination. 2HDN and 2HDLL were both seen to bind to the 
M100 oligonucleotide with clear shifted bands (Figure 5.16). EMSAs containing 2HDLL 
presented with a more intense shifted band than those containing 2HDN, but the shifts were 
evident at very similar protein concentrations. 
 
 
Figure 5.16: Examples of M100 binding by 2HDLL and 2HDN.  * denotes the 
unbound oligonucleotide band. Concentrations range from 80 pM-5 µM protein, proceeding 
in a twofold concentration series. The leftmost lane of each set contains no protein. (A) 
2HDLL titrated against M100. (B) 2HDN titrated against M100. 
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Some binding was observed for 2HDN and 2HDLL to the Isl1GA and Lhx3GSU sequences 
(Figure 5.17). However, this binding manifested as a disappearance of unbound 
oligonucleotide at higher concentrations, indicating weaker, possibly non-specific, binding. 
2HD23 bound in the same manner as 2HDN (Figure 5.18). As such, 2HD17 was not tested, 
as the information it could provide was considered redundant. 
 
 
Figure 5.17: Binding to single homeodomain binding site oligonucleotides by 
2HDN and 2HDLL. * denotes the unbound oligonucleotide band. Concentrations range 
from 80 pM-5 µM protein, proceeding in a twofold concentration series. The leftmost lane of 
each set contains no protein. (A) 2HDN against Isl1GA. (B) 2HDN against Lhx3GSU. (C) 
2HDLL against Isl1GA. (D) 2HDLL against Lhx3GSU. 
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Figure 5.18: Comparison of DNA binding behaviour for 2HDN and 2HD23. * 
denotes the unbound oligonucleotide band. The leftmost lane of each set contains no protein. 
Protein concentrations range from 40 nM-5 µM, proceeding in a twofold dilution series. (A) 
2HDN against M100. (B) 2HD23 against M100. (C) 2HDN against Lhx3GSU. (D) 2HD23 
against Lhx3GSU. 
 
Together, these results show that tethering the two homeodomains results in altered 
specificity of DNA binding compared to the individual homeodomains. That all fusion 
homeodomain/homeodomain constructs show the same changes in specificity suggests that 
the native LIM:LID interaction that brings the two homeodomains into proximity in the 
context of the ternary complex does not play a direct role in determining the overall 
specificity of DNA-binding by these homeodomains. However, the slightly tighter binding of 
2HDLL compared to the fusions with synthetic linkers does suggest that the LIM:LID 
regions could have an indirect influence on binding, perhaps by restricting the conformations 
of the homeodomains to allow the adoption of a structure that facilitates tighter DNA 
binding. 
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5.8 Quantitation of DNA-binding affinities 
Densitometry was used to obtain an estimate of the dissociation constants for the protein-
DNA complexes as described in Section 5.5, Section 5.6, and Section 5.7. Although there are 
limitations that prevent the technique from being truly quantitative, it can be useful in 
identifying broad trends. Table 5.3 lists Kds derived from EMSAs, in the combinations 
described above. 
 
Table 5.3: Kds (M) of homeodomain:DNA complexes, as determined from 
EMSAs (n = 2-3). * denotes combinations that were only measured once and are 
indicative only. N/A indicates combinations for which dissociation constants could not be 
calculated. 
Protein construct M100 Lhx3GSU Isl1GA 
NHD1 3.0 ± 2 × 10
-6 
2.0 ± 0.9 × 10
-6
 5.9 ± 0.3 × 10
-6
 
LLHD1 N/A N/A N/A 
GST-NHD1 2 × 10
-6 
* 4 ± 4 × 10
-6
 6 ± 5 × 10
-6
 
NHD3 4 ± 3 × 10
-6
 9 ± 3 × 10
-9
 2 ± 1 × 10
-6
 
LLHD3 1 × 10
-6 
* 1.5 × 10
-8 
* N/A 
GST-NHD3 5 ± 5 × 10
-7
 5 ± 3 × 10
-6
 2 × 10
-6 
* 
2HDLL 2.4 ± 0.3 × 10
-8
 4 ± 2 × 10
-6
 7 ± 5 × 10
-7
 
2HDN 1.6 ± 0.4 × 10
-7
 4.4 ± 0.9 × 10
-7
 5 ± 2 × 10
-7
 
 
The majority of binding events for which Kds could be estimated by this method have a Kd in 
the micromolar range (Table 5.3). These values are around the limit of measurement by this 
method and in the range for non-specific protein-DNA interactions [334]. In contrast, the 
dissociation constants in the nM range were considered to be specific interactions. These high 
affinity interactions include NHD3 against Lhx3GSU, 2HDLL and 2HDN against M100, and 
GST-NHD3 against M100. Interestingly, all of these strong interactions include Lhx3HD, 
suggesting that it drives DNA binding to either its own target (Lhx3GSU) as a single protein 
or to motor neuron genes (M100) as part of Isl1 and Lhx3-containing complexes. It is notable 
that two copies of Lhx3HD within a dimer (GST-NHD3) showed approximately the same 
strength of binding to M100 as 2HDLL, the tightest binding fusion construct mimic of the 
ternary complex. These data also indicate that Isl1HD does not strongly bind DNA in an 
independent manner, but may contribute to the binding in multiprotein DNA-binding 
complexes.  
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5.9 Further investigations into characterising the binding of 
homeodomain-DNA complexes 
Given that data from EMSAs is semi-quantitative, and several interactions appear to lie at or 
below the limit of detection, attempts were made to obtain additional quantitative binding 
data. 
 
5.9.1 Trialling the use of circular dichroism to observe changes in the 
stability of homeodomains upon DNA binding 
Far-UV CD can be used to monitor changes in protein stability or folding that result from 
binding to DNA. As shown in Section 5.4, NHD1 and NHD3 both exhibit spectra consistent 
with an alpha-helical structure. However, before observing the behaviour of protein-DNA 
complexes in CD, the behaviour of DNA by itself was assessed, to ensure the signal from the 
DNA would not interfere with the protein signals, or vice versa. 
 
5.9.1.1 Observing the melting behaviour of DNA in circular dichroism 
Spectra recorded of the M100 oligonucleotide from 10-90 °C did not result in significant 
signal changes in the range of 200-225 nm, meaning the DNA should not interfere with the 
homeodomain spectra in the same region (Figure 5.19). However, the DNA signal at 247 nm 
did shift over the temperature gradient, similar to the disappearance of signal seen upon 
protein unfolding at shorter wavelengths (Section 5.4.1, Figure 5.10). This shift could be 
exploited as a way to estimate the melting temperature of the DNA in CD - that is, the 
temperature at which the two strands of DNA dissociate. 
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Figure 5.19: Far-UV CD signals of oligonucleotides.  (A) Far-UV CD spectra of 
M100 oligonucleotide, taken every 2 degrees from 10 °C to 90 °C, with lowest temperatures 
shown in red, and higher temperatures progressing through a rainbow, with highest 
temperatures in purple. (B) Melt curves of oligonucleotides, using the signal at 247 nm. 
 
The melting temperatures of the oligonucleotides used were estimated, and compared with 
the theoretical melting temperatures of the sequences used (Table 5.4). A negative control 
oligonucleotide, HDC, was included. The sequence of HDC was derived from the sequence 
of Isl1GA, removing the TAAT core homeodomain binding site. The estimated melting 
temperatures from recorded spectra were considered close enough to the theoretical values to 
demonstrate that the change in signal at 247 nm does report dissociation of dsDNA. 
 
Table 5.4: Observed and theoretical melting temperatures of DNA sequences 
used in far-UV CD. Theoretical melting temperatures reported are from the manufacturer 
of the oligonucleotides (Integrated DNA Technologies; Coralville, IA). 
Oligonucleotide 
name 
Sequence Theoretical melting 
temperature (°C) 
Observed melting 
temperature (°C) 
M100 GCGCATTAGCCAAATTACG 
CGCGTAATCGGTTTAATGC 
64 63 
Isl1GA GCACCGCGTAATATCTGCG 
CGTGGCGCATTATAGACGC 
68 68 
Lhx3GSU ACTTAGCTAATTAAATGTG 
TGAATCGATTAATTTACAC 
54 55 
HDC CACGTGCCGTCAGCGGTAC 
GTGCACGGCAGTCGCCATG 
69 74 
 
5.9.1.2 Observing the foldedness of homeodomains in the presence of DNA 
It has been established in the literature that upon binding of DNA, homeodomains become 
more helical in structure [335, 336]. This was explored with NHD1 and NHD3 (Figure 5.20). 
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Both curves shift to the right, with a more intense signal at ~208 nm, indicating a more folded 
conformation.  
 
 
Figure 5.20 CD spectra of homeodomain with and without DNA (M100).  
Bound spectra were generated by subtracting the spectrum of M100 alone from the spectra of 
each homeodomain protein in the presence of M100. 
 
5.9.1.3 Homeodomains melt at a higher temperature in the presence of DNA 
Combinations of NHD1 and NHD3 with different oligonucleotides were subjected to thermal 
melts analysed by far-UV CD. For all oligonucleotides tested the homeodomains melted at a 
higher temperature in the presence of an oligonucleotide (Table 5.5). Notably, this increase in 
melting temperatures included samples with the negative control oligonucleotide, HDC. 
Binding to this oligonucleotide should be weak and non-specific in nature.  
 
Table 5.5: Comparison of homeodomain melting temperatures (°C) with and 
without DNA present.  Melting temperatures were estimated as the point of 50% intensity 
of proportional CD for each sample, measured at 222 nm. 
 Oligonucleotide 
None M100 Isl1GA Lhx3GSU HDC 
NHD1 43 68 73 67 73 
NHD3 43 68 74 65 66 
 
The melting temperatures of the oligonucleotides was also assessed (Table 5.6). Although the 
DNA melting temperatures generally increase in the presence of the homeodomains, the 
changes are generally less than for the proteins upon addition of oligonucleotide.  
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Table 5.6: Comparison of DNA melting temperatures (°C) with and without 
homeodomain present.  Melting temperatures were estimated as the point of 50% 
intensity of proportional CD for each sample, measured at 247 nm. 
Oligonucleotide Alone with NHD1 with NHD3 
M100 63 68 68 
Isl1GA 68 73 74 
Lhx3GSU 55 66 67 
HDC 74 78 71 
 
It is notable that the melting temperatures of the oligonucleotide and protein in any 
combination are extremely similar, except in the case of the HDC oligonucleotide. The 
similar melting temperatures observed are consistent with stabilisation of both entities by 
complex formation, and dissociation of the protein-DNA complex leading to unfolding. For 
HDC, interaction with NHD1 appears to be stabilising for both the protein and the DNA, 
whereas with NHD3 the interaction is stabilising for the protein but apparently destabilising 
for the DNA. The mechanisms for such binding and stabilising behaviours are not known. 
 
5.9.2 Quantification of binding affinities 
Microscale thermophoresis (MST) and isothermal titration calorimetry (ITC) were attempted 
to acquire more quantitative information about the binding of homeodomain:DNA 
interactions. 
 
5.9.2.1 MST 
Thermophoresis is a phenomenon in which different particles move differently within a 
temperature gradient. In microscale thermophoresis experiments, application of a small 
thermal pulse sets up a temperature gradient, and molecules will move into or out of the hot 
spot depending on their properties. This results in changes of local concentration which can 
be measured, as one partner is fluorescently tagged and so can be monitored. By setting up a 
concentration series with the partner protein, binding affinities can be determined, because 
the thermophoretic behaviour of the labelled molecule changes according to whether or not it 
is bound by the titrated partner [337]. For the experiments described here, the DNA was 
fluorescently labelled (Section 2.6.4, Appendix A). 
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Unfortunately, this approach did not work well for these homeodomain-DNA interactions. 
Some sample data is shown for 2HDLL and M100 experiments, but similar problems were 
experienced with other pairs. For this interaction, which appears to be a high affinity 
interaction by EMSAs (Section 5.7), the expected outcome was a standard monophasic or 
biphasic hyperbolic binding curve indicating high affinity specific binding, with or without 
non-specific binding at higher protein concentrations. Instead any changes in fluorescence 
were very small and the data were very noisy at higher concentrations (Figure 5.21), with 
similar results seen when the MST power was increased twofold. 
 
 
Figure 5.21: Microscale thermophoresis data for the interaction between 
2HDLL and M100. Data were taken at 20% MST power. Error bars represent standard 
deviation, with 5 technical replicates. 
 
One reason for these problems could be the experimental set up. The M100 oligonucleotide 
was used at a concentration of 50 nM to enable detectable fluorescence. As the 
2HDLL:M100 interaction appears to be of high affinity (~50 nM according to EMSA data), 
this oligonucleotide concentration may be too close to the Kd for valid measurement of the 
affinity of the interaction. However, similar results were also seen for apparently lower 
affinity interactions. 
 
One quality control check for this technique is to record the fluorescence of all the samples 
before thermophoresis. As all samples contain the same amount of DNA (and so fluorescence 
label), they should have the same intensity of fluorescence, but here there was significant 
variation observed (Figure 5.22). The same effect was noted for sample capillaries with 
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different coatings (which can resolve this problem for some molecules [338]). In general, 
there was lower fluorescence at the higher concentrations, so it is possible that binding of 
2HDLL to the M100 oligonucleotide could have quenched the fluorescence of the 
oligonucleotide, influencing the thermophoresis measurements taken. This was unexpected, 
as these oligonucleotides are identical to those used for fluorescent EMSAs and the 
fluorescent tag is not immediately adjacent to the binding site. However, due to these 
difficulties, it was concluded that MST was not a suitable technique for studying this system. 
 
 
Figure 5.22: Capillary fluorescence scan of 2HDLL:M100 samples prior to 
thermophoresis measurements.  Concentration range proceeds in a twofold dilution 
series from 75 µM (leftmost) to 2.3 nM (rightmost). 50 nM M100 oligonucleotide was 
present in each sample. 
 
5.9.2.2 ITC 
ITC measures the heat released (or absorbed) from binding events. The data gathered from 
this technique can give precise thermodynamic information including Kds, binding 
stoichiometry, and enthalpies of binding. ITC titrations were performed using the 
homeodomains from each of Lhx3 (NHD3) and Isl1 (NHD1) against their respective target 
binding sequences, as well as against M100 and the negative control oligonucleotide HDC 
(sequences listed in Table 5.4). Note that these oligonucleotides were not fluorescently 
labelled. 
 
These experiments showed some promise. However, these data could not be fitted to 
reasonable titration curves, as the fits obtained reported aberrant stoichiometries of binding. 
Optimisation of experimental conditions is required in order to obtain data of sufficient 
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quality for quantitative analysis. In particular, as this technique is very sensitive to 
concentration, more careful estimates of concentrations for both protein and DNA could help 
to resolve the observed inconsistencies associated with stoichiometry. Additionally, higher 
concentrations of materials are required for more complete titrations for better estimations of 
binding affinities (Figure 5.23). These optimisation experiments could not be carried out 
during the timeframe of this thesis. Nevertheless, qualitative assessment of these preliminary 
data based on the shapes of the binding curves indicates higher levels of binding by Lhx3HD 
than Isl1HD. 
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Figure 5.23: ITC titrations of homeodomains against binding sequences. (A) 
NHD1 against the negative control HDC; (B) NHD3 against the negative control HDC; (C) 
NHD1 against Isl1GA; (D) NHD3 against Lhx3GSU; (E) NHD1 against M100; (F) NHD3 
against M100. Note that these curves are not scaled to each other. 
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5.10 Discussion 
The work described here shows two very similar DNA-binding domains, with markedly 
different DNA-binding behaviours. Whereas Isl1HD and Lhx3HD show similar properties in 
terms of folding and stability, they exhibit very different DNA-binding properties. Isl1 was 
seen to bind DNA only in a weak, probably non-specific manner, but Lhx3 bound with much 
higher affinity to a specific sequence (Lhx3GSU). The DNA-binding behaviour of Isl1 is 
unusual for a homeodomain, and bears closer examination. 
 
5.10.1 Comparing the observed binding behaviour to the reported 
behaviour in the literature 
The DNA-binding specificity of homeodomains has been extensively studied, both in 
individual cases and in a high throughput manner [46, 63, 69, 339-342]. These studies have 
been successful in identifying a plethora of consensus sequences for specific homeodomains, 
as well as providing quantitative data on the homeodomain-DNA interaction. Specific 
binding to DNA is normally observed with affinities in the nanomolar range, with non-
specific binding being with approximately micromolar affinity [343, 344]. These 
measurements support the EMSA data presented in Sections 5.5-5.8, in which NHD3 and 
2HDLL were seen to bind to one target sequence with nanomolar affinity, and all other 
binding combinations were observed with affinities in the micromolar range.  
 
Although cooperative binding was not observed between NHD1 and NHD3, many instances 
of cooperative binding between different homeodomain proteins have been observed, 
including some that resulted in altered specificity [345-349]. Many of these examples involve 
proteins from the Pre-B-cell leukaemia transcription factor (Pbx) or Meis family [350-354]. 
These proteins contain homeodomains, but are generally involved in DNA-binding only in 
the presence of an additional homeodomain [349, 355, 356]. Similar to the behaviour seen 
with Isl1 and Lhx3, the combination of a homeodomain protein and a Pbx/Meis protein in 
complex shows different DNA-binding preferences to the individual proteins [350]. There is 
limited data to show if Pbx or Meis proteins can bind to DNA in isolation. However, the 
mechanism of action of Pbx/Meis-homeodomain complexes has been explored, and a short 
YPWM motif in the partner protein was shown to interact with the Pbx/Meis homeodomain, 
forming the basis for complex formation and the change in binding specificity [357, 358]. No 
143 
 
such motif can be found in the sequence of either Isl1 or Lhx3, meaning that though the 
behaviour of these proteins may be similar, the mechanisms are probably different. 
 
Another instance of a homeodomain with markedly different DNA-binding behaviour is the 
transcriptional regulator homeodomain-only protein (Hopx) [359]. Hopx is a small protein 
that consists almost entirely of a homeodomain fold [360]. This homeodomain has not been 
shown to bind to DNA, but was shown to act to regulate expression of genes in many 
contexts, including during development [360-364]. The inability of Hopx to bind DNA arises 
from its sequence, which has a very low level of conservation compared to other mammalian 
homeodomains [360]. Specifically, Hopx is missing key DNA-binding residues at positions 
2, 4, 51, 53, and 55 of the homeodomain fold. Whereas Isl1 may behave like Hopx in terms 
of DNA-binding, it does not share these sequence discrepancies (discussed further in Section 
5.10.3). 
 
5.10.2 Isl1 binding in the literature 
The data presented here are in contrast with published literature on Isl1. Several papers report 
in vitro specific binding of Isl1 to DNA and showed evidence of this binding in EMSAs [44, 
104, 126, 130, 136, 332]. It should be noted that the work presented here is the only study 
that used the isolated homeodomain of Isl1. All other studies used fusion proteins containing 
Isl1, and/or used un-purified full length Isl1 in complex mixtures of proteins such as cell 
lysates. In those environments, there is the potential for Isl1 to interact with other proteins. 
Any resulting DNA-binding does not necessarily reflect the properties of Isl1 alone, as Isl1 
forms many protein-protein interactions with other DNA-binding proteins as part of its 
function (Section 1.5). This is especially the case with experiments performed using full 
length Isl1 produced in reticulocyte lysate, as reticulocytes are known to express Ldb1, a 
binding partner of Isl1 that could bridge interactions between Isl1 and other DNA-binding 
proteins [365, 366]. 
 
Nevertheless, other indirect evidence does support the data in this chapter that suggests that 
isolated Isl1HD is unable to bind DNA strongly. Many transcription factor binding site 
databases now exist, providing a valuable resource for investigating transcription factor 
protein-DNA interactions. These databases either lack, or have poor quality, binding data for 
Isl1, but have plentiful data for Lhx3 and most other LIM-homeodomain proteins [3, 367-
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370]. Although those studies do not address negative data, a consistent absence of Isl1 in the 
databases implies that weak or no binding is the norm for Isl1 in the absence of binding 
partners. 
 
5.10.3 Checking Isl1HD sequence against overall homeodomain conservation 
Homeodomain-DNA interactions have in general been well characterised [68, 340, 342, 371]. 
It is possible to compare the amino acid sequence of Isl1 with that of other homeodomains to 
try and detect sequence differences that may explain its unusually poor DNA-binding 
behaviour. 
 
Many residue positions in the canonical 60 residue homeodomain fold are highly conserved 
(Figure 5.24). This is especially seen in the third alpha-helix, comprising residues 41-58, 
which binds the major groove of DNA (Section 1.2.2.3). Nearly half (28 from ~60) of the 
positions in the homeodomain sequence have one amino acid identity that occurs in 50% or 
more sequences. These residues can be classified as contributing to DNA-binding, or to 
protein fold stability (Table 5.7). 
 
 
Figure 5.24: Sequence conservation across 213 human homeodomains.  This 
figure was generated using Skylign, inputting 213 human homeodomain sequences from the 
Homeodomain Resource Databank that were aligned using Clustal Omega [67, 372, 373]. 
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Table 5.7: Conserved amino acids in the homeodomain fold . Prevalence was 
calculated from a set of 213 60-residue homeodomain sequences [69, 374]. 
Position Isl1 amino 
acid 
Conserved 
amino acid 
Prevalence Position Role 
49 F F 98% Helix 3 Hydrophobic core 
48 W W 98% Helix 3 Hydrophobic core 
16 L L 96% Helix 1 Hydrophobic core 
53 R R 95% Helix 3 DNA interacting 
51 N N 90% Helix 3 DNA interacting 
40 L L 88% Flexible loop Hydrophobic core 
20 Y F 87% Helix 1 Hydrophobic core 
5 R R 86% N-terminal tail DNA interacting 
12 Q Q 84% Helix 1 Unclear 
55 K K 81% Helix 3 DNA interacting 
35 V A 76% Helix 2 Unclear 
52 K R 74% Helix 3 Salt bridge 
45 I V 73% Helix 3 Hydrophobic core 
25 R Y 70% Flexible loop DNA interacting 
17 R E 69% Helix 1 Salt bridge 
50 Q Q 68% Helix 3 DNA interacting 
31 K R 66% Helix 2 DNA interacting 
34 L L 66% Helix 2 Hydrophobic core 
6 T T 63% N-terminal tail Unclear 
38 T L 56% Helix 2 Hydrophobic core 
9 N T 56% Helix 1 Unclear 
57 K K 55% Helix 3 DNA interacting 
8 L F 53% N-terminal tail Hydrophobic core 
26 P P 52% Flexible loop Introduces turn 
42 P E 52% Helix 3 Salt bridge 
13 L L 51% Helix 1 Unclear 
44 V Q 50% Helix 3 Unclear 
2 T R 50% N-terminal tail DNA interacting 
  
Of the 28 conserved residues listed, Isl1 differs from the conserved residue primarily in 
regions that influence fold stability [374]. Notably, residue 25 in Isl1 is a tyrosine, whereas it 
is arginine in the majority of other homeodomains. This position is classified as lying in a 
DNA-interacting loop, so could influence DNA binding in Isl1. However, it cannot fully 
explain the DNA-binding behaviour of Isl1, as Lhx3 also has a tyrosine residue at this 
position. Overall, there are no residues where the sequence in Isl1 varies from the canonical 
or highly conserved sequences that would account for weakened DNA binding.  
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5.10.4 Potential non-canonical roles for Isl1HD 
Alternative roles for Isl1HD are possible. Homeodomains were recently found to be involved 
in several cellular functions beyond canonical DNA binding. These include binding of 
methylated DNA and acting as nuclear localisation sequences, as detailed below. 
 
5.10.4.1 Methylated DNA binding 
A recent paper highlighted the potential of homeodomains to bind methylated DNA, offering 
a potential novel role for Isl1 [103]. However, upon closer observation of the data presented 
this is thrown into question. In the publication, several residues were identified as being 
crucial for this interaction, specifically those in positions 43, 47, and 54 of the canonical 
homeodomain fold. For binding methylated DNA the following residues are favoured: 
arginine at position 43, a valine or isoleucine at position 47, and a valine or alanine at 
position 54. These are all relatively common residues: of the 213 sequences analysed above, 
30% of homeodomains contained R43, 80% contained a valine or isoleucine at position 47, 
and 40% contained either a valine or an alanine at position 54. Of the sequences analysed 
10% fulfilled all three of these requirements, with this figure expanding to 53% for sequences 
containing two or more requirements. 
 
These numbers suggest that many homeodomains may have the potential to bind methylated 
DNA (assuming the identified residues do direct such binding), in direct contradiction of the 
findings of the study, which showed that most homeodomains cannot bind methylated DNA. 
It is worth noting that even with structural data providing a very clear picture of sequence 
preferences for homeodomain-DNA binding, it is still not possible to pinpoint the interactions 
responsible for dictating the specificity of these interactions. 
 
5.10.4.2 Homeodomains as nuclear localisation sequences 
Homeodomains can act to direct cell localisation, in addition to their DNA binding capability. 
Examples have been found of homeodomains containing both nuclear export sequences and 
nuclear localisation sequences [297, 375, 376]. Helix 3 of the canonical homeodomain 
contains a sequence (RRMKWKK) that could function as a nuclear localisation sequence 
[297]. Given that this region is highly conserved across all homeodomain containing proteins, 
it is possible that the homeodomain of Isl1 can target the protein to the nucleus. However, the 
full Isl1 protein is comparatively small, and should be able to diffuse into the nucleus without 
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the aid of nuclear transport chaperones [377]. Additionally, the sequence at the beginning of 
the LIM domains of Isl1 contains a canonical nuclear localisation sequence, which is more 
likely to play a role in the localisation of Isl1 (See Section 4.2.2.8). 
 
5.10.5 Consequences of a weak DNA-binding Isl1 
It is possible that isolated Isl1 does not bind DNA with an affinity sufficient for 
transcriptional regulation. Rather, it may be necessary for Isl1 to interact with other DNA-
binding proteins, through its LIM and LID regions, to target DNA. Interestingly, of the LIM-
HD proteins, only Isl1 and its close homolog Isl2 contain identified LIDs. Their role in the 
ternary complex may be to modify the properties of Lhx protein, with small contributions 
from the homeodomain in the Isl protein contributing to DNA binding. This aspect of ternary 
complex formation and DNA binding is explored in the following Chapter. 
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6 Structural studies on the 2HDLL:M100 
complex 
Although the qualitative DNA binding data from Chapter 5 show there are differences in 
DNA binding behaviour between the individual homeodomains and the homeodomains in 
ternary complex mimics, they do not fully explain the differences. In this chapter, attempts 
were made to gather more detailed structural information about the 2HDLL:M100 complex, 
to better understand how Lhx3 and Isl1 bind their target DNA sites. 
 
The whole 2HDLL:M100 complex was chosen for study, as structures are already available 
for Isl1HD and Isl1LID:Lhx3LIM. Additionally, DNA-binding data indicate that the binding 
behaviour of the Lhx3 and Isl1 homeodomains alters when the two are in close proximity, 
such as in a protein fusion like 2HDLL. Attempts were not made to crystallise isolated 
2HDLL due to expected flexibility of the linker region. 
 
6.1 The 2HDLL:M100 complex is monodisperse in solution 
Size exchange chromatography coupled with multi-angle laser light scattering analysis (SEC-
MALLS) was used to establish the stoichiometry of the 2HDLL:M100 complex. This 
technique also provides information about sample heterogeneity, which could hamper 
structure determination efforts. 
 
2HDLL and M100 were mixed in at 100 µM in a 1:1 ratio and subjected to SEC-MALLS 
(Figure 6.1). The elution profile shows a major peak at ~23 mins and two smaller peaks at 
~34 and 38 min. Only the first peak was of a high enough intensity to register scattering or 
UV absorbance (Figure 6.1B). It showed strong absorbance at both 280 nm and 260 nm, 
indicating that both protein and DNA are present. The difference in signal intensity between 
the peaks indicates that the majority of the protein and DNA in solution are in complex.  
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Figure 6.1: Elution profiles of 2HDLL:M100 from SEC-MALLS. SEC-MALLS 
was conducted at 1 mL/min, room temperature, in 20 mM sodium phosphate 
monobasic/dibasic pH 7.4, 100 mM NaCl, 1 mM DTT. (A) Measurements of differential 
refractive index, as well as molar mass estimate of major peak. (B) UV absorbance and 
scattering readings from 3 different angles. 
 
Using Astra (Wyatt Technology) analysis to estimate the mass of the major species eluting 
from SEC-MALLS yields a value of 50-51 kDa, which is in good agreement the expected 
size of 49 kDa for the 2HDLL:M100 complex with 1:1 stoichiometry, as the error of 
estimating solution weight average molecular weight by this approach is ~10% [378]. The 
smaller peaks may represent uncomplexed protein or DNA, but due to the low signal 
intensity this could not be investigated. The lack of higher molecular weight peaks indicates 
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that the complex itself is not forming higher molecular weight species (higher order 
oligomers or aggregates). These data indicate that the protein-DNA complex forms a 
monodisperse complex with at least moderate affinity (greater than Kd ~10
-7 
M) under near-
physiological buffer conditions, making it a suitable candidate for structural studies [379]. 
 
6.2 Attempting to solve the structure of 2HDLL:M100 through 
crystallography 
Several different oligonucleotides were used in attempts to crystallise the 2HDLL:M100 
complex (Table 6.1). Each contained the M100 sequence with a one-base overhang, with the 
exception of M100c20b, which was blunt-ended. Crystallisation screens were set up with one 
well for each buffer condition containing 2HDLL:M100, and a second containing only M100, 
for ready identification of crystals containing only DNA. 
 
Table 6.1: Oligonucleotide sequences used for crystallography trials.  
Name Sequence (5’-3’) 
M100c21 ACGCCATTAGCCAAATTACGC 
 GCGGTAATCGGTTTAATGCGT 
M100c20 ACGCATTAGCCAAATTACGC 
 GCGTAATCGGTTTAATGCGT 
M100c20b CCGCATTAGCCAAATTACGC 
GGCGTAATCGGTTTAATGCG 
M100c14 TCATTAGCCAAATTA 
 GTAATCGGTTTAATT 
 
6.2.1 Initial crystallisation condition screening 
Initially screening was conducted using M100c21, as this oligonucleotide most closely 
mimicked the sequence used in DNA binding studies. The one-base overhang in the design 
can be useful in helping DNA to form extended structures that encourage regular crystal 
formation [334]. Unfortunately, while nucleation (as evidenced by the formation of 
microcrystals or spherulites) was observed in protein-DNA wells in several conditions, these 
species dissolved upon contact, or were too small for recovery (Figure 6.2). In all cases where 
nucleation was observed in protein-DNA wells, it was also observed in the DNA-only 
condition, suggesting that DNA was the entity undergoing nucleation. The species observed 
for the protein-DNA samples were highly birefringent, which is consistent with nucleic acid 
crystallisation [380, 381]; however, no evidence could be obtained to determine whether or 
not protein was present. 
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Figure 6.2: Examples of nucleation in 2HDLL:M100c21 wells. (A) and (B) from 
Morpheus screen; (C) from Index HT; (D) from JCSG+ HT. 
 
Different versions of the M100 oligonucleotide were then designed - the original M100 
oligonucleotide was shortened into one version 20 bases long (M100c20), and one version 14 
bases long (M100c14), based on oligonucleotide lengths that have previously been successful 
in giving homeodomain-DNA structures by X-ray crystallography (Table 6.1) [65, 330, 382, 
383]. A one-base overhang was retained in both oligonucleotides. 
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Both 2HDLL:M100c14 and 2HDLL:M100c20 crystal screens resulted in conditions with 
evidence of protein-DNA nucleation (Figure 6.3). However, screening with M100c14 did not 
result in any 2HDLL:M100c14 crystals. Overall there were relatively few conditions that 
showed evidence of nucleation, and those that did were consistent with DNA-only crystals, as 
crystals observed in 2HDLL:M100c14 drops looked the same as those in M100c14-only 
drops. 
 
The initial crystallisation trials for 2HDLL:M100c20 were more promising. Many conditions 
showed protein-DNA nucleation, but while the majority of these were consistent with DNA-
only crystals in the corresponding DNA-only wells, several conditions gave rise to likely 
protein-DNA crystals (Figure 6.3). While there was still nucleation or crystallisation 
observed in the corresponding DNA-only drops for these conditions, in all cases there were 
differences in morphology observed between the two wells. Before pursuing optimisation, 
tests were carried out to establish whether protein was present in these crystals. 
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Figure 6.3: Conditions showing 2HDLL:M100c20 crystallisation.  (A), (C), (E), 
and (G) are conditions containing protein and DNA; (B), (D), (F), and (H) contain only DNA. 
(A) and (B) from PEG Ion, condition A7; (C) and (D) from Crystal Suite, condition H3; (E) 
and (F) from JCSG+ HT, condition H4; (G) and (H) from Natrix, condition F5. 
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The putative protein-DNA crystals observed in the 2HDLL:M100c20 trays were small but 
could be recovered from the crystal trays. However, their small size meant that mounting 
crystals and obtaining diffraction signals was difficult. For this reason, a gel-based method 
was used to check for the presence of protein. Crystals were recovered from several 
conditions and dissolved, before being analysed by SDS-PAGE with visualisation using 
SYPRO Ruby staining (Figure 6.4, Section 2.6.7.2). SYPRO Ruby can be used to visualise as 
little as ~5 ng of protein, making it suitable for detecting the small amounts of protein 
contained in recovered crystals [384-386].  
 
 
Figure 6.4: SYPRO Ruby stained SDS-PAGE of putative 2HDLL:M100 
crystals. Mark12 ladder was included for size estimation. Lanes 1-9 contain dissolved 
crystal. The negative control lane contains sample prepared by mimicking recovering a 
crystal in a clear drop. The positive control lane contains the entire contents of a 
crystallography drop, taken from a drop with no signs of nucleation.  
 
Crystal Screen condition H3 (lane 7, Figure 6.4) and Natrix condition F4 (lane 8, Figure 6.4) 
both showed strong bands at the correct molecular weight for 2HDLL, indicating that these 
crystals contain protein. JCSG condition H11 (lane 3, Figure 6.4) also showed a moderately 
strong band, but while recovering these crystals a ‘skin’ was also recovered from the drop. 
This skin may have contained protein, so whether there was protein in the crystals was not 
confirmed here. The components found in Crystal Screen H3 and Natrix F4 are listed in 
Table 6.2. 
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Table 6.2: Initial crystallisation conditions that grew putative protein-DNA 
crystals. 
Screen ID Components 
H3, Crystal Screen 0.2 M Magnesium chloride hexahydrate  
0.1 M Tris, pH 8.5 
3.4 M 1,6-Hexanediol 
F4, Natrix 0.08 M Strontium chloride hexahydrate 
0.04 M Sodium cacodylate, pH 6 
35% (+/−)-2-Methyl-2,4-pentanediol (MPD) 
12 mM spermine tetrahydrochloride 
 
6.2.2 Optimising 2HDLL:M100c20 crystals 
Both crystallisation conditions contained a divalent cation and chloride-containing salt, as 
well as a diol-based precipitant, and neither condition was extremely acidic or basic. With 
this in mind, gradient screens were designed to optimise crystal growth. Two four-gradient 
screens were designed around these initial crystallisation conditions, varying the 
concentration of precipitant, the divalent cation, and the pH. These screens successfully 
replicated the original crystallisation condition, and some larger crystals were observed in 
conditions with lower concentrations of precipitant. 
 
Larger crystals were seen in the gradient screen containing hexanediol (Figure 6.5). However, 
while they still looked morphologically different from the corresponding M100c20 crystals 
(Figure 6.5C), they more closely resembled the DNA-only crystals from initial screening 
(Figure 6.5D). 
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Figure 6.5: Optimised crystals grown in the hexanediol gradient screen.  (A) 
Protein-DNA well, condition F5; (B) protein-DNA well, condition E5; (C) DNA only crystals 
from initial screening condition (JSCG+ H4); (D) DNA only crystals grown in optimisation 
condition E5. 
 
Crystals grown in the MPD gradient screen were more morphologically consistent with the 
initial crystals observed (Figure 6.6). These crystals were larger than those observed in the 
initial screen, but precipitation was present in the optimisation screen that was not seen in the 
initial screen. Crystals obtained from both sets of optimisation trays were taken to the 
Australian Synchrotron for diffraction screening, but no diffraction was observed. 
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Figure 6.6: Optimised crystals grown in the MPD gradient screen.  (A) Protein-
DNA well from MPD optimisation screen condition A3; (B) Protein-DNA well from MPD 
optimisation screen condition B9; (C) Protein-DNA well from initial screening condition 
crystals (Natrix F5); (D) Protein-DNA well from MPD optimisation screen condition C9. 
 
As the M100c20 oligonucleotide showed the most promise from the crystallisation trials 
described above, a variant of this oligonucleotide, but without the 1-base overhang 
(M100c20b; Table 6.1), was tested. The removal of the overhang no longer predisposes the 
DNA to form long strands through the crystals, which may reduce the overall chance of 
nucleation, but may also allow the protein-DNA complex to pack in an overall more 
favourable way. However, this strategy only resulted in DNA-only crystals. No protein-DNA 
screening conditions were found to have crystals likely to contain both the protein and the 
DNA, as all observed crystals closely resembled those seen in the corresponding DNA-only 
condition.  
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As the attempts to crystallise the 2HDLL:M100 complex did not result in diffracting crystals, 
alternative strategies were pursued to obtain structural information about the complex. 
 
6.3 Investigating low resolution structure with small angle X-ray 
scattering 
Small angle X-ray scattering (SAXS) was pursued as an alternative strategy to 
crystallography, as a technique that could provide information about the shape and 
component disposition of the complex in solution. 
 
6.3.1 SAXS background  
SAXS is based on the principle that particles exposed to a focussed X-ray beam will cause 
scattering of the X-rays (reviewed in [387]). This scattering is recorded at a detector, across 
varying angles of diffraction (Figure 6.7). The intensity and distribution of scattering reflects 
properties of the particle being measured [388]. Fourier transforms of scattering profiles 
result in a distribution of atom-pair distances, weighted by the product of their scattering 
factors. Different samples have different scattering factors. For example, DNA scatters more 
than protein, so a more intense signal will be observed from two atoms within a DNA 
oligonucleotide, compared to two atoms within a protein of the same spacing.  
 
 
Figure 6.7: Schematic of SAXS, showing the diffraction and detection of X -
rays. Figure adapted from [387]. 
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SAXS data can be used to make inferences about various structural characteristics, such as 
overall solution conformation and conformational flexibility of the particle [389]. However, 
SAXS can only be used to obtain structural information when data is recorded from pure, 
homogenous samples. SAXS analysis relies on aggregated data, so any impurities or 
heterogeneity within the sample will skew downstream analyses [390]. This thesis will not go 
into depth on the mathematical background of SAXS analysis, but several key parameters are 
explained below. 
 
6.3.1.1 Experimental terms 
SAXS data is commonly presented in the form of X-Y plots of q against I(q), with varying 
manipulations applied (discussed in [387, 391, 392]). q is the length of the scattering vector 
(Figure 6.7) and is related to the wavelength of the applied radiation, through the formula:  
 
 
Equation 1 
 
In Equation 1, θ is half the angle of the scattering, with reference to the forward scattering 
(Figure 6.7). λ is the wavelength of the incident beam. q can be expressed in nm-1 or Å-1. In 
some studies, variables called s or h are used in the place of q. Definitions of these terms can 
vary, so all data presented in this thesis will use q. 
 
The function I(q) is a measure of the intensity of the scattering, in absolute units (cm
-1
). I(q) 
values are the product of the volume of the particle (V), the electron density of the particle 
(ρ), the forward scattering (I0), and the form factor P(q), which is a function that reflects the 
shape of the particle emitting scattering: 
 
 
Equation 2 
 
Plotting q against I(q) then reflects the intensity of scattering across a range of q angles. 
Commonly used plots include the logarithmic plot, Guinier plot, and Kratky plot, each of 
which provides different assessments about the sample quality and or particle properties.    
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6.3.1.2 Plots 
The logarithmic plot is commonly used to confirm the dispersity of the sample [392]. The 
logarithmic plot shows both q and I(q) on a logarithmic scale. For a homogenous and 
monodisperse sample, the logarithmic plot will be a flat line at low q. An upturn as q 
approaches 0 is an indication of aggregation, and a downturn is an indication of interparticle 
interference, a phenomenon whereby molecules in solution repel each other [393]. Both 
phenomena can skew downstream analyses. 
 
The Guinier plot, q
2
 against ln[I(q)], is used to calculate Rg and to estimate I(0) by 
extrapolation [394-396]. I(0) cannot be directly measured because of the beamstop placement 
in experimental setups. Because of its similarity to the logarithmic plot, this plot can also 
reveal information about the dispersity of the sample. The Guinier plot is generally only used 
to present data at low q (where qRg is less than 1.3), as this region is the most linear; this is 
referred to as the Guinier region [395, 397]. 
 
The Kratky plot displays scattering data in a form that provides an indication of flexibility in 
the sample (Figure 6.8) [389, 398]. The dimensionless Kratky plot removes any influence of 
concentration differences, which allows for direct comparisons between different data sets 
[397, 399].  In both forms of the plot, the height of the peak at low s, in comparison to the 
increasing linear trend at higher s, is indicative of flexibility. 
 
 
Figure 6.8: Examples of Kratky plots.  Figure adapted from [389]. 
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6.3.1.3 Calculated terms 
One important calculated parameter is the radius of gyration (Rg), which is an indicator of the 
size and shape of a particle [395]. It is the mean root square of distances from the centre of 
the particle being analysed. The Rg is used for modelling calculations and can be a useful 
indicator of data quality. Rg is calculated from the inverse Fourier transform of I(q), but can 
also be visualised as the gradient of the curve of the Guinier plot. 
 
The molecular weight of the particle being observed can also be calculated from SAXS data 
[390, 400]: 
 
 
Equation 3 
 
Equation 3 uses Avogadro’s number (NA), along with the properties of the particle in the 
chosen solvent, namely electron density (ρ) and partial specific volume (v), as well as the 
concentration of the particle (C) and I(0). This metric allows confirmation of the size of the 
particle and can reveal polydispersity present in the sample. Due to the relationship with 
concentration, inaccurate concentration measurements can affect the calculated molecular 
weight, making it less accurate. 
 
6.3.2 Trialling SAXS with the 2HDLL:M100 complex 
Data were collected using 2HDLL and the M100c20 oligonucleotide, using the 
SAXS/WAXS beamline at the Australian Synchrotron. Initially, two experimental set ups 
were used: static SAXS, where each sample is exposed to X-rays in a capillary, and SEC-
SAXS, where the sample is injected into a SEC column, in-line with a SAXS apparatus such 
that eluting material from the SEC column is then exposed to X-rays. Both experimental set 
ups were utilised to determine the optimal conditions for observation of the 2HDLL:M100 
complex. It was important to ensure that small amounts of potentially unbound protein and 
DNA seen in the SEC-MALLS data (Figure 6.1) would not influence the SAXS 
measurements and downstream analyses (Section 6.1). Extensive standards have been 
established for reporting of SAXS data [390]. Appendix E contains complete reporting of 
sample details, data collection, and analysis.  
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6.3.3 SEC-SAXS indicates the 2HDLL:M100 complex is homogenous 
SEC-SAXS was performed using the same column as previously used in SEC-MALLS 
experiments, allowing for easy identification of the complex (Section 6.3.1). The elution 
profile looked very similar to that seen during SEC-MALLS, with the majority of the signal 
detected belonging to the 2HDLL:M100 complex peak (Figure 6.9). 
 
 
Figure 6.9: Elution profile of 2HDLL:M100 on SEC-SAXS, showing 
absorbance at three wavelengths.  (A) Full elution profile. (B) 2HDLL:M100 elution 
peak, showing absorbance and Rg values. 
 
Rg analysis of each frame measured show an overall stable Rg across the elution peak, of 
approximately 39 Å (Figure 6.9B). This provides additional evidence that the complex is 
homogenous, and gives a figure for comparison in static SAXS data analysis. Due to the 
dilution of the sample as it runs through the SEC apparatus, the signal:noise ratios for SEC-
SAXS data were too low for modelling purposes. Static SAXS was conducted at a higher 
concentration, providing a higher signal:noise ratio that was more suitable for downstream 
structural analysis. 
 
6.3.4 Analysing static SAXS data 
Data for M100 and M100: 2HDLL were collected across a range of different concentration 
samples (Section 2.6.8). Data for 2HDLL was collected at a single concentration. Complete 
parameters and statistics from analysis can be found in Appendix E; below is a summary of 
the features of the data. 
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Logarithmic plots show that most of the data sets are homogenous, as indicated by the 
linearity of the data at low values of log(q) (Figure 6.10, Section 6.3.1.2). The datasets for the 
lowest concentration samples show lower signal:noise ratios than desired, but all samples had 
sufficient signal intensity for analysis.  
 
 
 
Figure 6.10: Baseline subtracted static SAXS data for concentration series.  
Logarithmic plots of (A) M100 and (B) 2HDLL:M100. Plots show a concentration series 
with the highest concentration being shown in red, then progressing through a rainbow. 
 
Rg analysis for M100 samples showed an Rg consistently between 21.44 and 22.38 Å (Table 
6.3). However, the reported Rgs for 2HDLL:M100 samples were found to be concentration 
dependent, with higher concentrations reporting higher Rgs. This was especially noticeable 
for the highest concentration 2HDLL:M100 sample and can be observed in differing 
gradients of the datasets in Guinier plots (Figure 6.11). This variation was taken as an 
indication of potential aggregation, given that the SEC-SAXS data indicates the Rg should be 
around 39 Å. For this reason 2HDLL:M100 data sets E and F, which were consistent with the 
SEC-SAXS data, were used for structural analysis. 
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Table 6.3: Experimental Rgs (Å) for M100 and 2HDLL:M100 SAXS samples.  
Sample M100 2HDLL:M100 
 Rg Max qRg Rg Max qRg 
A 21.44 1.26 47.89 0.97 
B 21.82 1.25 42.65 1.15 
C 22.28 1.29 40.74 1.23 
D 22.38 1.26 40.38 1.19 
E 21.88 1.3 38.97 1.28 
F 21.82 1.3 36.61 1.3 
 
 
Figure 6.11: Guinier plots of M100 alone and 2HDLL:M100 SAXS datasets.    
(A) Guinier region of M100 samples, showing the points used for Rg analysis and linear fits; 
(B) Guinier region of 2HDLL:M100 samples, showing the points used for Rg analysis, and 
linear fits. qRg maxima used for fitting are listed in Table 6.3. 
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Kratky plots showed that data for the DNA alone (M100) gave rise to a curve consistent with 
that of a folded species, whereas 2HDLL alone and 2HDLL:M100 samples gave rise to 
curves characteristic of a species with both folded and flexible regions (Figure 6.12). The 
flexible nature of the complex could explain why crystallography efforts failed (Section 6.2). 
 
 
Figure 6.12: Kratky plots of SAXS data.  Measured data with M100 alone A (light 
blue), 2HDLL alone (black), and 2HDLL:M100 A (dark blue). 
 
The dimensionless Kratky plot can be used to more directly compare the flexibility of 
different particles (Section 6.3.1.2). This plot again suggests that 2HDLL is flexible, by the 
plateaued peak shape and the dispersion of the data at higher qRg values (Figure 6.13). The 
data for M100 suggests an ordered species, and the data for 2HDLL:M100 shows an 
intermediate state between the two.  
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Figure 6.13: Dimensionless Kratky plots of SAXS data.  Dotted line indicates the 
point at which qRg = √3, (qRg)2I(q)/I(0) = 1.104; this point is a local maximum for folded 
globular proteins. 
 
It is reasonable to assume that if the flexible 2HDLL bound DNA it would have reduced 
flexibility and therefore a different overall shape. Thus, data from 2HDLL in isolation was 
not used to model 2HDLL bound to M100. In contrast, based on existing structural data for 
homeodomain-DNA complexes, the much more rigid M100 is unlikely to be significantly 
affected by binding (Section 1.2.2.3). 
 
6.3.5 Modelling the 2HDLL:M100 complex 
The modelling program MONSA was used to construct potential envelopes of the 
2HDLL:M100 complex. MONSA is an ab initio modelling algorithm that uses iterative 
dummy atom modelling to find a solution that most closely matches the inputted SAXS data 
[401]. Baseline subtracted data, the proportional volumes of each species in solution, and the 
dmax (maximum dimension of the particle being modelled) are the only inputs for required for 
MONSA. The Rg may also be supplied as an additional modelling constraint. 
 
MONSA can be used to model complexes, by inputting multiple data sets and specifying 
which complex components are present in each data set. MONSA can also accommodate 
phases with different scattering densities. In this case, this allows the DNA and protein 
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components to be distinguished. For modelling the 2HDLL:M100 complex, data sets for both 
the complex and the DNA alone were input, for the reasons outlined at the end of the 
previous section. 
 
The inherent flexibility within the complex means that as the data reaches higher q values, it 
will not tend towards 0 as quickly as would a highly ordered species, which impacts the 
modelling performance, as MONSA assumes that the data tends towards 0. To prevent this 
from affecting the models generated, the data was truncated to a q cut off of 0.3. The signals 
beyond this point are dominated by short range internal density fluctuations, which MONSA 
does not consider as it uses uniform density modelling for each component. As a result, 
truncation of the data should not impact the validity of the fits generated. 
 
Due to uncertainty around the dmax of the complex, as well as the Rg, these parameters were 
varied for different iterations of modelling. Each combination of parameters was used to 
generate three iterations of modelling. The resulting ensemble of models showed varying 
conformations of the complex. Four representative models will be discussed, as they illustrate 
the variations and similarities present within the ensemble (Figure 6.14). 
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Figure 6.14: Examples of 2HDLL:M100 models generated using MONSA.  
These models were generated by restricting the Rg of 2HDLL during modelling. (A) Rg of 35; 
(B) Rg of 37; (C) Rg of 39; (D) Rg of 42. The parts of the model corresponding to DNA are 
shown in green and the protein component is shown in gold. 
 
In all of these models the DNA appears to have been modelled effectively as a roughly rod-
like or elongated volume. The models also place the protein in close proximity to the DNA, 
indicative of an interaction, but also show a substantial volume of protein that does not 
appear to contact the DNA. This volume potentially represents the LIM:LID part of the 
construct that lies between the two homeodomains of 2HDLL.  
 
There was significant variation amongst the models in terms of how much of the protein was 
placed in contact with the DNA. Several models showed an extended interaction interface 
between the DNA and the protein, suggesting that both homeodomains bind the DNA (Figure 
6.14 C and D), but others showed only a small portion of protein interacting with the DNA, 
which could indicate single homeodomain binding (Figure 6.14 A and B). In those models 
where the protein is not interacting along the length of the DNA, it is interesting to note that 
the protein-DNA interface is primarily localised to one end of the DNA, as opposed to the 
centre. This may reflect a tight interaction between Lhx3HD and the AAATTA site in the 
M100c20 oligonucleotide. While these models show different conformations, they all show a 
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similar fit to the data (Figure 6.15). Since all of the models fit the data equally well, it cannot 
be determined which conformation is more likely to represent the 2HDLL:M100 complex. 
Indeed, it is possible that all of these conformations are represented in solution.  
 
 
Figure 6.15: Assessing the fits of 2HDLL:M100 models generated. The same 
models are used as in Figure 6.14. (A) Plot of fits overlayed on experimental data for 
2HDLL:M100; (B) Difference plot of fits to 2HDLL:M100; (C) Plot of fits overlayed on 
experimental data for M100; (B) Difference plot of fits to M100. Difference plots were 
generated by calculating the difference between the experimental data and the fit, then 
dividing by the error of the fit.  
 
It is not possible to determine how Isl1HD is interacting with the DNA from the SAXS data 
presented in this chapter. More data is required to gain further insight into the conformational 
and structural interplay between the protein and DNA components of this complex. As the 
2HDLL:M100 complex has been shown here to be flexible in nature, it may not be possible 
to obtain one definitive structure of the complex. 
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6.4 Discussion 
This chapter has sought to gain insight into the structure of the Lhx3:Isl1 DNA-binding 
module. Due to the flexible nature of the 2HDLL:M100 observed in SAXS, it is not yet 
possible to construct a definitive model of how this complex binds DNA. However, the data 
presented here have provided hints as to the main features of binding. 
 
Chapter 5 showed that the Isl1 homeodomain in isolation is unable to bind DNA with high 
affinity or specificity. The additional SAXS data presented in this chapter shows that when 
brought into close proximity to Lhx3HD within fusion constructs, Isl1HD can potentially bind 
to DNA. This data gives rise to the following question about the function of Isl1: if the 
protein only makes a small contribution to DNA-binding in the context of a larger complex, 
how does this affect its function? Several theories are plausible. 
 
6.4.1 Mechanisms of Isl1 and Lhx3 cooperation 
When Isl1 and Lhx3 are in combination they preferentially bind a sequence different to that 
bound by Lhx3 only (Section 5.7) [99]. Consequently, the two homeodomains must be 
somehow influencing the binding preferences of each other. 
 
6.4.1.1 The potential for homeodomain heterodimerisation 
One simple explanation for this would be a direct interaction occurring between Isl1HD and 
Lhx3HD. Although the involvement of homeodomains in protein-protein interactions is not 
common, dimerisation of homeodomains has been previously observed [342, 371, 402]. The 
DNA binding specificities of these heterodimers were shown to be different to those of the 
individual homeodomains. In many cases, these interactions rely on residues upstream or 
downstream of one of the homeodomains. However, there are only six residues between the 
end of the Lhx3 LIM domains (definitions as judged by solved crystal structures (PDB: 2JTN 
and 2RGT)) and the beginning of the canonical homeodomain. If the residues immediately 
upstream of the Lhx3 homeodomain were involved in an interaction with Is1lHD, there would 
likely be steric hindrance between the Isl1 homeodomain and the Lhx3 LIM domains. 
Further, DNA binding experiments using Isl1/Lhx3 fusion constructs in this thesis have 
demonstrated that the linker sequence between the two is not important in binding specificity 
of the complex, as binding behaviour is similar whether there is a native linker (2HDN) or a 
glycine-serine linker (2HD23) (Section 5.7). This would mean that any interaction between 
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the two homeodomains would occur through the homeodomains themselves, which is 
unlikely. 
 
6.4.1.2 A kinetic explanation for changing DNA-binding preferences 
Another potential explanation is that Isl1 does bind to DNA but has kinetic properties (e.g. 
rapid off-rates) that make it difficult to observe by the methods used herein. If this were the 
case, the binding of Lhx3 to DNA, and the tethering of the protein components through LIM-
LID complexes could lock the DNA-bound Isl1HD in place. The presence of Isl1HD could alter 
the specificity of Lhx3HD, by making it sterically less favourable to bind a TAATTA site, and 
more favourable to bind a CATTAGCCAAATTA sequence, which has room for two 
homeodomains to be bound simultaneously. This type of mechanisms resembles the way that 
homeodomains are thought to bind non-specifically to DNA, and then move around and 
along the DNA until they find a binding site of high affinity [403]. This binding mechanism 
would be especially relevant in an in vivo environment. Since Isl1 appears to be unable to 
stably bind DNA independently, it seems likely that the Lhx3:Isl1 interaction would form 
first, and then the complex would bind cognate sites in DNA. Having two DNA binding 
domains linked together through protein complex formation, with one being a tighter binder 
than the other, has shown to be an effective way for a complex to search for recognition sites 
on DNA more effectively [404]. 
 
6.4.2 Future directions 
Efforts to obtain a high resolution crystal structure of the 2HDLL:M100 complex were 
unsuccessful. However, the SAXS data has provided new insight into the flexibility of the 
complex. Further investigations into the conformation of the complex with further SAXS 
experiments may extend our knowledge more. These investigations are currently underway, 
as more SAXS data was gathered in November 2018. This data focussed on 2HDLL and 
M100c20b, but also on other protein constructs in combination with M100: 2HDN, LLHD3, 
and NHD3. Although initial analysis of this additional SAXS data looks promising, thorough 
analysis and modelling could not be conducted in the timeframe of this thesis. These other 
protein constructs may be useful in gathering further structural insights. The flexibility seen 
in the conformation of 2HDLL, both alone and in complex with M100, may potentially be 
due to movement between the LIM:LID regions and the homeodomains respectively. If this is 
the case, SAXS data for the 2HDN:M100 complex may not be influenced by the flexibility 
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that prevents rigorous structural modelling of the 2HDLL:M100 complex. Since 2HDN 
appears to bind DNA in a very similar manner to 2HDLL (Section 5.7), it may then also be of 
interest to attempt to solve the structure of 2HDN:M100 through X-ray crystallography.  
 
The binding behaviour of 2HDLL to M100 could also be further characterised to provide 
more information about how binding is facilitated. This includes the use of surface plasmon 
resonance (SPR) to probe the kinetic properties of binding, as well as uncovering which 
specific amino acids are involved in binding through HSQC (heteronuclear single quantum 
coherence) NMR titrations.  
 
A larger focus on the DNA side of the interaction may also provide new information. Varying 
the spacing of the CATTAG and AAATTA sites within the M100 oligonucleotide and 
checking the binding with 2HDLL could help to indicate whether a direct Isl1:Lhx3 
interaction influences the DNA binding of the overall complex. It would also be intriguing to 
check the binding behaviour of GST-NHD3 dimers to such DNA mutants, to see if they still 
follow the same binding trends as 2HDLL. 
 
6.4.3 Conclusion 
Without a clearer structural picture of how the motor neuron complex is binding DNA, it is 
impossible to precisely define the DNA-binding behaviour of Isl1. At this stage, it appears 
likely that Isl1 does contribute to DNA-binding when in complex with a binding partner, such 
as Lhx3. It is possible that this behaviour is functionally relevant, and acts as a mechanism by 
which Isl1 can act in combination with many different DNA-binding proteins, allowing 
precise targeting of specific DNA sequences in an efficient manner. This could provide a 
partial explanation for how Isl1 plays a role in regulating gene expression in such a diverse 
range of tissues, even though it does not appear to bind DNA when in isolation. 
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7 Conclusions 
This thesis has investigated the protein-DNA and protein-protein interactions that allow Isl1 
to function as a transcriptional regulator with diverse roles across many tissues, in the hopes 
of gaining new insights into how Isl1 acts in a wide variety of cellular contexts. 
 
Chapters 3 and 4 investigated the protein interaction domains of Isl1, searching for novel 
binding partners through yeast two-hybrid library screening. These screens were successful in 
identifying putative novel binding partners for Isl1, with Mkln1 being a potential binding 
partner of interest based on its ability to bind both Isl1LIM and Ldb1LID/Isl1LIM in two 
orthologous systems. Other potential binding partners identified herein may also be of 
interest, although close assessment of the literature suggests that some may not represent 
biologically relevant interactions (Chapter 4). This identification of binding events that may 
be real but are not biologically relevant highlights the need for good moderation of large 
screening datasets of this type, and for thorough validation of putative interactions. 
 
Chapters 5 and 6 shifted the focus onto the mechanisms by which Isl1 and Lhx3 interact with 
DNA as isolated LIM-HD proteins or when in combination. Chapter 5 probed the DNA-
binding behaviour of the two homeodomains and reveals that Lhx3 and Isl1 have very 
different DNA binding behaviours, despite being very similar in terms of sequence, fold and 
stability. It appears that Isl1 is not able to bind to DNA, including its reported recognition 
sequences, with high affinity in the absence of a protein binding partner that promotes DNA-
binding. In Chapter 6, the behaviour of the Isl1 and Lhx3 homeodomains in complex was 
further investigated, with the key goal being determination of a structure of the 
2HDLL:M100 complex. Although an atomic resolution structure was not produced, SAXS 
has provided new insights into this apparently dynamic complex (Section 6.3). The 
combination of EMSA data presented in Chapter 5 and SAXS data presented in Chapter 6 
provide biophysical evidence that the Isl1 homeodomain can bind to DNA directly to 
modulate the stronger binding of Lhx3. Additional structural and biophysical studies, 
informed by the presented data herein, should provide confirmation of how these two 
homeodomain proteins can bind different DNA sites as single entities or through combined 
efforts. 
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7.1 The role of the Isl1 in a broader context 
Aside from its role in the motor neuron complex, the action of the Isl1 homeodomain is also 
relevant to the other roles of the Isl1 protein. The data presented here using Isl1/Lhx3 fusion 
constructs provides hints about how Isl1 can play a role in many different contexts. 
 
As Isl1 has been shown to play a role regulating gene expression in many tissues (Section 
1.4), it may be that weak DNA binding is essential to its function. Making a smaller 
contribution to DNA binding affinity could allow Isl1 to participate in a wider range of 
protein-DNA complexes, targeting a broader range of DNA sequences than would be 
possible if it bound DNA with a higher affinity or increased specificity. It is also possible that 
the combination of a weakly DNA-binding Isl1 in complex with another protein that binds 
DNA more strongly allows more rapid identification and binding of target sequences, which 
can be crucial in a developmental context, where cell fate decisions are made with precise 
timing [403, 404]. This ability to use non-specific binding to search for specific gene targets 
is a known feature of homeodomains [405]. 
 
The influence of Isl1 on the DNA-binding of partner proteins could be easily investigated 
through the production and study of other fusion constructs containing Isl1HD and another 
DNA-binding domain. Studying the DNA-binding behaviour of such fusion constructs would 
allow a broader insight into how the Isl1 homeodomain influences the DNA-binding 
preferences of other proteins. As Isl1 is thought to cooperate with a wide variety of 
transcription factors in vivo, it is likely that it influences the binding specificities of at least 
some other protein binding partners in a similar manner to that seen in the case of the motor 
neuron complex. 
 
It is plausible that the primary role of Isl1 is as a protein-protein adaptor, bringing together 
other transcription factors so that they may bind DNA. In support of this statement, Isl1 and 
Isl2 are the only LIM-homeodomain proteins to have two known protein-protein interaction 
interfaces (LIM domains and LIDs), and so are the only proteins in the LIM-HD transcription 
factor family that can form higher order complexes through those two interfaces. However, 
all the LIM-HD proteins have uncharacterised C-termini, so dual protein-binding sites may 
not be exclusive to the Islet proteins. Moreover, the Islet proteins may also contain additional 
interaction domains that have not yet been identified. 
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It must be noted that LIM domains themselves can bind to multiple binding partners 
concurrently. Examples of this include the case of the hematopoietic transcriptional complex 
that contains Lmo2 [406, 407], and the cytoskeletal complex that contains another LIM-
domain containing protein, Testin [408, 409]. In situations such as this, binding partners are 
in very close proximity, meaning they have the opportunity to interact with each other, as 
well as with the LIM domain protein. The LIDs appear to be more limited in their ability to 
interact with other partners. To date they appear to bind only one protein at any instance, and 
whereas Ldb1LID can interact with multiple partners [51], Isl1LID preferentially binds only 
Lhx3 and Lhx4, with apparently lower affinity binding to Lmx1b [54]. The LIDs from Isl1 
and Isl2 have another proposed role in shielding the Isl1 LIM domains from non-specific or 
off-target interactions [54]. However, it may be possible for the intramolecular LIM:LID 
interaction to co-exist with another LIM domain based protein-protein interaction. This may 
act as a mechanism by which higher order complexes are formed: initial binding of a protein 
to the Isl1LIM domains, before displacement of the Isl1LID and formation of further protein-
protein interactions. 
 
From the data presented here, it is clear that the study of both protein-protein and protein-
DNA interactions are important in examining the function of Isl1. Data from Chapter 5 
suggests that Isl1 may not be able to function as a DNA-binding transcription factor without 
the presence of additional protein binding partners. Given that the specificity of the Lhx3:Isl1 
complex is different to that of an independent Lhx3, it appears that Isl1 can influence the 
DNA-binding specificity of its protein binding partners. In vivo, this is potentially a 
mechanism by which Lhx3:Isl1 complexes can target different areas of the genome than 
Lhx3-only containing complexes. This behaviour extends to other transcriptional complexes 
containing Isl1. For example, Isl1 has been found to influence the DNA-binding preferences 
of the transcription factor Phox2a during cranial motor neuron development, in a similar 
fashion to its behaviour with Lhx3 [105]. Further work may identify other instances of Isl1 
modulating the DNA-binding specificity of its protein-protein interaction partners. 
 
It may be that the weak binding of Isl1 to DNA is an advantage in the context of multi-
protein complexes binding to DNA. Assuming that this property helps Isl1-containing 
complexes find their targets more quickly (see above), Isl1 may refine the in vivo DNA-
targeting properties of any transcriptional complex it is a part of, and allow that complex to 
find its genomic targets efficiently. As Isl1 can bind multiple partners, it could influence the 
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DNA-binding properties of many different transcriptional complexes, and thereby direct 
development in a broad range of contexts. 
 
Further study is needed to determine whether this model of the action of Isl1 is correct. 
Investigation of the DNA-binding behaviour of Isl1 in the context of different protein binding 
partners will generate a more complete picture of the role of Isl1 in transcriptional regulation 
of gene expression, giving new insight into how the interplay of protein-protein and protein-
DNA interactions can influence gene regulation. 
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Appendix A - Oligonucleotides used for binding 
studies 
Listed in Table A.1 are all the sequences of oligonucleotides used for binding studies, as well 
as any modifications. 
 
Oligonucleotide 
name Sequence (5’-3’) Modifications 
Experiments 
used for 
Isl1GA 
ACCGCGTAATATCTG 
TGGCGCATTATAGAC 
5’ fluorescein EMSAs, MST 
GCACCGCGTAATATCTGCG 
CGTGGCGCATTATAGACGC 
None CD, ITC 
Lhx3GSU 
ACTTAGCTAATTAAATGTG 
TGAATCGATTAATTTACAC 
5’ fluorescein EMSAs, MST 
ACTTAGCTAATTAAATGTG 
TGAATCGATTAATTTACAC 
None CD, ITC 
M100 
CGGCCATTAGCCAAATTACGGC 
GCCGGTAATCGGTTTAATGCCG 
5’ fluorescein EMSAs, MST 
GCGCATTAGCCAAATTACG 
CGCGTAATCGGTTTAATGC 
None CD, ITC 
HDC CACGTGCCGTCAGCGGTAC 
GTGCACGGCAGTCGCCATG 
None CD, ITC 
M100c21 ACGCCATTAGCCAAATTACGC 
 GCGGTAATCGGTTTAATGCGT 
None Crystallography 
M100c20 ACGCATTAGCCAAATTACGC 
 GCGTAATCGGTTTAATGCGT 
None Crystallography 
M100c20b CCGCATTAGCCAAATTACGC 
GGCGTAATCGGTTTAATGCG 
None Crystallography 
M100c14 TCATTAGCCAAATTA 
 GTAATCGGTTTAATT 
None Crystallography 
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Appendix B - Amino acid sequences of protein 
fusion tags 
Listed in Table B.1 are the sizes and amino acid sequences of protein fusion tags used 
throughout this thesis. 
 
Table B.1: Fusion protein tags used. Linkers and protease cleavage sites are 
highlighted in green. 
Tag 
Size 
(kDa) Sequence 
FLAG (+ linker) 2.1 MDYKDDDDKGSTRTHNR 
HA (+ linker) 2.4 MYPYDVPDYASRGSTRTHNR 
MBP (+ linker) 41.0 MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTV
EHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGL
LAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALS
LIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQ
EPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAK
AGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTIN
GPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAG
INAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVA
LKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWY
AVRTAVINAASGRQTVDEALKDAQTNSSSGGGGS  
GST (+ 3C site) 26.8 MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEG
DKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIAD
KHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDF
MLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDK
YLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGPL
GS 
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Appendix C - Sequencing primers 
Various sequencing primers were used throughout this thesis for either confirmation of 
correct subcloning, or identification of inserts in vectors. Primers and the vectors they were 
used with are listed in Table C.1. 
 
Table C.1: sequencing primers used.  All primers anneal either upstream (forward) or 
downstream (reverse) of the MCS, unless otherwise specified. 
Primer name Primer sequence (5’-3’) Vector 
T7 (forward) TAATACGACTCACTATAGGG pcDNA3.1 
pET-DUET 
BGH (reverse) CGCCAGGGTTTTCCCAGTCACGAC pcDNA3.1 
malE (forward) GGTCGTCAGACTGTCGATGAAGCC pMAL 
pMAL3 (reverse) CGCCAGGGTTTTCCCAGTCACGAC pMAL 
pGAD (forward) GTATAACGCGTTTGGAATC pGAD10 
pGADT7-RecAB 
pGAD (reverse) CTTAGAGGAGTATAGTTACAT pGAD10 
pGADT7-RecAB 
pGBT9 (forward) TCATCGGAAGAGAGTAG pGBT9 
pGBT9 (reverse) CGTTTTAAAACCTAAGAGTCAC pGBT9 
pGBT9ab (forward) AATAATGGTTTCTTAGACGTC pGBT9 antibiotic 
resistance gene 
pGBT9ab (reverse) TGCAAGCAGCAGATTAC pGBT9 antibiotic 
resistance gene 
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Appendix D - Library titering experiments 
Library titering experiments were performed to confirm that large scale library screening was 
being conducted correctly. This involved inoculating appropriate selective media with known 
dilutions of both parental yeast strains, as well as mated yeast (Table D.1). Dilutions were 
chosen as recommended by the Clontech Matchmaker® Gold Yeast Two-Hybrid System 
User Manual. 
 
Table D.1: Conditions used for library titering experiments  
Yeast strain Media Dilutions 
Y187 pre-transformed with 
preys 
SD-L 1:100 
1:1000 
1:10000 
Mated yeast SD-L-W, SD-W, SD-L 1:10 
1:100 
1:1000 
1:10000 
 
After incubating for 3 days (30 °C), colonies were then counted, and calculations performed 
to determine the viability of the yeast library, the viability of the mated yeast, the number of 
clones screened, and the mating efficiency (Tables D.2, D.3, D.4, and D.5 respectively). In all 
cases, the library-containing Y187 yeasts were the limiting partner in determining mating 
efficiency. 
 
Table D.2: Library viabilities.  Viability is calculated by dividing the number of 
colonies observed by the dilution factor and volume of inoculum. Viability is measured in 
colony forming units (cfu) per mL. 
Library screen 
Average number of 
prey colonies per plate 
Viability of library (cfu × 
10
6
/mL) 
Ldb1LID/Isl1LIM 1056 211 
Isl1LIM (2014) 714 143 
Isl1LIM (2016) 300 60 
Isl1∆LIM (2.5 mM 3-AT) 300 60 
Isl1∆LIM (2 mM 3-AT) 193 39 
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Table D.3: Viability of mated yeast in interaction screening.  
Library screen 
Colonies grown of mated yeast Viability of 
mated yeast 
(cfu/mL) 
10
-2
 
dilution 
10
-3
 
dilution 
10
-4
 
dilution 
10
-5
 
dilution 
Ldb1LID/Isl1LIM >300 83 20 2 2,000,000 
Isl1LIM (2014) >300 >300 >300 59 59,000,000 
Isl1LIM (2016) >300 >300 255 43 43,000,000 
Isl1∆LIM (2.5 mM 3-AT) >300 >300 255 42 42,000,000 
Isl1∆LIM (2 mM 3-AT) >300 >300 >300 81 81,000,000 
 
Table D.4: Screening efficiencies of yeast two-hybrid library screens.  Number 
of clones screened is calculated by multiplying the viability of the mated yeast by the total 
volume of culture. 
Library screen 
Viability of 
mated yeast 
(cfu/mL) 
Resuspended total 
volume of mated 
yeast (mL) 
Number of clones 
screened (millions) 
Ldb1LID/Isl1LIM 2,000,000 11.4 23 
Isl1LIM (2014) 59,000,000 11.9 702 
Isl1LIM (2016) 43,000,000 12.3 529 
Isl1∆LIM (2.5 mM 3-AT) 42,000,000 12.3 517 
Isl1∆LIM (2 mM 3-AT) 81,000,000 13.6 1102 
 
Table D.5: Mating efficiencies of yeast two-hybrid library screens.  Mating 
efficiency is calculated by dividing the viability of mated yeast by the viability of the library. 
Library screen 
Viability of library 
(cfu × 10
6
/mL) 
Viability of mated 
yeast (cfu × 10
6
/mL) 
Mating 
efficiency (%) 
Ldb1LID/Isl1LIM 211 2 0.9 
Isl1LIM (2014) 143 59 41 
Isl1LIM (2016) 60 43 72 
Isl1∆LIM (2.5 mM 3-AT) 60 42 70 
Isl1∆LIM (2 mM 3-AT) 39 81 210 
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Appendix E - SAXS reporting 
Full SAXS experimental details and parameters related to data processing and modelling are 
listed in Tables E.1 and E.2. Tables E.3 and E.4 report parameters from analyses of static 
SAXS data sets. 
 
Table E.1: SAXS Experimental details . This includes sample details and data 
collection parameters. 
 2HDLL M100c20B 2HDLL:M100 
Sample Details    
Organism Mus musculus Mus musculus Mus musculus 
Source Expressed;  
see Section 5.3 
IDT  
Sequence See Appendix G Table 6.1  
Extinction coefficient 1.024  
(A280, 0.1% w/v) 
30933.25  
(A260, 
0.1% w/v) 
Unknown 
Partial specific volume 
(cm
3
 g
-1
) 
0.731 0.59 0.696 
Particle contrast from sequence 
and solvent constituents (10
10
 cm
-2
) 
2.953  
(12.404-9.452) 
5.344  
(14.795-9.452) 
3.23  
(12.68-9.452) 
Mw from chemical composition 45152 12015 57167 
SEC-SAXS 
Column  Superose 12 10 x 300 mm 
Loading concentration  
(mg mL
-1
) 
2.55 3 3 
Injection volume (µL) 99 100 100 
Flow rate (mL min
-1
) 1 1 1 
Static SAXS 
Concentration (mg mL
-1
) 0.26 0.75 0.69 
Solvent 20 mM sodium phosphate monobasic/dibasic, pH 7.4, 
100 mM NaCl, 1 mM DTT 
Data collection parameters 
Instrument Australian Synchrotron SAXS/WAXS beamline with 
Dectris PILATUS 1M detector 
Wavelength (Å) 1.07812 
Beam size (µm) 250 × 450 
Camera length (m) 0.9 
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q measurement range (A
-1
) 0.006-0.34 
Absolute scaling method Comparison with scattering from 1 mm pure H2O 
Normalisation To transmitted intensity by beam-stop counter 
Monitoring for radiation damage X-ray dose maintained below 210 Gy 
Exposure time 1 sec, 40 exposures per sample 
Sample configurations SEC-SAXS 
Aspiration of samples into a capillary from a 96-well 
plate  
Sample temperature 27 °C 
 
Table E.2: Data processing details and parameters. 
Data reduction, analysis and interpretation 
SAXS data reduction ScatterBrain 2.82 
Extinction coefficient estimate ProtParam 
Calculation of volume and contrast MULCh 1.1 
Basic analyses (Guinier, Kratky, P(r)) PRIMUSqt from ATSAS 
Shape/bead modelling MONSA 
Three-dimensional graphic model representation PyMOL 2.0.6 
Structural parameters 
 2HDLL M100 2HDLL:M100 
Guinier analysis 
I(0) (cm
-1
) 0.0069* 0.024* 0.034* 
Rg (Å) 33.77 ± 1.97 19.27 ± 0.10 34.74 ± 0.29 
qmin (Å
-1
) 0.00636 0.00636 0.00636 
qRg max (qmin = 0.00636) 1.29 1.29 1.34 
Coefficient of correlation, R
2
 0.75 0.95 0.91 
M from I(0) 
(ratio to predicted) 
34098.15  
(0.92) 
18985.65 (1.55) 50730.31 (1.03) 
P(r) analysis  
I(0) (cm
-1
) 0.007041 ± 
0.000174 
0.02373 ± 
0.00009 
0.03459 ± 0.00032 
Rg (Å) 35.56 ± 1.37 20.0 ± 0.12 36.39 ± 0.42 
Dmax (Å) 122 67 130 
q range (Å
 -1
) 0.00860268-
0.235868 
0.0145871-
0.344776 
0.0213196-
0.238108 
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Χ2 0.8014 0.76 0.7155 
Mw from I(0) 
 (ratio to predicted) 
34794.94 
(0.93515) 
18772.06 
(1.53655) 
51610  
(1.04422) 
Porod volume (Å
 -3
)  
(ratio Vp/calculated Mw) 
71400  
(1.2792) 
14600  
(0.7967) 
67000  
(0.9037) 
* Errors in I(0) as reported in PRIMUSqt are smaller than the significant figures reported for I(0) 
 
Table E.3: Parameters from Guinier analyses of datasets. 
Sample 
concentration 
(µg/mL) Rg I(0) 
Pearson’s 
R for fit q-range 
qRg 
max 
Mw 
from 
I(0) 
Ratio of 
Mw to 
expected 
M100 alone 
969 21.43±0.23 0.021 0.95 0.01792-
0.106842 
1.29 12867 1.05 
485 21.60±0.27 0.011 0.92 0.015265-
0.104188 
1.28 13480 1.10 
242 22.01±0.82 0.0056 0.76 0.015265-
0.105515 
1.3 13725 1.12 
121 21.89±0.84 0.0029 0.79 0.01261-
0.101534 
1.29 14215 1.16 
61 21.73±1.27 0.0015 0.83 0.015265-
0.108169 
1.28 14705 1.20 
30 21.85±1.58 0.0015 0.86 0.011283-
0.108169 
1.29 29410 2.40 
2HDLL:M100 
3969 47.89±2.28 0.23 0.82 0.015265-
0.029866 
0.92 60240 1.22 
1985 45.85±3.10 0.1 0.89 0.023229-
0.043139 
0.88 52382 1.06 
992 40.72±0.36 0.049 0.98 0.01261-
0.049776 
1.22 51335 1.04 
496 40.72±0.78 0.024 0.97 0.011283-
0.048448 
1.05 50287 1.02 
248 38.69±0.87 0.011 0.92 0.009955-
0.055085 
1.26 46097 0.93 
124 36.91±0.44 0.005 0.97 0.00995-
0.060394 
1.25 41906 0.85 
2HDLL alone 
2550 39.36±1.31 0.042 0.98 0.021902-
0.056412 
1.18 21199 0.57 
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Table E.4: Parameters from P(r) analyses of all datasets.  
Sample 
concentration 
(µg/mL) Rg I(0) Dmax q range 
Q value 
for fit 
Porod 
volume 
M100 alone 
969 22.13±0.08 0.0214 68 0.0206 to 
0.3731 
0.78 19500 
485 22.22±0.13 0.0109 67 0.0206 to 
0.3692 
0.78 19600 
242 22.06±0.22 0.0055 65 0.0219 to 
0.3626 
0.79 21800 
121 22.19±0.41 0.0029 65 0.0179 to 
0.3652 
0.79 19500 
61 21.23±0.50 0.0014 60 0.0126 to 
0.3678 
0.81 14100 
30 21.99±0.63 0.0015 65 0.0126 to 
0.362 
0.80 13300 
2HDLL:M100 
3969 42.64±0.00 0.2127 125 0.0139-
0.1665 
0.57 107000 
1985 46.28±0.51 0.1022 200 0.0126-
0.1732 
0.65 115000 
992 42.85±0.33 0.0493 160 0.0113-
0.1957 
0.75 125000 
496 42.00±0.50 0.0237 145 0.0113-
0.1957 
0.71 114000 
248 39.64±0.40 0.0110 120 0.0139-
0.2063 
0.79 96000 
124 38.21±0.75 0.0050 118 0.0113-
0.2156 
0.78 56400 
2HDLL alone 
2550 40.38±0.26 0.04237 133 0.0113-
0.2023 
0.77 75600 
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Appendix F - Amino acid sequences of Mkln1 
constructs and Isl1 constructs 
The amino acid sequences for Isl1 and Mkln1 constructs used throughout Chapter 4 are listed 
in Tables F.1 and F.2. 
 
Table F.1: Amino acid sequences of Isl1 constructs used for interaction 
testing. 
Construct Size (kDa) Sequence 
Isl1FL 38.1 GSKRLISLCVGCGNQIHDQYILRVSPDLEWHAACLKC
AECNQYLDESCTCFVRDGKTYCKRDYIRLYGIKCAKC
SIGFSKNDFVMRARSKVYHIECFRCVACSRQLIPGDEF
ALREDGLFCRADHDVVERASLGAGDPLSPLHPARPLQ
MAAEPISARQPALRPHVHKQPEKTTRVRTVLNEKQLH
TLRTCYAANPRPDALMKEQLVEMTGLSPRVIRVWFQ
NKRCKDKKRSIMMKQLQQQQPNDKTNIQGMTGTPM
VAASPERHDGGLQANPVEVQSYQPPWKVLSDFALQS
DIDQPAFQQLVNFSEGGPGSNSTGSEVASMSSQLPDTP
NSMVASPIEA 
Isl1LIM 14.9 GSKRLISLCVGCGNQIHDQYILRVSPDLEWHAACLKC
AECNQYLDESCTCFVRDGKTYCKRDYIRLYGIKCAKC
SIGFSKNDFVMRARSKVYHIECFRCVACSRQLIPGDEF
ALREDGLFCRADHDVVER 
Isl1∆LIM 24.1 GSHDVVERASLGAGDPLSPLHPARPLQMAAEPISARQP
ALRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANPR
PDALMKEQLVEMTGLSPRVIRVWFQNKRCKDKKRSI
MMKQLQQQQPNDKTNIQGMTGTPMVAASPERHDGG
LQANPVEVQSYQPPWKVLSDFALQSDIDQPAFQQLVN
FSEGGPGSNSTGSEVASMSSQLPDTPNSMVASPIEA 
Ldb1LID/Isl1LIM 20.2 GSDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAAN
GIDDEGGSGGHMGSGGKRLISLCVGCGNQIHDQYILR
VSPDLEWHAACLKCAECNQYLDESCTCFVRDGKTYC
KRDYIRLYGIKCAKCSIGFSKNDFVMRARSKVYHIECF
RCVACSRQLIPGDEFALREDGLFCRADHDVVER 
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Table F.2: Amino acid sequences of Mkln1 constructs used for interaction 
testing. 
Construct 
Size 
(kDa) Sequence 
Mkln1FL 81.6 MAAGGAVAVAPECRLLPYALHKWSSFSSTYLPENILVDKPND
QSSRWSSESNYPPQYLILKLERPAIVQNITFGKYEKTHVCNLKK
FKVFGGMNEENMTELLSSGLKNDYNKETFTLKHKIDEQMFPC
RFIKIVPLLSWGPSFNFSIWYVELSGIDDPDIAQPCLNWYSKYR
EQEAIRLCLKHFRQHNYTEAFESLQKKTKIALEHPMLTDMHD
KLVLKGDFDACEELIEKAVNDGLXNQYISQQEYKPRWSQIIPK
STKGDGETQXLADFWAYSVKENQWTCISRDTEKENGPSARSC
HKMCIDIQRRQIYTLGRYLNSSVRNSKSLKSDFYRYDIDTNTW
MLLSEDTAADGGPKLVFDHXMCMDSEKHMIYTLGGRILTCNG
SVDDSRASEPQFSGLFAFNCQCQTWKLLREDSCNAGPEDIQSRI
GHCMLFHSKNRCLYVFGGQRSRTYLNDFFSYDVDSDHVDIISD
GTKKDSGMVPMTGFTQRATIDPELNEIHVLSGLSKDKEKREEN
VRNSFWIYDIVRNSWSCVYKNDQATKDNLSKSLQEEEPCPRFA
HQLVYDELHKVHYLFGGNPGKSCSPKMRLDDFWSLKLCRPSK
DYLLRHCKYLIRRHRFEEKAQMDPLSALKYLQNDLYITVDHS
DPEETKEFQLLASALFKSGSDFTALGFSDVDHTYAQRTQLFDT
LVNFFPDSMTPPKGNLVDLITL 
Mkln1ND 19.2 MAAGGAVAVAPECRLLPYALHKWSSFSSTYLPENILVDKPND
QSSRWSSESNYPPQYLILKLERPAIVQNITFGKYEKTHVCNLKK
FKVFGGMNEENMTELLSSGLKNDYNKETFTLKHKIDEQMFPC
RFIKIVPLLSWGPSFNFSIWYVELSGIDDPDIVQPCLNW 
Mkln1NL 23.7 MAAGGAVAVAPECRLLPYALHKWSSFSSTYLPENILVDKPND
QSSRWSSESNYPPQYLILKLERPAIVQNITFGKYEKTHVCNLKK
FKVFGGMNEENMTELLSSGLKNDYNKETFTLKHKIDEQMFPC
RFIKIVPLLSWGPSFNFSIWYVELSGIDDPDIVQPCLNWYSKYR
EQEAIRLCLKHFRQHNYTEAFESLQKKTKIAL 
Mkln1NK 71.8 MAAGGAVAVAPECRLLPYALHKWSSFSSTYLPENILVDKPND
QSSRWSSESNYPPQYLILKLERPAIVQNITFGKYEKTHVCNLKK
FKVFGGMNEENMTELLSSGLKNDYNKETFTLKHKIDEQMFPC
RFIKIVPLLSWGPSFNFSIWYVELSGIDDPDIVQPCLNWYSKYR
EQEAIRLCLKHFRQHNYTEAFESLQKKTKIALEHPMLTDMHD
KLVLKGDFDACEELIEKAVNDGLFNQYISQQEYKPRWSQIIPKS
TKGDGEDNRPGMRGGHQMVIDVQTETVYLFGGWDGTQDLA
DFWAYSVKENQWTCISRDTEKENGPSARSCHKMCIDIQRRQIY
TLGRYLDSSVRNSKSLKSDFYRYDIDTNTWMLLSEDTAADGG
PKLVFDHQMCMDSEKHMIYTFGGRILTCNGSVDDSRASEPQFS
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GLFAFNCQCQTWKLLREDSCNAGPEDIQSRIGHCMLFHSKNRC
LYVFGGQRSKTYLNDFFSYDVDSDHVDIISDGTKKDSGMVPM
TGFTQRATIDPELNEIHVLSGLSKDKEKREENVRNSFWIYDIVR
NSWSCVYKNDQATKDNLSKSLQEEEPCPRFAHQLVYDELHKV
HYLFGGNPGKSCSPKMRLDDFWSLK 
Mkln1LC 62.5 YREQEAIRLCLKHFRQHNYTEAFESLQKKTKIALEHPMLTDMH
DKLVLKGDFDACEELIEKAVNDGLFNQYISQQEYKPRWSQIIP
KSTKGDGEDNRPGMRGGHQMVIDVQTETVYLFGGWDGTQDL
ADFWAYSVKENQWTCISRDTEKENGPSARSCHKMCIDIQRRQI
YTLGRYLDSSVRNSKSLKSDFYRYDIDTNTWMLLSEDTAADG
GPKLVFDHQMCMDSEKHMIYTFGGRILTCNGSVDDSRASEPQ
FSGLFAFNCQCQTWKLLREDSCNAGPEDIQSRIGHDFFSYDVD
SDHVDIISDGTKKDSGMVPMTGFTQRATIDPELNEIHVLSGLSK
DKEKREENVRNSFWIYDIVRNSWSCVYKNDQATKDNLSKSLQ
EEEPCPRFAHQLVYDELHKVHYLFGGNPGKSCSPKMRLDDFW
SLKLCRPSKDYLLRHCKYLIRKHRFEEKAQMDPLSALKYLQN
DLYITVDHSDPEETKEFQLLASALFKSGSDFTALGFSDVDHTY
AQRTQLFDTLVNFFPDSMTPPKGNLVDLITL 
Mkln1CC 58.4 LEHPMLTDMHDKLVLKGDFDACEELIEKAVNDGLFNQYISQQ
EYKPRWSQIIPKSTKGDGEDNRPGMRGGHQMVIDVQTETVYL
FGGWDGTQDLADFWAYSVKENQWTCISRDTEKENGPSARSC
HKMCIDIQRRQIYTLGRYLDSSVRNSKSLKSDFYRYDIDTNTW
MLLSEDTAADGGPKLVFDHQMCMDSEKHMIYTFGGRILTCNG
SVDDSRASEPQFSGLFAFNCQCQTWKLLREDSCNAGPEDIQSRI
GHDFFSYDVDSDHVDIISDGTKKDSGMVPMTGFTQRATIDPEL
NEIHVLSGLSKDKEKREENVRNSFWIYDIVRNSWSCVYKNDQ
ATKDNLSKSLQEEEPCPRFAHQLVYDELHKVHYLFGGNPGKS
CSPKMRLDDFWSLKLCRPSKDYLLRHCKYLIRKHRFEEKAQM
DPLSALKYLQNDLYITVDHSDPEETKEFQLLASALFKSGSDFTA
LGFSDVDHTYAQRTQLFDTLVNFFPDSMTPPKGNLVDLITL 
Mkln1KC 52.4 TETVYLFGGWDGTQDLADFWAYSVKENQWTCISRDTEKENG
PSARSCHKMCIDIQRRQIYTLGRYLDSSVRNSKSLKSDFYRYDI
DTNTWMLLSEDTAADGGPKLVFDHQMCMDSEKHMIYTFGGR
ILTCNGSVDDSRASEPQFSGLFAFNCQCQTWKLLREDSCNAGP
EDIQSRIGHCMLFHSKNRCLYVFGGQRSKTYLNDFFSYDVDSD
HVDIISDGTKKDSGMVPMTGFTQRATIDPELNEIHVLSGLSKD
KEKREENVRNSFWIYDIVRNSWSCVYKNDQATKDNLSKSLQE
EEPCPRFAHQLVYDELHKVHYLFGGNPGKSCSPKMRLDDFWS
LKLCRPSKDYLLRHCKYLIRKHRFEEKAQMDPLSALKYLQND
LYITVDHSDPEETKEFQLLASALFKSGSDFTALGFSDVDHTYA
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QRTQLFDTLVNFFPDSMTPPKGNLVDLITL 
Mkln1FC 10.8 KHRFEEKAQMDPLSALKYLQNDLYITVDHSDPEETKEFQLLAS
ALFKSGSDFTALGFSDVDHTYAQRTQLFDTLVNFFPDSMTPPK
GNLVDLITL 
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Appendix G - Amino acid sequences of 
homeodomain constructs 
The amino acid sequences for all homeodomain constructs used throughout this thesis are 
listed in Table G.1. 
 
Table G.1: Amino acid sequences of homeodomain containing constructs.  
Construct 
name Size (kDa) Sequence 
NHD1 9.6 GSARQPALRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANP
RPDALMKEQLVEMTGLSPRVIRVWFQNKRCKDKKRSIMMK 
NHD3 9.6 GSYETAKQREAEATAKRPRTTITAKQLETLKSAYNTSPKPARH
VREQLSSETGLDMRVVQVWFQNRRAKEKRLKKDAGRQRW 
LLHD3 27.2 GSGTPMVAASPERHDGGLQANPVEVQSYQPPWGGSGGHMGS
GGTPEIPMCAGCDQHILDRFILKALDRHWHSKCLKCSDCHVP
LAERCFSRGESVYCKDDFFKRFGTKCAACQLGIPPTQVVRRA
QDFVYHLHCFACVVCKRQLATGDEFYLMEDSRLVCKADYET
AKQREAEATAKRPRTTITAKQLETLKSAYNTSPKPARHVREQ
LSSETGLDMRVVQVWFQNRRAKEKRLKKDAGRQRW 
LLHD1 32.2 GSDVMVVGEPTLMGGEFGDEDERLITRLENTQFDAANGIDDE
GGSGGHMGSGGKRLISLCVGCGNQIHDQYILRVSPDLEWHAA
CLKCAECNQYLDESCTCFVRDGKTYCKRDYIRLYGIKCAKCSI
GFSKNDFVMRARSKVYHIECFRCVACSRQLIPGDEFALREDGL
FCRADHDVVERASLGAGDPLSPLHPARPLQMAAEPISARQPA
LRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANPRPDALM
KEQLVEMTGLSPRVIRVWFQNKRCKDKKRSIMMK 
2HDLL 37 GSEKTTRVRTVLNEKQLHTLRTCYAANPRPDALMKEQLVEM
TGLSPRVIRVWFQNKRCKDKKRSIMMKQLQQQQPNDKTNIQ
GMTGTPMVAASPERHDGGLQANPVEVQSYQPPWGGSGGHM
GSGGTPEIPMCAGCDQHILDRFILKALDRHWHSKCLKCSDCH
VPLAERCFSRGESVYCKDDFFKRFGTKCAACQLGIPPTQVVRR
AQDFVYHLHCFACVVCKRQLATGDEFYLMEDSRLVCKADYE
TAKQREAEATAKRPRTTITAKQLETLKSAYNTSPKPARHVRE
QLSSETGLDMRVVQVWFQNRRAKEKRLKKDAGRQRW 
2HDN 20.8 GSARQPALRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANP
RPDALMKEQLVEMTGLSPRVIRVWFQNKRCKDKKRSIMMKQ
LQQQQPNDKTNIQGMTYETAKQREAEATAKRPRTTITAKQLE
TLKSAYNTSPKPARHVREQLSSETGLDMRVVQVWFQNRRAK
211 
 
EKRLKKDAGRQRW 
2HD17 20 ARQPALRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANPRP
DALMKEQLVEMTGLSPRVIRVWFQNKRCKDKKRSIMMKGGS
GGSGGSGGSGGSGGYETAKQREAEATAKRPRTTITAKQLETL
KSAYNTSPKPARHVREQLSSETGLDMRVVQVWFQNRRAKEK
RLKKDAGRQRW 
2HD23 19.7 ARQPALRPHVHKQPEKTTRVRTVLNEKQLHTLRTCYAANPRP
DALMKEQLVEMTGLSPRVIRVWFQNKRCKDKKRSIMMKGGS
GGSGGSGGSGGSGGSGGSGGREAEATAKRPRTTITAKQLETL
KSAYNTSPKPARHVREQLSSETGLDMRVVQVWFQNRRAKEK
RLKKDAGRQRW 
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Appendix H - Protein Purification 
Figure H.1 shows the purity of purified homeodomain constructs not featured in Figure 5.6.  
  
 
Figure H.1: Further examples of purifications of homeodomain constructs.  
SDS-PAGE gels showing cation exchange elution fractions for (A) GST-NHD1; (B) GST-
NHD3; (C) LLHD1; (D) LLHD3; (E) 2HDN; (F) 2HD23. 
 
